<SEC-DOCUMENT>0001437749-21-012046.txt : 20210513
<SEC-HEADER>0001437749-21-012046.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513160626
ACCESSION NUMBER:		0001437749-21-012046
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		21919593

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dyai20210331_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dyai="http://www.dyadic.com/20210331" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31">
 <head>
  <title>dyai20210331_10q.htm</title>
  <!-- Generated by ThunderDome Portal -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001213809</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">DYADIC INTERNATIONAL INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
<ix:nonFraction id="c73543538" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c73543539" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c73543544" contextRef="i_2021-03-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c73543545" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c73543546" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction>
<ix:nonFraction id="c73543547" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction>
<ix:nonFraction id="c73543548" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c73543550" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c73543549" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c73543551" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c73543555" contextRef="i_2021-03-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c73543556" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c73543557" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000,000</ix:nonFraction>
<ix:nonFraction id="c73543558" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000,000</ix:nonFraction>
<ix:nonFraction id="c73543559" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">39,807,659</ix:nonFraction>
<ix:nonFraction id="c73543560" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">39,747,659</ix:nonFraction>
<ix:nonFraction id="c73543561" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">27,554,157</ix:nonFraction>
<ix:nonFraction id="c73543562" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">27,494,157</ix:nonFraction>
<ix:nonFraction id="c73543567" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:numdotdecimal" decimals="INF">12,253,502</ix:nonFraction>
<ix:nonFraction id="c73543568" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:numdotdecimal" decimals="INF">12,253,502</ix:nonFraction>
<ix:nonFraction id="c73543703" contextRef="d_2021-01-01_2021-03-31" unitRef="Pure" name="dyai:NumberOfResearchOrganizations" scale="0" format="ixt:numdotdecimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c73543760" contextRef="d_2021-01-01_2021-03-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c73543764" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:numdotdecimal" decimals="INF">8</ix:nonFraction>
<ix:nonFraction id="c73543765" contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:numdotdecimal" decimals="INF">5</ix:nonFraction>
<ix:nonFraction id="c73543766" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:numdotdecimal" decimals="INF">7</ix:nonFraction>
<ix:nonFraction id="c73543767" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:numdotdecimal" decimals="INF">9</ix:nonFraction>
<ix:nonFraction id="c73543786" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfSuppliers" scale="0" format="ixt:numdotdecimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c73543792" contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfSuppliers" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c73543795" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfSuppliers" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c73543806" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c73543807" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c73543846" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c73543847" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c73543851" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="dyai:DeferredTaxAssetsValuationAllowanceCoveragePercent" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>
<ix:nonNumeric contextRef="d_2017-06-30_2017-06-30" name="dyai:CollaborativeArrangementDurationOfAgreement" id="c73544044" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonFraction id="c73544054" contextRef="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember" unitRef="USD" name="dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment" scale="0" format="ixt:numdotdecimal" decimals="INF">936,000</ix:nonFraction>
<ix:nonNumeric contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember" name="dyai:CollaborativeArrangementDurationOfAgreement" id="c73544055" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonFraction id="c73544058" contextRef="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember" unitRef="EUR" name="dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment" scale="6" format="ixt:numdotdecimal" decimals="-6">1</ix:nonFraction>
<ix:nonFraction id="c73544061" contextRef="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember" unitRef="EUR" name="dyai:CollaborativeArrangementMaximumObligationForResearchAndDevelopment" scale="6" format="ixt:numdotdecimal" decimals="-6">8.0</ix:nonFraction>
<ix:nonFraction id="c73544064" contextRef="i_2017-06-30_CapitalizedContractCostAxis-ResearchServicesAgreementMember" unitRef="EUR" name="dyai:CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" scale="6" format="ixt:numdotdecimal" decimals="-5">1.5</ix:nonFraction>
<ix:nonNumeric contextRef="d_2017-06-30_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember" name="dyai:CollaborativeArrangementDurationOfAgreement" id="c73544066" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonFraction id="c73544074" contextRef="d_2017-06-30_2017-06-30" unitRef="EUR" name="dyai:CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" scale="6" format="ixt:numdotdecimal" decimals="-5">1.1</ix:nonFraction>
<ix:nonFraction id="c73544049" contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember" unitRef="EUR" name="dyai:CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction>
<ix:nonFraction id="c73544106" contextRef="i_2020-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember" unitRef="USD" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">284,709</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c73544184" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c73544185" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c73544186" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c73544190" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_OwnershipAxis-ContractorMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c73544194" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="c73544201" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember_VestingAxis-SharebasedCompensationAwardTrancheTwoThroughFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c73544202" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c73544205" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-EmployeesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c73544208" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c73544211" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-08_2021-01-08_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c73544215" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-21_2021-01-21_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c73544218" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-03-22_2021-03-22_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c73544221" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonFraction id="c73544311" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:numdotdecimal" decimals="INF">12,253,502</ix:nonFraction>
<ix:nonFraction id="c73544312" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="6" format="ixt:numdotdecimal" decimals="-5">18.9</ix:nonFraction>
<ix:footnote xml:lang="en-us" id="fe854cce7-7819-4440-b61b-0330189eab0a">Represents the following stock options granted:




Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary.




One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date.


One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date.


One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f1a568bde-b180-41e5-8730-f648b8c1a213">Represents the following stock options exercised:




A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0">The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the three months ended March 31, 2021 and 2020, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended  December 31, 2020.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fd641e60f-9c4a-4be0-b3fc-9172db74071d">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dyai-20210331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2021-01-01_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-05-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:OneCROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:OneCROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:OneCROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_FairValueByAssetClassAxis-CashMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ShortTermCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_InvestmentTypeAxis-CorporateBondSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-CashMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ShortTermCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_InvestmentTypeAxis-CorporateBondSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2017-06-30_2017-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-VLPbioMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:VLPbioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-06-30_CapitalizedContractCostAxis-ResearchServicesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">dyai:ServiceFrameworkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-06-30_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">dyai:ServiceFrameworkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-BDIMember_TypeOfArrangementAxis-ServiceAgreementToPerformResearchProjectMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:BDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dyai:ServiceAgreementToPerformResearchProjectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-04-26_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-NovovetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:NovovetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-24_2020-06-24_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-24</xbrli:startDate><xbrli:endDate>2020-06-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-01_OwnershipAxis-AlphazymeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:AlphazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:IDBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:IDBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:IDBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:IDBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-04-28_PlanNameAxis-The2011PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-04-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-01-01_PlanNameAxis-The2011PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-16_2021-04-16_PlanNameAxis-The2011PlanMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_PlanNameAxis-The2011PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PlanNameAxis-The2011PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_OwnershipAxis-ContractorMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:ContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_OwnershipAxis-ContractorMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:ContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember_VestingAxis-SharebasedCompensationAwardTrancheTwoThroughFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyai:SharebasedCompensationAwardTrancheTwoThroughFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-08_2021-01-08_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-08_2021-01-08_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-21_2021-01-21_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-21_2021-01-21_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-22_2021-03-22_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-22_2021-03-22_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-08-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-13</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dyai:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-13</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-08-13_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dyai:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-13</xbrli:startDate><xbrli:endDate>2020-08-13</xbrli:endDate></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fe854cce7-7819-4440-b61b-0330189eab0a" fromRefs="c73544255 c73544256"></ix:relationship>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f1a568bde-b180-41e5-8730-f648b8c1a213" fromRefs="c73544259 c73544260"></ix:relationship>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0" fromRefs="c73543987 c73543988 c73543989 c73543990 c73544034 c73544035 c73544036 c73544037"></ix:relationship>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fd641e60f-9c4a-4be0-b3fc-9172db74071d" fromRefs="c73543987 c73543988 c73543989 c73543990 c73544034 c73544035 c73544036 c73544037"></ix:relationship></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2021-01-01_2021-03-31">10-Q</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(Mark One)</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 4%;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-03-31">&#x2612;</ix:nonNumeric></td><td style="width: 96%;"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td></tr>
<tr><td colspan="2" style="width: 4%; text-align: center;">For the quarterly period ended<b> </b><b><span style="background-color:#ffffff;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2021-01-01_2021-03-31">March 31, 2021</ix:nonNumeric></span></b></td></tr>
<tr><td style="width: 4%;">&#xa0;</td><td style="width: 96%;">&#xa0;</td></tr>
<tr><td style="width: 4%;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-03-31">&#x2610;</ix:nonNumeric></td><td style="width: 96%;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td></tr>
</tbody></table>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">For the transition period from _____ to ______</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt; text-indent: 36pt; text-align: center;">Commission File Number: <b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2021-01-01_2021-03-31">000-55264</ix:nonNumeric></b></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt; text-indent: 36pt; text-align: center;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;text-indent:72pt;"><img alt="dyai-20200930_g1copy.jpg" src="dyai-20200930_g1copy.jpg" /><b>DYADIC INTERNATIONAL, INC.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in its Charter)</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 47%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2021-01-01_2021-03-31">Delaware</ix:nonNumeric></b></td><td style="width: 6%; text-align: center;">&#xa0;</td><td style="width: 47%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2021-01-01_2021-03-31">45-0486747</ix:nonNumeric></b></td></tr>
<tr><td style="width: 47%; text-align: center;">State or Other Jurisdiction of Incorporation or Organization</td><td style="width: 6%; text-align: center;">&#xa0;</td><td style="width: 47%; text-align: center;">I.R.S. Employer Identification No.</td></tr>
</tbody></table>
<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 47%; text-align: center;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2021-01-01_2021-03-31">140 Intracoastal Pointe Drive, Suite 404</ix:nonNumeric></b></td><td style="width: 6%; text-align: center;">&#xa0;</td><td style="width: 47%; text-align: center;">&#xa0;</td></tr>
<tr><td style="width: 47%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2021-01-01_2021-03-31">Jupiter</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2021-01-01_2021-03-31">Florida</ix:nonNumeric></b></td><td style="width: 6%; text-align: center;">&#xa0;</td><td style="width: 47%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2021-01-01_2021-03-31">33477</ix:nonNumeric></b></td></tr>
<tr><td style="width: 47%; text-align: center;">Address of Principal Executive Offices</td><td style="width: 6%; text-align: center;">&#xa0;</td><td style="width: 47%; text-align: center;">Zip Code</td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2021-01-01_2021-03-31">561</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2021-01-01_2021-03-31">743-8333</ix:nonNumeric></b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 20%;">&#xa0;</td><td colspan="3" rowspan="1" style="text-align: center; width: 40%;">Registrant&#x2019;s Telephone Number, Including Area Code</td><td style="width: 20%;">&#xa0;</td></tr>
<tr><td style="width: 20%;">&#xa0;</td><td style="width: 20%; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="text-align: center; width: 20%; border-bottom: thin solid rgb(0, 0, 0);">N/A</td><td style="width: 20%; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 20%;">&#xa0;</td></tr>
<tr><td style="width: 20%;">&#xa0;</td><td colspan="3" rowspan="1" style="width: 20%; text-align: center;">Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report</td><td style="width: 20%;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#xa0;&#xa0;&#xa0;&#xa0; &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2021-01-01_2021-03-31">Yes</ix:nonNumeric>&#xa0;&#x2612; No&#xa0;&#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2021-01-01_2021-03-31">Yes</ix:nonNumeric>&#xa0;&#x2612; No&#xa0;&#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td colspan="3" style="vertical-align: bottom; width: 23%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer &#x2610;</p> </td><td colspan="3" style="vertical-align: middle; width: 47%;">&#xa0;</td><td colspan="6" style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#x2610;</p> </td></tr>
<tr><td colspan="3" style="vertical-align: bottom; width: 23%;">&#xa0;</td><td colspan="3" style="vertical-align: middle; width: 47%;">&#xa0;</td><td colspan="6" style="vertical-align: bottom; width: 30%;">&#xa0;</td></tr>
<tr><td colspan="3" style="vertical-align: bottom; width: 23%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2021-01-01_2021-03-31">Non-accelerated filer</ix:nonNumeric> &#x2612;</p> </td><td colspan="3" style="vertical-align: top; width: 47%;">&#xa0;</td><td colspan="6" style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-03-31">&#x2612;</ix:nonNumeric></p> </td></tr>
<tr><td colspan="3" style="vertical-align: bottom; width: 23%;">&#xa0;</td><td colspan="3" style="vertical-align: top; width: 47%;">&#xa0;</td><td colspan="6" style="vertical-align: bottom; width: 30%;">&#xa0;</td></tr>
<tr><td colspan="3" style="vertical-align: middle; width: 23%;">&#xa0;</td><td colspan="3" style="vertical-align: middle; width: 47%;">&#xa0;</td><td colspan="6" style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-03-31">&#x2610;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#xa0;&#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-03-31">&#x2610;</ix:nonNumeric> No&#xa0;&#x2612;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td colspan="3" style="vertical-align: bottom; width: 41%; border-color: rgb(0, 0, 0); border-style: solid; border-width: thin;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Title of each class</p> </td><td colspan="3" style="vertical-align: bottom; width: 18%; border-top: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Trading Symbol(s)</p> </td><td colspan="3" style="vertical-align: bottom; width: 41%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Name of each exchange on which registered</p> </td></tr>
<tr><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 41%; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2021-01-01_2021-03-31">Common Stock, par value $0.001 per share</ix:nonNumeric></p> </td><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18%; border-right: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2021-01-01_2021-03-31">DYAI</ix:nonNumeric></p> </td><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 41%; border-right: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2021-01-01_2021-03-31">NASDAQ</ix:nonNumeric> Stock Market LLC</p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The number of shares outstanding of each of the registrant&#x2019;s Common Stock as of&#xa0;May 12, 2021&#xa0;was&#xa0;<ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2021-05-12">27,554,157</ix:nonFraction>.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="text-decoration: underline; ">TABLE OF CONTENTS</span></b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td colspan="3" style="vertical-align: bottom; width: 9%;">&#xa0;</td>
      <td colspan="3" style="vertical-align: bottom; width: 86%;">&#xa0;</td>
      <td colspan="3" style="vertical-align: bottom; width: 5%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td>
     </tr>

     <tr>
      <td colspan="6" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#financial" style="-sec-extract:exhibit;">PART I FINANCIAL INFORMATION</a></p> </td>
      <td colspan="3" style="vertical-align: middle; width: 5%;">&#xa0;</td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 1.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#financial" style="-sec-extract:exhibit;">Financial Statements</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#financial">3</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 2.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#managements" style="-sec-extract:exhibit;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#managements">20</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 3.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#quantitative" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures about Market Risk</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#quantitative">29</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 4.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#controls" style="-sec-extract:exhibit;">Controls and Procedures</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#controls">29</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: middle; width: 9%;">&#xa0;</td>
      <td colspan="3" style="vertical-align: middle; width: 86%;">&#xa0;</td>
      <td colspan="3" style="vertical-align: middle; width: 5%; text-align: center;">&#xa0;</td>
     </tr>

     <tr>
      <td colspan="6" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#part2" style="-sec-extract:exhibit;">PART II OTHER INFORMATION</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;">&#xa0;</td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 1.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#legal" style="-sec-extract:exhibit;">Legal Proceedings</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#legal">29</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 1A.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#risk" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#risk">29</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 2.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#unregistered" style="-sec-extract:exhibit;">Unregistered Sales of Equity Securities and Use of Proceeds</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#unregistered">30</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 3.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#defaults" style="-sec-extract:exhibit;">Defaults Upon Senior Securities</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#defaults">30</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 4.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#minesafety" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#minesafety">30</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 5.</p> </td>
      <td colspan="3" style="vertical-align: bottom; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#otherinfo" style="-sec-extract:exhibit;">Other Information</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%; text-align: center;"><a class="tocPGNUM" href="#otherinfo">30</a></td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 6.</p> </td>
      <td colspan="3" style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#exhibits" style="-sec-extract:exhibit;">Exhibits</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#exhibits">30</a></p> </td>
     </tr>

     <tr>
      <td colspan="6" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#signatures" style="-sec-extract:exhibit;">Signatures</a></p> </td>
      <td colspan="3" style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#signatures">31</a></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM">
        &#xa0;
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  </div>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Information (other than historical facts) set forth in this Quarterly Report contains forward-looking statements within the meaning of the Federal securities laws, which involve many risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements generally can be identified by use of the words &#x201c;expect,&#x201d; &#x201c;should,&#x201d; &#x201c;intend,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;will,&#x201d; &#x201c;project,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;potential,&#x201d; or &#x201c;continue&#x201d; and other similar terms or variations of them or similar terminology. Such forward-looking statements are included under Item 2 &#x201c;Management&#x2019;s Discussion and Analysis&#x201d;. Dyadic International, Inc., and its subsidiaries cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve many risks, uncertainties or other factors within and/or beyond Dyadic&#x2019;s control. These factors include, but are not limited to, (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic&#x2019;s and third parties&#x2019; research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on our key customers and collaborators;&#xa0;(8) our ability, and the ability of the contract research organizations with whom we are currently working with, to advance vaccine candidates into, and successfully complete, preclinical studies and clinical trials; (9) the commercialization of our vaccine candidates, if approved; (10)&#xa0;the pharmaceutical and biotech industry, governmental regulatory and other agencies&#x2019; willingness to adopt, utilize and approve the use of the C1 gene expression platform; (11) the risk of theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological materials owned by us and/or Danisco US, Inc. and VTT Technical Research Centre of Finland Ltd; (12) speculative nature and illiquidity of equity securities received as consideration from sub-licenses; (13) our expectations concerning the impact of the novel coronavirus identified as &#x201c;COVID-19&#x201d; on our business and operating results; and (14) other factors discussed in Dyadic&#x2019;s publicly available filings, including information set forth under the caption &#x201c;Risk Factors&#x201d; in this Form 10-Q and our Form 10-K filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#xa0;30,&#xa0;2021. We caution you that the foregoing list of important factors is not exclusive. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we operate in a highly regulated, competitive and rapidly changing environment. Our competitors have far greater resources, infrastructure and market presence than we do which makes it difficult for us to enter certain markets, and/or to gain or maintain customers. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Before investing in our common stock, investors should carefully read the information set forth under the caption &#x201c;Risk Factors&#x201d; in this Form 10-Q and elsewhere in our Form 10-K filed with the SEC on March&#xa0;30,&#xa0;2021 which could have a material adverse effect on our business, results of operations and financial condition.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We qualify all our forward-looking statements by these cautionary statements. In addition, with respect to all our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="financial" title="financial" href="#"></a>PART I</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Item 1. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Financial Statements</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543508" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">13,055,558</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543509" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">20,637,045</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Short-term investment securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543510" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">14,177,441</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543511" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">8,457,452</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543512" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">157,201</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543513" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">112,247</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543514" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">384,963</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543515" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">294,199</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543516" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">216,189</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543517" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">280,555</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543518" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">27,991,352</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543519" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">29,781,498</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-current assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Investment in Alphazyme</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543521" contextRef="i_2021-03-31" unitRef="USD" name="dyai:PrepaidResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">284,709</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543522" contextRef="i_2020-12-31" unitRef="USD" name="dyai:PrepaidResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">284,709</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543523" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">6,151</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543524" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">6,225</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total assets</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543525" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">28,282,212</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543526" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">30,072,432</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities and stockholders&#x2019; equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543529" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,473,813</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543530" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,013,099</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543531" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">277,668</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543532" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">489,756</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred research and development obligations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543533" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">842,248</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543534" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">123,016</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543535" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,593,729</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543536" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,625,871</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commitments and contingencies (Note 4)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c73543538">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c73543539">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stockholders&#x2019; equity:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Preferred stock, $<span style="-sec-ix-hidden:c73543544"><span style="-sec-ix-hidden:c73543545">.0001</span></span> par value:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Authorized shares - <span style="-sec-ix-hidden:c73543546"><span style="-sec-ix-hidden:c73543547">5,000,000</span></span>; <span style="-sec-ix-hidden:c73543548"><span style="-sec-ix-hidden:c73543550"><span style="-sec-ix-hidden:c73543549"><span style="-sec-ix-hidden:c73543551">none</span></span></span></span> issued and outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543542" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543543" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock, $<span style="-sec-ix-hidden:c73543555"><span style="-sec-ix-hidden:c73543556">.001</span></span> par value:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Authorized shares - <span style="-sec-ix-hidden:c73543557"><span style="-sec-ix-hidden:c73543558">100,000,000</span></span>; issued shares - <span style="-sec-ix-hidden:c73543559">39,807,659</span> and <span style="-sec-ix-hidden:c73543560">39,747,659</span>, outstanding shares - <span style="-sec-ix-hidden:c73543561">27,554,157</span> and <span style="-sec-ix-hidden:c73543562">27,494,157</span> as of March 31, 2021 and December 31, 2020, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543553" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">39,808</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543554" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">39,748</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543563" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">98,549,890</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543564" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">98,013,079</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Treasury stock, shares held at cost - <span style="-sec-ix-hidden:c73543567"><span style="-sec-ix-hidden:c73543568">12,253,502</span></span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543565" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">18,929,915</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543566" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">18,929,915</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c73543569" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">53,971,300</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c73543570" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">50,676,351</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543571" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">25,688,483</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543572" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">28,446,561</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total liabilities and stockholders&#x2019; equity</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543573" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">28,282,212</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543574" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">30,072,432</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>(Unaudited)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Revenues:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Research and development revenue</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543580" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">460,520</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543581" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">315,372</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Costs and expenses:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Costs of research and development revenue</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543583" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:numdotdecimal" decimals="INF">390,762</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543584" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:numdotdecimal" decimals="INF">278,182</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Research and development</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543585" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,808,098</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543586" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">755,453</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543587" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,554,007</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543588" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,653,392</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Foreign currency exchange loss (gain), net</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543589" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">28,272</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543590" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">10,867</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total costs and expenses</b></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543591" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">3,781,139</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543592" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">2,697,894</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Loss from operations</b></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543593" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,320,619</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543594" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,382,522</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest income</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543595" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" format="ixt:numdotdecimal" decimals="INF">25,670</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543596" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" format="ixt:numdotdecimal" decimals="INF">168,383</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net loss</b></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">(<ix:nonFraction id="c73543597" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,294,949</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">(<ix:nonFraction id="c73543598" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,214,139</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per common share</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543599" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.12</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543600" contextRef="d_2020-01-01_2020-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.08</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted weighted-average common shares outstanding</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543601" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">27,533,268</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543602" contextRef="d_2020-01-01_2020-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">27,452,490</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS</b>&#x2019;<b> EQUITY</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>(Unaudited)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Common Stock</em></em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Treasury Stock</em></em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Additional</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Accumulated</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Amount</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Amount</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Paid-in Capital</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Deficit</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</em></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 30%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543617" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">39,747,659</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543618" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,748</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543619" contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">12,253,502</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543620" contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543621" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">98,013,079</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543622" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">50,676,351</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543623" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">28,446,561</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543625" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543627" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543628" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">421,071</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543629" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543630" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">421,071</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543631" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">60,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543632" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">60</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543633" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543634" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543635" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">115,740</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543636" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543637" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">115,800</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543639" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543641" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73543642" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543643" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,294,949</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543644" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,294,949</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at March 31, 2021</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543645" contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">39,807,659</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543646" contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,808</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c73543647" contextRef="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">12,253,502</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c73543648" contextRef="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543649" contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">98,549,890</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c73543650" contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">53,971,300</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543651" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">25,688,483</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>(Unaudited)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from operating activities</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543657" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,294,949</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543658" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,214,139</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation expense</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543660" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">421,071</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543661" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">426,939</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Amortization of held-to-maturity securities, net</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543662" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="0" format="ixt:numdotdecimal" decimals="INF">63,951</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543663" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="0" format="ixt:numdotdecimal" decimals="INF">107,256</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign currency exchange loss (gain), net</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543664" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">28,272</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543665" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">10,867</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Interest receivable</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543667" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" format="ixt:numdotdecimal" decimals="INF">44,954</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543668" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">102,565</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accounts receivable</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543669" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">131,800</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543670" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">35,258</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Prepaid expenses and other current assets</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543671" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">64,297</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543672" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">10,529</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accounts payable</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543673" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">480,455</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543674" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">292,361</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued expenses</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543675" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">212,088</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543676" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">326,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred research and development obligation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543677" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">719,232</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543678" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">163,799</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net cash used in operating activities</b></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c73543679" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,906,513</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c73543680" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,996,345</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from investing activities</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Purchases of held-to-maturity investment securities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543682" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">11,283,940</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73543683" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">11,652,385</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from maturities of investment securities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543684" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">5,500,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543685" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">13,350,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net cash (used in) provided by investing activities</b></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c73543686" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,783,940</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c73543687" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,697,615</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from financing activities</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from exercise of options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543689" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">115,800</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543690" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">175,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net cash provided by financing activities</b></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c73543691" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">115,800</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c73543692" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">175,000</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of exchange rate changes on cash</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c73543693" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,834</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c73543694" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,983</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net decrease in cash and cash equivalents</b></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c73543695" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">7,581,487</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c73543696" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">126,713</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at beginning of period</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543697" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">20,637,045</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543698" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">4,823,544</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and cash equivalents at end of period</b></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c73543699" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">13,055,558</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c73543700" contextRef="i_2020-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">4,696,831</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Notes to Consolidated Financial Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="c1856453" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1:</em></b>&#xa0;&#xa0;&#xa0;&#xa0;<b>Organization and Summary of Significant Accounting Policies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Description of Business</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dyadic International, Inc. (&#x201c;Dyadic&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, or the &#x201c;Company&#x201d;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office&#xa0;in the Netherlands and predominantly <span style="-sec-ix-hidden:c73543703">three</span> research organizations performing services in the Netherlands, Finland and Israel. Over the past <em style="font: inherit;">two</em> plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to <em style="font: inherit;">third</em> parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the <i>Thermothelomyces heterothallica </i>(formerly known as <i>Myceliophthora thermophila</i>) fungus, which the Company named <em style="font: inherit;">C1.</em> The <em style="font: inherit;">C1</em> technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> December 31, 2015, </em>the Company sold its industrial technology business to Danisco USA (&#x201c;Danisco&#x201d;), the industrial biosciences business of DuPont (NYSE: DD)&#xa0;(the &#x201c;DuPont Transaction&#x201d;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the <em style="font: inherit;">C1</em> technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the <em style="font: inherit;">C1</em> technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic <em style="font: inherit;"> may </em>owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary <em style="font: inherit;">C1</em> technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs and other biological products at flexible commercial scales. Currently, the Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies to leverage its <em style="font: inherit;">C1</em> technology to help develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. The Company is also working on several COVID-<em style="font: inherit;">19</em> related vaccine and antibody opportunities, including its proprietary COVID-<em style="font: inherit;">19</em> vaccine candidate, DYAI-<em style="font: inherit;">100,</em> towards a <em style="font: inherit;">first</em>-in-human Phase <em style="font: inherit;">1</em> clinical trial.&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Effective <em style="font: inherit;"> April 17, 2019, </em>our common stock began trading on the NASDAQ Stock Market LLC&#x2019;s NASDAQ Capital Market, under the symbol &#x201c;DYAI&#x201d;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dyai:ImpactOfCOVID19PolicyPolicyTextBlock" id="c73546953" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Impact of COVID-<em style="font: inherit;">19</em></i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The outbreak of COVID-<em style="font: inherit;">19</em> has led to adverse impacts on the U.S. and global economies and created uncertainty regarding&#xa0;the potential impact to the Company&#x2019;s employees, operations, and research projects.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date, some of our employees are still working remotely. The extent to which the COVID-<em style="font: inherit;">19</em> pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that <em style="font: inherit;"> may </em>emerge concerning the severe acute respiratory syndrome coronavirus <em style="font: inherit;">2</em> (SARS-CoV-<em style="font: inherit;">2</em>) and its&#xa0;variants and the actions taken and the level of success to contain or treat the SARS-CoV-<em style="font: inherit;">2</em> virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or <em style="font: inherit;">third</em>-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-<em style="font: inherit;">19</em> pandemic has subsided, the Company <em style="font: inherit;"> may </em>continue to experience adverse impacts to its business because of economic recession or depression that has occurred or <em style="font: inherit;"> may </em>occur in the future. Given the daily evolution of the COVID-<em style="font: inherit;">19</em> outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are <em style="font: inherit;">not</em> able to accurately estimate the effects of the COVID-<em style="font: inherit;">19</em> outbreak to our results of operations, financial condition, or liquidity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">7</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. However, in the event our financing needs for the foreseeable future are <em style="font: inherit;">not</em> able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company <em style="font: inherit;"> may </em>decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the <em style="font: inherit;">C1</em> expression platform in humans. There is <em style="font: inherit;">no</em> assurance that external funding will be available at acceptable terms, if at all, and the Company <em style="font: inherit;"> may, </em>therefore, self-fund these vital projects.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c73546954" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Basis of Presentation </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em>&#xa0;included in our Form <em style="font: inherit;">10</em>-K which was filed with the SEC on <em style="font: inherit;"> March&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021.</em><b><i> </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented.&#xa0;The results of the Company&#x2019;s operations for any interim periods are <em style="font: inherit;">not</em> necessarily indicative of the results of operations for any other interim period or for a full fiscal year.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Since concluding the DuPont Transaction, the Company has conducted business in <span style="-sec-ix-hidden:c73543760">one</span> operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:UseOfEstimates" id="c73546955" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c73546956" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#x2019;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#x201c;FDIC&#x201d;) and the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) insured limit on domestic currency and the Netherlands&#x2019; FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company&#x2019;s revenue was generated from&#xa0;<span style="-sec-ix-hidden:c73543764">eight</span> and&#xa0;<span style="-sec-ix-hidden:c73543765">five</span> customers, respectively.&#xa0;As of&#xa0;<em style="font: inherit;"> March 31, 2021</em> and&#xa0;<em style="font: inherit;"> December 31, 2020</em>, the Company&#x2019;s accounts receivable was from&#xa0;<span style="-sec-ix-hidden:c73543766">seven</span> and <span style="-sec-ix-hidden:c73543767">nine</span>&#xa0;customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company&#x2019;s customers could adversely affect its operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States.&#xa0;For the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> March 31, 2021</em>, the Company had <ix:nonFraction id="c73543770" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt-sec:numwordsen" decimals="INF">six</ix:nonFraction>&#xa0;customers outside of the United States (i.e. European and Asian customers) that accounted for approximately&#xa0;<ix:nonFraction id="c73543771" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">76.7</ix:nonFraction>%&#xa0;or&#xa0;$<ix:nonFraction id="c73543772" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">353,000</ix:nonFraction>&#xa0;of the revenue. For the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> March 31, 2020</em>, the Company had&#xa0;<ix:nonFraction id="c73543774" contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> customers outside of the United States that accounted for approximately&#xa0;<ix:nonFraction id="c73543775" contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">58.0</ix:nonFraction>% or $<ix:nonFraction id="c73543776" contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">183,000</ix:nonFraction>&#xa0;of the revenue.&#xa0;As of&#xa0;the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> March 31, 2021</em>, the Company had&#xa0;<ix:nonFraction id="c73543778" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> customers outside of the United States (i.e. European and Asian customers) that accounted for approximately <ix:nonFraction id="c73543779" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">46.0</ix:nonFraction>%&#xa0;or $<ix:nonFraction id="c73543780" contextRef="i_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt:numdotdecimal" decimals="INF">174,000</ix:nonFraction>&#xa0;of accounts receivable.&#xa0;As of&#xa0;<em style="font: inherit;"> December 31, 2020</em>, the Company had&#xa0;<ix:nonFraction id="c73543781" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt-sec:numwordsen" decimals="INF">seven</ix:nonFraction> customers outside of the United States that accounted for approximately&#xa0;<ix:nonFraction id="c73543782" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">41.6</ix:nonFraction>% or&#xa0;$<ix:nonFraction id="c73543783" contextRef="i_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt:numdotdecimal" decimals="INF">123,000</ix:nonFraction> of accounts receivable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">8</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses several contract research organizations (&#x201c;CROs&#x201d;) to conduct its research projects. As of and for the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> March 31, 2021</em>, <span style="-sec-ix-hidden:c73543786">three</span> CROs accounted for approximately $<ix:nonFraction id="c73543787" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember" unitRef="USD" name="dyai:ResearchServicesPurchased" scale="0" format="ixt:numdotdecimal" decimals="INF">2,017,000</ix:nonFraction> or <ix:nonFraction id="c73543788" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">98.1</ix:nonFraction>%&#xa0;of total research services we purchased and $<ix:nonFraction id="c73543789" contextRef="i_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember" unitRef="USD" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,324,000</ix:nonFraction> or <ix:nonFraction id="c73543790" contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">89.8</ix:nonFraction>% of the accounts payable. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020, </em><span style="-sec-ix-hidden:c73543792">one</span> CRO accounted for approximately&#xa0;$<ix:nonFraction id="c73543793" contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember" unitRef="USD" name="dyai:ResearchServicesPurchased" scale="0" format="ixt:numdotdecimal" decimals="INF">855,000</ix:nonFraction>, or <ix:nonFraction id="c73543794" contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>% of&#xa0;total research services we purchased. As of&#xa0;<em style="font: inherit;"> December 31, 2020</em>, <span style="-sec-ix-hidden:c73543795">one</span> CRO accounted for approximately $<ix:nonFraction id="c73543796" contextRef="i_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember" unitRef="USD" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">690,000</ix:nonFraction> or <ix:nonFraction id="c73543797" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">68.1</ix:nonFraction>%&#xa0;of the accounts payable. The loss of this CRO or a combination of the Company&#x2019;s CROs could adversely affect its operations.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="margin-left: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c73546957" escape="true"><p style="margin-left: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">We treat highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:InvestmentPolicyTextBlock" id="c73546958" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Investment Securities</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months or less, and long-term investment securities mature over <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#x2019;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company&#x2019;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of&#xa0;<em style="font: inherit;"> March 31, 2021</em> and&#xa0;<em style="font: inherit;"> December 31, 2020</em>, all of our money market funds were invested in U.S. Government money market funds. The Company did <em style="font: inherit;">not</em> have any investment securities classified as trading as of&#xa0;<em style="font: inherit;"> March 31, 2021</em> or&#xa0;<em style="font: inherit;"> December 31, 2020</em>.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="c73546959" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Receivable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#x2019;s best estimate of the amount of probable credit losses in the Company&#x2019;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. There was <span style="-sec-ix-hidden:c73543806"><span style="-sec-ix-hidden:c73543807">no</span></span> allowance for doubtful accounts as of&#xa0;<em style="font: inherit;"> March 31, 2021</em> and&#xa0;<em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="c1856454" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543884" contextRef="i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">293,323</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543885" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">130,532</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543886" contextRef="i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">91,640</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543887" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">163,667</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543888" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">384,963</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543889" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">294,199</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">9</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude></ix:nonNumeric>
   <ix:exclude>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" id="c73546960" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Prepaid Expenses and Other Current Assets</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="c1856455" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543892" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="0" format="ixt:numdotdecimal" decimals="INF">94,841</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543893" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="0" format="ixt:numdotdecimal" decimals="INF">204,988</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543894" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">120,534</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543895" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">72,403</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543896" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:PrepaidTaxes" scale="0" format="ixt:numdotdecimal" decimals="INF">814</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543897" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidTaxes" scale="0" format="ixt:numdotdecimal" decimals="INF">3,164</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543898" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">216,189</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543899" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">280,555</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dyai:AccountsPayablePolicyPolicyTextBlock" id="c73546963" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Payable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts payable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="c1856456" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543902" contextRef="i_2021-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,337,755</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543903" contextRef="i_2020-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">904,572</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543904" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">93,071</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543905" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">24,496</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543906" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AccountsPayableOtherCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">42,987</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543907" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableOtherCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">84,031</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543908" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,473,813</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543909" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,013,099</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dyai:AccruedExpensesPolicyPolicyTextBlock" id="c73546964" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accrued expenses consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c1856457" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543912" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">175,210</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543913" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">447,881</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543914" contextRef="i_2021-03-31" unitRef="USD" name="dyai:AccruedResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">42,006</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543915" contextRef="i_2020-12-31" unitRef="USD" name="dyai:AccruedResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">28,508</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543916" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">60,452</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543917" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">13,367</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543918" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">277,668</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543919" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">489,756</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="c73546965" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Revenue Recognition </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has <em style="font: inherit;">no</em> pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from <em style="font: inherit;">third</em>-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which <em style="font: inherit;"> may </em>include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to research collaborations and agreements: </i>The Company typically&#xa0;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the <em style="font: inherit;">5</em>-step process outlined in ASC Topic <em style="font: inherit;">606</em> (&#x201c;Topic <em style="font: inherit;">606&#x201d;</em>): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic <em style="font: inherit;">606</em> to measure the progress toward complete satisfaction of a performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the input methods, revenue will be recognized on the basis of the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and <em style="font: inherit;">third</em>-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">10</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to grants: </i>The Company <em style="font: inherit;"> may </em>receive grants&#xa0;from governments, agencies, and other private and <em style="font: inherit;">not</em>-for-profit organizations. These grants&#xa0;are intended to be used to partially or fully fund the Company&#x2019;s research collaborations, including opportunities arising in connection with COVID-<em style="font: inherit;">19</em> that the Company is pursuing with certain collaborators. However, most, if <em style="font: inherit;">not</em> all, of such potential grant revenues, if received, is expected to be earmarked for <em style="font: inherit;">third</em> parties to advance the research required, including preclinical and clinical trials for SARS-CoV-<em style="font: inherit;">2</em> vaccines and/or antibodies candidates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Milestone payments: </i>At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#x2019;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has <em style="font: inherit;">not</em> recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which the<i> </i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <em style="font: inherit;">not</em> recognized any royalty revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We invoice customers based on our contractual arrangements with each customer, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are <em style="font: inherit;">not</em> required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of <em style="font: inherit;">one</em> year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c73546966" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Research and Development Costs </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development (&#x201c;R&amp;D&#x201d;) costs are expensed as incurred. R&amp;D costs are for the Company&#x2019;s internally funded pharmaceutical programs and other governmental and commercial projects.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">11</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock" id="c1856458" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543924" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseOutsideContractedServices" scale="0" format="ixt:numdotdecimal" decimals="INF">1,659,194</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543925" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseOutsideContractedServices" scale="0" format="ixt:numdotdecimal" decimals="INF">613,790</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543926" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">148,162</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543927" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">123,638</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543928" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" scale="0" format="ixt:numdotdecimal" decimals="INF">742</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543929" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" scale="0" format="ixt:numdotdecimal" decimals="INF">18,025</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543930" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty" scale="0" format="ixt:numdotdecimal" decimals="INF">1,808,098</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543931" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty" scale="0" format="ixt:numdotdecimal" decimals="INF">755,453</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="c73546967" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Foreign Currency Transaction Gain or Loss</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c73546968" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Fair Value Measurements</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into <em style="font: inherit;">three</em> levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 3%; vertical-align: top;">&#xa0;</td><td style="width: 3%; vertical-align: top;"><i>&#x2022;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">1</em></i> &#x2013; Quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr><td style="width: 3%; vertical-align: top;">&#xa0;</td><td style="width: 3%; vertical-align: top;"><i>&#x2022;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">2</em></i> &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr><td style="width: 3%; vertical-align: top;">&#xa0;</td><td style="width: 3%; vertical-align: top;"><i>&#x2022;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">3</em></i> &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.</td></tr>
</tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company&#x2019;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#xa0;approximates fair value due to the short-term maturities of these instruments. The Company&#x2019;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the <em style="font: inherit;">third</em>-party broker service for disclosure purposes.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" id="c73546969" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Non-Marketable Investments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do <em style="font: inherit;">not</em> have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes <em style="font: inherit;"> may </em>include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which <em style="font: inherit;"> may </em>include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company&#x2019;s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, <em style="font: inherit;"> may </em>have <em style="font: inherit;">no</em> or limited revenues, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be or <em style="font: inherit;"> may </em>never become profitable, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to secure additional funding or their technologies, services or products <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be successfully developed or introduced into the market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c73546970" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) was enacted on <em style="font: inherit;"> December 22, 2017 </em>and became effective <em style="font: inherit;"> January 1, 2018. </em>The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from <em style="font: inherit;">35%</em> to <em style="font: inherit;">21%</em> and repeal of the corporate alternative minimum tax (&#x201c;AMT&#x201d;). The TCJA&#x2019;s reduction in the U.S. statutory tax rate had <em style="font: inherit;">no</em> additional impact on the consolidated financial statement for the year ended&#xa0;<em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the&#xa0;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, there were <span style="-sec-ix-hidden:c73543846"><span style="-sec-ix-hidden:c73543847">no</span></span> provision for income taxes and unrecognized tax benefits recorded. As of&#xa0;<em style="font: inherit;"> March 31, 2021</em> and&#xa0;<em style="font: inherit;"> December 31, 2020</em>, deferred tax assets were approximately $<ix:nonFraction id="c73543848" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" format="ixt:numdotdecimal" decimals="-5">10.2</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c73543849" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" format="ixt:numdotdecimal" decimals="-5">9.4</ix:nonFraction> million, respectively. Due to the Company&#x2019;s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a <ix:nonFraction id="c73543850" contextRef="d_2021-01-01_2021-03-31" unitRef="Pure" name="dyai:DeferredTaxAssetsValuationAllowanceCoveragePercent" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>% valuation allowance against deferred tax assets as of&#xa0;<em style="font: inherit;"> March 31, 2021</em> and&#xa0;<em style="font: inherit;"> December 31, 2020</em>.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="c73546971" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Comprehensive Income (Loss)</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#x2019; equity but are excluded from net income (loss) under GAAP. The Company does <em style="font: inherit;">not</em> have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does <em style="font: inherit;">not</em> separately present a statement of comprehensive income (loss) in its consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c73546972" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We recognize all share-based payments to employees, consultants, and our board of directors (&#x201c;Board of Directors&#x201d;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c73546973" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the effect of the potential exercise of options to purchase <ix:nonFraction id="c73543856" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">5,324,215</ix:nonFraction>&#xa0;and <ix:nonFraction id="c73543857" contextRef="d_2020-01-01_2020-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">4,663,390</ix:nonFraction> shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c73546974" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b>&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which modifies the measurement of expected credit losses of certain financial instruments. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will be effective for the Company beginning in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> The Company does <em style="font: inherit;">not</em> expect ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> to have a material impact on our consolidated financial positions, results of operations, and cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em>&#xa0;<i>Income Taxes (Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes</i>. The amendments of this update simplify the accounting for income taxes by removing certain exceptions&#xa0;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> on&#xa0;<em style="font: inherit;"> January 1, 2021, </em>and&#xa0;adoption of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> did&#xa0;<em style="font: inherit;">not</em> have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either <em style="font: inherit;">not</em> applicable or <em style="font: inherit;">not</em> significant to our consolidated financial statements.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
   <p style="text-indent: 9pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="c1856459" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2:</em></b>&#xa0;&#xa0;&#xa0;&#xa0;<b>Cash, Cash Equivalent, and Investments </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company&#x2019;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company&#x2019;s cash, available-for-sale securities, and investment securities by major security type as of&#xa0;<em style="font: inherit;"> March 31, 2021</em>, and&#xa0;<em style="font: inherit;"> December 31, 2020</em>:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="CE2D0B32-FB65-4AAE-A216-9572C0A689B9" escape="true" continuedAt="c2B42CB73-A681-496B-A8B4-DD49EC033D7E">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2021 (Unaudited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 10%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543971" contextRef="i_2021-03-31_FairValueByAssetClassAxis-CashMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="INF">1,217,419</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73543974" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:Cash" scale="0" format="ixt:numdotdecimal" decimals="INF">1,217,419</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543976" contextRef="i_2021-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="INF">11,838,139</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543979" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">11,838,139</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543981" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="INF">13,055,558</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543984" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">13,055,558</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543987" contextRef="i_2021-03-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">14,161,252</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543988" contextRef="i_2021-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ShortTermCorporateBondsMember" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="0" format="ixt:numdotdecimal" decimals="INF">1,658</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c73543989" contextRef="i_2021-03-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="0" format="ixt:numdotdecimal" decimals="INF">17,847</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73543990" contextRef="i_2021-03-31_InvestmentTypeAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">14,177,441</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543992" contextRef="i_2021-03-31" unitRef="USD" name="dyai:CashCashEquivalentsAndInvestmentsFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">27,216,810</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543993" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="0" format="ixt:numdotdecimal" decimals="INF">1,658</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c73543994" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="0" format="ixt:numdotdecimal" decimals="INF">17,847</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73543995" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:InvestmentsAndCash" scale="0" format="ixt:numdotdecimal" decimals="INF">27,232,999</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="c2B42CB73-A681-496B-A8B4-DD49EC033D7E">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020 (Audited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544018" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CashMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="INF">149,015</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544021" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Cash" scale="0" format="ixt:numdotdecimal" decimals="INF">149,015</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73544023" contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="INF">20,488,030</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73544026" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">20,488,030</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73544028" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="INF">20,637,045</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73544031" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">20,637,045</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><ix:nonFraction id="c73544034" contextRef="i_2020-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">8,473,461</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><ix:nonFraction id="c73544035" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ShortTermCorporateBondsMember" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="0" format="ixt:numdotdecimal" decimals="INF">22,473</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(<ix:nonFraction id="c73544036" contextRef="i_2020-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="0" format="ixt:numdotdecimal" decimals="INF">6,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><ix:nonFraction id="c73544037" contextRef="i_2020-12-31_InvestmentTypeAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">8,457,451</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544039" contextRef="i_2020-12-31" unitRef="USD" name="dyai:CashCashEquivalentsAndInvestmentsFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">29,110,506</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544040" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="0" format="ixt:numdotdecimal" decimals="INF">22,473</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c73544041" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="0" format="ixt:numdotdecimal" decimals="INF">6,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544042" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InvestmentsAndCash" scale="0" format="ixt:numdotdecimal" decimals="INF">29,094,496</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_________________</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">1</em>) Definition of the <em style="font: inherit;">three</em>-level fair value hierarchy:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;">&#xa0;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">1</em> - Quoted prices (unadjusted) in active markets for identical assets or liabilities</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;">&#xa0;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">2</em> - Other inputs that are directly or indirectly observable in the markets</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;">&#xa0;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">3</em> - Inputs that are generally unobservable</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">2</em>) Short-term investment securities will mature within <em style="font: inherit;">12</em> months or less, from the applicable reporting date.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">3</em>) The premium paid to purchase held-to-maturity investment securities was $<ix:nonFraction id="c73543941" contextRef="d_2021-01-01_2021-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" scale="0" format="ixt:numdotdecimal" decimals="INF">283,940</ix:nonFraction> and $<ix:nonFraction id="c73543942" contextRef="d_2020-01-01_2020-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" scale="0" format="ixt:numdotdecimal" decimals="INF">196,385</ix:nonFraction>&#xa0;for the&#xa0;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, respectively. The premium paid to purchase held-to-maturity investment securities was $<ix:nonFraction id="c73543945" contextRef="d_2020-01-01_2020-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" scale="0" format="ixt:numdotdecimal" decimals="INF">282,946</ix:nonFraction> for the year ended&#xa0;<em style="font: inherit;"> December 31, 2020</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company&#x2019;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than <em style="font: inherit;">not</em> the Company will be required to sell the investment before recovery of the investment&#x2019;s cost basis. As of&#xa0;<em style="font: inherit;"> March 31, 2021</em>, the Company does <em style="font: inherit;">not</em> consider any of its investments to be other-than-temporarily impaired.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c1856462" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3:</em></b>&#xa0;&#xa0;&#xa0;&#xa0;<b>Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-Held Companies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>BDI&#xa0;</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> June 30, 2017, </em>the Company entered into a strategic Research Services Agreement (the &#x201c;RSA&#x201d;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#x201c;BDI Pharma&#x201d;), and a Service Framework Agreement (the &#x201c;SFA&#x201d;, and together with the RSA, the &#x201c;R&amp;D Agreements&#x201d;), with VLP The Vaccines Company, S.L.U. (&#x201c;VLPbio&#x201d;), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#x201c;BDI Holdings&#x201d; and together with BDI Pharma and VLPbio, &#x201c;BDI&#x201d;).&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a <span style="-sec-ix-hidden:c73544044">two</span>-year period, with a focus on advancing Dyadic&#x2019;s proprietary <em style="font: inherit;">C1</em> technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#x2019;s previous <em style="font: inherit;">C1</em> gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#x2019;s proprietary <em style="font: inherit;">C1</em> technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Upon closing of the BDI transaction, the Company paid EUR <em style="font: inherit;">&#x20ac;1.0</em> million (the &#x201c;RSA Initial Payment&#x201d;) in cash to engage BDI to develop designated <em style="font: inherit;">C1</em> based product candidates and further improve the <em style="font: inherit;">C1</em> manufacturing process, in consideration of which Dyadic also received a <ix:nonFraction id="c73544052" contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember" unitRef="Pure" name="dyai:CollaborativeArrangementEquityInterestAcquired" scale="-2" format="ixt:numdotdecimal" decimals="3">16.1</ix:nonFraction>% equity interest in BDI Holdings and a <ix:nonFraction id="c73544053" contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-VLPbioMember" unitRef="Pure" name="dyai:CollaborativeArrangementEquityInterestAcquired" scale="-2" format="ixt:numdotdecimal" decimals="3">3.3</ix:nonFraction>% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR <span style="-sec-ix-hidden:c73544054">&#x20ac;936,000</span> over <span style="-sec-ix-hidden:c73544055">two</span> years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between <ix:nonFraction id="c73544056" contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember" unitRef="Pure" name="dyai:CollaborativeArrangementRevenueSharingPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% and <ix:nonFraction id="c73544057" contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MaximumMember" unitRef="Pure" name="dyai:CollaborativeArrangementRevenueSharingPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">75</ix:nonFraction>% of the net income from such selected product, depending upon the amount of BDI&#x2019;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR <span style="-sec-ix-hidden:c73544058">&#x20ac;1</span>&#xa0;million for a <ix:nonFraction id="c73544059" contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember" unitRef="Pure" name="dyai:CollaborativeArrangementRevenueSharingPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% share and EUR <em style="font: inherit;">&#x20ac;<span style="-sec-ix-hidden:c73544061">8.0</span></em> million for a <ix:nonFraction id="c73544062" contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MaximumMember" unitRef="Pure" name="dyai:CollaborativeArrangementRevenueSharingPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">75</ix:nonFraction>% share. If BDI does <em style="font: inherit;">not</em> enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR <span style="-sec-ix-hidden:c73544064">&#x20ac;1.5</span>&#xa0;million of the net income from Dyadic&#x2019;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $<ix:nonFraction id="c73544065" contextRef="i_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember" unitRef="USD" name="dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction> million (the &#x201c;SFA Commitment&#x201d;) in contract research services specified by Dyadic over <span style="-sec-ix-hidden:c73544066">two</span> years since the closing of the BDI transaction.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has concluded that BDI is <em style="font: inherit;">not</em> a Variable Interest Entity (&#x201c;VIE&#x201d;), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is <em style="font: inherit;">not</em> the primary beneficiary of BDI as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of BDI or its operations. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investments in BDI, and the financial results of BDI are <em style="font: inherit;">not</em> included in the Company&#x2019;s consolidated financial results.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD <em style="font: inherit;"><span style="-sec-ix-hidden:c73544074">$1.1</span></em> million (EUR <em style="font: inherit;">&#x20ac;1.0</em> million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $<ix:nonFraction id="c73544075" contextRef="i_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember" unitRef="USD" name="dyai:CollaborativeArrangementOutstandingCommitment" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction> million paid by Dyadic were expensed as the related research services were performed by BDI. In <em style="font: inherit;"> June 2019, </em>BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA in <em style="font: inherit;">2019.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> February 18, 2021, </em>the Company entered into a separate service agreement with BDI to perform a research&#xa0;project unrelated to the R&amp;D Agreements.&#xa0;For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, approximately&#xa0;$<ix:nonFraction id="c73544078" contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-BDIMember_TypeOfArrangementAxis-ServiceAgreementToPerformResearchProjectMember" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:numdotdecimal" decimals="INF">15,000</ix:nonFraction> recorded in the cost of research and development revenue was associated with this new service agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Novovet and Luina Bio&#xa0;</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> April 26, 2019, </em>the Company entered into a sub-license agreement (the &#x201c;Luina Bio Sub-License Agreement&#x201d;) with Luina Bio Pty Ltd. (&#x201c;Luina Bio&#x201d;) and Novovet Pty Ltd (&#x201c;Novovet&#x201d;). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on <em style="font: inherit;"> December 31, 2015, </em>a worldwide sub-license to certain patent rights and know-how related to&#xa0;Dyadic&#x2019;s proprietary <em style="font: inherit;">C1</em> gene expression platform&#xa0;for the exclusive and sole purpose of commercializing&#xa0;certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a <ix:nonFraction id="c73544081" contextRef="i_2019-04-26_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-NovovetMember" unitRef="Pure" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% equity interest in Novovet (&#x201c;Novovet Up-Front Consideration&#x201d;) in accordance with the terms of Novovet&#x2019;s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic&#x2019;s proprietary <em style="font: inherit;">C1</em> gene expression platform.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does <em style="font: inherit;">not</em> have sufficient equity to finance its activities without additional financial support from <em style="font: inherit;">third</em> party investors or lenders. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of Novovet as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will <em style="font: inherit;">not</em> consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but <em style="font: inherit;">not</em> control, over Novovet.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date Novovet has <em style="font: inherit;">not</em> raised the capital required to move this opportunity forward, and therefore, the Company has <em style="font: inherit;">not</em> transferred its <em style="font: inherit;">C1</em> technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a <ix:nonFraction id="c73544092" contextRef="i_2019-04-26_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-NovovetMember" unitRef="Pure" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% equity interest in Novovet, does <em style="font: inherit;">not</em> yet meet the revenue recognition criteria under ASC <em style="font: inherit;">606.</em> The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its <em style="font: inherit;">C1</em> technology is completed and Novovet receives adequate financing required to commence its research and development activities.&#xa0;The Company intends to terminate the Luina Bio Sub-License Agreement in <em style="font: inherit;">2021</em> should Novovet be unable to raise the required funding.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Alphazyme&#xa0;</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> May 5, 2019, </em>the Company entered into a sub-license agreement (the &#x201c;Alphazyme Sub-License Agreement&#x201d;) with Alphazyme, LLC (&#x201c;Alphazyme&#x201d;). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on <em style="font: inherit;"> December 31, 2015, </em>a sub-license to certain patent rights and know-how related to&#xa0;Dyadic&#x2019;s proprietary <em style="font: inherit;">C1</em> gene expression platform&#xa0;for the purpose of commercializing&#xa0;certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> June 24, 2020, </em>the Company entered into an Amended and Restated Non-Exclusive Sub-License Agreement (the &#x201c;Amended Sub-License Agreement&#x201d;) with Alphazyme.&#xa0;Pursuant to the Amended Sub-License Agreement and in consideration of Dyadic&#x2019;s transfer of its <em style="font: inherit;">C1</em> technology, Alphazyme issued&#xa0;<ix:nonFraction id="c73544099" contextRef="d_2020-06-24_2020-06-24_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember" unitRef="Pure" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" format="ixt:numdotdecimal" decimals="3">2.50</ix:nonFraction>% of the Class A shares of Alphazyme to Dyadic, and Dyadic became a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company has agreed to certain customary rights, covenants and obligations. In addition, and subject to achieving certain milestones, Alphazyme is obligated to pay a potential milestone payment and royalties, based on net sales, if any, which incorporate Dyadic&#x2019;s proprietary <em style="font: inherit;">C1</em> gene expression platform.&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> December 1, 2020, </em>the Company entered into an Amended and Restated Limited Liability Company Agreement with Alphazyme (the &#x201c;Amended Alphazyme LLC Agreement&#x201d;) was entered into.&#xa0;Under the Amended Alphazyme LLC Agreement,&#xa0;Alphazyme obtained an additional capital contribution&#xa0;and Dyadic&#x2019;s ownership was diluted to <ix:nonFraction id="c73544101" contextRef="i_2020-12-01_OwnershipAxis-AlphazymeMember" unitRef="Pure" name="dyai:OwnershipPercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">1.99</ix:nonFraction>%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of Alphazyme as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investment&#xa0;in Alphazyme. The Company reports&#xa0;its investment in Alphazyme under the cost method of accounting, given that it does <em style="font: inherit;">not</em> have the ability to exercise significant influence or control,</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company recorded a gain of <span style="-sec-ix-hidden:c73544106">$284,709</span> from&#xa0;its investment in Alphazyme as a result of a <em style="font: inherit;">third</em>-party additional capital contribution obtained by Alphazyme.&#xa0;As of <em style="font: inherit;">March31,</em>&#xa0;<em style="font: inherit;">2021</em>, the Company does <em style="font: inherit;">not</em> consider its&#xa0;investment in Alphazyme to be impaired.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>IDBiologics, Inc.</i></b>&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> July 8, 2020, </em>the Company entered into a Common Stock Purchase Agreement (the &#x201c;IDBiologics Agreement&#x201d;) with IDBiologics, Inc (&#x201c;IDBiologics&#x201d;). IDBiologics is a private biotechnology company focused on the development of human monoclonal antibodies for the treatment and prevention of serious infectious diseases. The Company was founded in <em style="font: inherit;">2017</em> and seeded by Vanderbilt University Medical Center&#xa0;in response to the repeated threats of epidemics around the world, including Ebola in West Africa and Zika in the Americas. IDBiologics is developing a portfolio of monoclonal antibodies against SARS-CoV-<em style="font: inherit;">2,</em> influenza and Zika viruses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under the term of the IDBiologics Agreement, Dyadic agreed to receive <ix:nonFraction id="c73544114" contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember" unitRef="Share" name="dyai:CollaborativeArrangementNumberOfSharesToBeReceived" scale="0" format="ixt:numdotdecimal" decimals="INF">129,611</ix:nonFraction> shares of IDBiologics&#x2019; common stock, which represent <ix:nonFraction id="c73544115" contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember" unitRef="Pure" name="dyai:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" format="ixt:numdotdecimal" decimals="4">0.37</ix:nonFraction>% of IDBiologics&#x2019; outstanding equity, in exchange for the services to be provided by Dyadic. Such services&#xa0;include the use of Dyadic&#x2019;s <em style="font: inherit;">C1</em> technology to express a SARS-CoV-<em style="font: inherit;">2</em> monoclonal antibody which IDBiologics&#xa0;licensed from the Vanderbilt Vaccine Center. The shares of common stock of IDBiologics vested <ix:nonFraction id="c73544118" contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="dyai:CollaborativeArrangementVestingPercentages" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% upon the signing of the IDBiologics Agreement,&#xa0;<ix:nonFraction id="c73544119" contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" name="dyai:CollaborativeArrangementVestingPercentages" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% will vest upon the completion of Step <em style="font: inherit;">3</em> of a feasibility study required by the IDBiologics Agreement, and <ix:nonFraction id="c73544121" contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheThreeMember" unitRef="Pure" name="dyai:CollaborativeArrangementVestingPercentages" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% will vest at the end of the project.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company evaluated the nature of its equity interest in IDBiologics and determined that IDBiologics is a VIE due to the capital structure of the entity. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of IDBiologics as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of IDBiologics that most significantly impact the VIE. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investment in IDBiologics. Upon receipt its shares, Dyadic will account for the equity interest in IDBiologics under the cost method. <em style="font: inherit;">No</em> revenue from the IDBiologics Agreement was recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March&#xa0;</em><em style="font: inherit;">31,</em>&#xa0;<em style="font: inherit;">2021</em>, because the amount of consideration received was immaterial.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c1856463" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;"></div></div></div></div></ix:exclude><ix:exclude><div class="PGFTR" style="text-align: center; width: 100%"><div class="hf-row"><div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4:</em></b>&#xa0;&#xa0;&#xa0;&#xa0;<b>Commitments and Contingencies</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are <em style="font: inherit;">not</em> currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of <em style="font: inherit;">one</em> or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#x2019;s consolidated financial position, cash flows or results of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c1856464" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5:</em></b>&#xa0;&#xa0;&#xa0;&#xa0;<b>Share-Based Compensation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Description of Equity Plans</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The <em style="font: inherit;">2011</em> Equity Incentive Plan (the <em style="font: inherit;">&#x201c;2011</em> Plan&#x201d;) was adopted by the Company&#x2019;s Board of Directors on <em style="font: inherit;"> April 28, 2011 </em>and approved by the Company&#x2019;s stockholders on <em style="font: inherit;"> June 15, 2011. </em>The <em style="font: inherit;">2011</em> Plan serves as the successor to the Company&#x2019;s <em style="font: inherit;">2006</em> Stock Option Plan (the <em style="font: inherit;">&#x201c;2006</em> Plan&#x201d;). Since the effective date of the <em style="font: inherit;">2011</em> Plan, all equity awards were made from the <em style="font: inherit;">2011</em> Plan, and <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2006</em> plan. Under the <em style="font: inherit;">2011</em> Plan, <ix:nonFraction id="c73544158" contextRef="i_2011-04-28_PlanNameAxis-The2011PlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000,000</ix:nonFraction> shares of the Company&#x2019;s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the <em style="font: inherit;">2006</em> Plan or are subject to awards under the <em style="font: inherit;">2006</em> Plan which are forfeited or lapse unexercised and which following the effective date are <em style="font: inherit;">not</em> issued under the <em style="font: inherit;">2006</em> Plan. In accordance with the provisions of the <em style="font: inherit;">2011</em> Plan, the Board of Directors approved an increase of <ix:nonFraction id="c73544164" contextRef="d_2019-01-01_2019-01-01_PlanNameAxis-The2011PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction> shares to the plan on <em style="font: inherit;"> January 1, 2019 </em>and <em style="font: inherit;">2020.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">At our <em style="font: inherit;">2021</em> Virtual Annual Meeting of Shareholders (&#x201c;Annual Meeting&#x201d;) to be held on <em style="font: inherit;"> June 11, 2021, </em>shareholders will be asked to approve the Company&#x2019;s&#xa0;<em style="font: inherit;">2021</em> Equity Incentive Award Plan (the <em style="font: inherit;">&#x201c;2021</em> Plan&#x201d;), which was adopted, subject to shareholder approval, by the Board of Directors on <em style="font: inherit;"> April 9, 2021. </em>We are seeking&#xa0;stockholder approval of the <em style="font: inherit;">2021</em> Plan to increase the number of shares available for the grant of stock options, restricted stock awards and other awards by&#xa0;<ix:nonFraction id="c73545121" contextRef="d_2021-04-16_2021-04-16_PlanNameAxis-The2011PlanMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000,000</ix:nonFraction>&#xa0;in addition to&#xa0;the number of shares remaining available for the grant of new awards under the <em style="font: inherit;">2011</em>&#xa0;Plan as of <em style="font: inherit;"> April 16, 2021. </em>If this&#xa0;proposal is approved by our shareholders, the <em style="font: inherit;">2021</em> Plan will become effective as of the date of the Annual Meeting and as of such date, <em style="font: inherit;">no</em> additional awards will be&#xa0;granted under the <em style="font: inherit;">2011</em> Plan. If our shareholders do <em style="font: inherit;">not</em> approve this proposal, the <em style="font: inherit;">2021</em> Plan will <em style="font: inherit;">not</em> become effective and the <em style="font: inherit;">2011</em> Plan will continue to be effective in&#xa0;accordance with its terms, until its expiration date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of&#xa0;<em style="font: inherit;"> March 31, 2021</em>, the Company had <ix:nonFraction id="c73544177" contextRef="i_2021-03-31_PlanNameAxis-The2011PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">5,324,215</ix:nonFraction> stock options outstanding and an additional <ix:nonFraction id="c73544178" contextRef="i_2021-03-31_PlanNameAxis-The2011PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">1,388,386</ix:nonFraction>&#xa0;shares of common stock available for grant under the <em style="font: inherit;">2011</em> Plan. As of&#xa0;<em style="font: inherit;"> December 31, 2020</em>, there were <ix:nonFraction id="c73544180" contextRef="i_2020-12-31_PlanNameAxis-The2011PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">4,638,390</ix:nonFraction> stock options outstanding and <ix:nonFraction id="c73544181" contextRef="i_2020-12-31_PlanNameAxis-The2011PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">2,134,211</ix:nonFraction> shares of common stock available for grant under the <em style="font: inherit;">2011</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock Options </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company&#x2019;s <em style="font: inherit;">2011</em> Plan is <span style="-sec-ix-hidden:c73544184">ten</span> years except for certain options granted to the contractors which are <span style="-sec-ix-hidden:c73544185">one</span> or <span style="-sec-ix-hidden:c73544186">three</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Risk-free interest rate</i>. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected dividend yield</i>. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does <em style="font: inherit;">not</em> currently anticipate paying any in the foreseeable future.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected stock price volatility.</i> The expected stock price volatility was calculated based on the Company&#x2019;s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company&#x2019;s historical volatility since <em style="font: inherit;">2016,</em> as the DuPont Transaction resulted in significant changes in the Company&#x2019;s business and capital structure.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Expected life of option. </i>The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., <span style="-sec-ix-hidden:c73544190">5</span> or <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c73544191" format="ixt-sec:duryear">10</ix:nonNumeric> years) and certain contractors (i.e., <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_OwnershipAxis-ContractorMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c73544192" format="ixt-sec:duryear">2</ix:nonNumeric> or <em style="font: inherit;"><span style="-sec-ix-hidden:c73544194">3</span>years</em>).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The assumptions used in the Black-Scholes option pricing model for stock options granted during the&#xa0;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em> are as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c1856465" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544227" contextRef="d_2021-01-01_2021-03-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="4">0.13</ix:nonFraction>%-<ix:nonFraction id="c73544229" contextRef="d_2021-01-01_2021-03-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="4">0.55</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;%</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544233" contextRef="d_2021-01-01_2021-03-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="4">54.52</ix:nonFraction>%-<ix:nonFraction id="c73544235" contextRef="d_2021-01-01_2021-03-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="4">56.07</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c73544236" format="ixt-sec:duryear">2.00</ix:nonNumeric>-<ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c73544238" format="ixt-sec:duryear">6.25</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes the stock option activities during the&#xa0;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c1856466" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term (Years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544251" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">4,638,390</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544252" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.44</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c73544253" format="ixt-sec:duryear">5.64</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544254" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">13,701,610</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544255" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">745,825</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544256" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.25</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73544259" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">60,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544260" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.93</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544263" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544264" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73544267" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73544268" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544271" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">5,324,215</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544272" contextRef="i_2021-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.84</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c73544273" format="ixt-sec:duryear">6.03</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544274" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">14,209,431</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 44%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 10%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 11%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 13%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 10%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544275" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">4,016,141</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544276" contextRef="i_2021-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.28</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c73544277" format="ixt-sec:duryear">5.09</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544278" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" format="ixt:numdotdecimal" decimals="INF">12,927,908</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">_________________</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">1</em>) Represents the following stock options granted:</p>
   <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2022;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Annual share-based compensation awards on <em style="font: inherit;"> January 4,&#xa0;</em><em style="font: inherit;">2021</em>, including: (a) <ix:nonFraction id="c73544199" contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">417,500</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction id="c73544200" contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.16</ix:nonFraction> per share granted to executives and key personnel, upon <span style="-sec-ix-hidden:c73544201">one</span> year anniversary, or vesting&#xa0;annually in equal installments over <span style="-sec-ix-hidden:c73544202">four</span> years, (b) <ix:nonFraction id="c73544203" contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">227,500</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction id="c73544204" contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-DirectorMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.16</ix:nonFraction> per share granted to members of the Board of Directors, vesting upon <span style="-sec-ix-hidden:c73544205">one</span> year anniversary, (c) <ix:nonFraction id="c73544206" contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-EmployeesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">23,325</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction id="c73544207" contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-EmployeesMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.16</ix:nonFraction> per share granted to employees, vesting annually in equal installments over <span style="-sec-ix-hidden:c73544208">four</span> years and (d) <ix:nonFraction id="c73544209" contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ConsultantMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction id="c73544210" contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ConsultantMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.16</ix:nonFraction> per share granted to a consultant, vesting upon <span style="-sec-ix-hidden:c73544211">one</span> year anniversary.</p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2022;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> January 8,&#xa0;</em><em style="font: inherit;">2021</em>, <ix:nonFraction id="c73544213" contextRef="d_2021-01-08_2021-01-08_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">35,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction id="c73544214" contextRef="d_2021-01-08_2021-01-08_TitleOfIndividualAxis-DirectorMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.50</ix:nonFraction> per share granted to a new member of the Board of Directors, vesting in <span style="-sec-ix-hidden:c73544215">one</span> year from the grant date.</p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2022;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> January 21, 2021, </em><ix:nonFraction id="c73544216" contextRef="d_2021-01-21_2021-01-21_TitleOfIndividualAxis-ConsultantMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">7,500</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction id="c73544217" contextRef="d_2021-01-21_2021-01-21_TitleOfIndividualAxis-ConsultantMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.65</ix:nonFraction> per share granted to a consultant, vesting in <span style="-sec-ix-hidden:c73544218">one</span> year from the grant date.</p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2022;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> March 22, 2021, </em><ix:nonFraction id="c73544219" contextRef="d_2021-03-22_2021-03-22_TitleOfIndividualAxis-ConsultantMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">30,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction id="c73544220" contextRef="d_2021-03-22_2021-03-22_TitleOfIndividualAxis-ConsultantMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.87</ix:nonFraction> per share granted to a consultant, vesting in <span style="-sec-ix-hidden:c73544221">one</span> year from the grant date.</p> </td></tr>
</tbody></table>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 27pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">2</em>) Represents the following stock options exercised:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#xa0;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td><td> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">A total of <ix:nonFraction id="c73544223" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">60,000</ix:nonFraction> stock options exercised with a weighted average exercise price of $<ix:nonFraction id="c73544224" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.93</ix:nonFraction>.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Compensation Expenses</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had <em style="font: inherit;">no</em> impact on the Company&#x2019;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Total non-cash stock option compensation expense was allocated among the following expense categories:&#xa0;&#xa0;&#xa0;&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="c1856467" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544283" contextRef="d_2021-01-01_2021-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">377,052</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544284" contextRef="d_2020-01-01_2020-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">380,251</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73544285" contextRef="d_2021-01-01_2021-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">44,019</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73544286" contextRef="d_2020-01-01_2020-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">46,688</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544287" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">421,071</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c73544288" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">426,939</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c1856468" escape="true">
   <b>Note <em style="font: inherit;">6:</em></b>&#xa0;&#xa0;&#xa0;&#xa0;
   <b>Shareholders</b>&#x2019;
   <b> Equity</b>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Issuances of Common Stock</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the&#xa0;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, there were <ix:nonFraction id="c73544291" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">60,000</ix:nonFraction> shares of the Company&#x2019;s common stock issued as a result of the exercise of stock options with a weighted average issue price of $<ix:nonFraction id="c73544292" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.93</ix:nonFraction> per share. For the&#xa0;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020</em>, there were <ix:nonFraction id="c73544294" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction> shares of the Company&#x2019;s common stock issued as a result of the exercise of stock options with a weighted average issue price of $<ix:nonFraction id="c73544295" contextRef="d_2020-01-01_2020-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.78</ix:nonFraction> per share.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:54pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Changes in Stockholders Equity</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="CDEAAB20-0B0C-47BA-8DE6-95401D676DA8" escape="true" continuedAt="c8D3A585F-7B0C-4F42-9F23-439AB977324D">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2021 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544323" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,748</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73544324" contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544325" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">98,013,079</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73544326" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">50,676,351</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544327" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">28,446,561</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544328" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544329" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544330" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">421,071</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544331" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544332" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">421,071</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock issued</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544333" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">60</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544334" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544335" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">115,740</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544336" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544337" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">115,800</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73544338" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73544339" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73544340" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c73544341" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,294,949</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c73544342" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,294,949</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c73544343" contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,808</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(<ix:nonFraction id="c73544344" contextRef="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c73544345" contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">98,549,890</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(<ix:nonFraction id="c73544346" contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">53,971,300</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c73544347" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">25,688,483</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <ix:continuation id="c8D3A585F-7B0C-4F42-9F23-439AB977324D">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2020 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544358" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,613</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73544359" contextRef="i_2019-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544360" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">96,105,851</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c73544361" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">41,351,078</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544362" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">35,864,471</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544363" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544364" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544365" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">426,939</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c73544366" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73544367" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">426,939</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%">Stock issued</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"><ix:nonFraction id="c73544368" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"><ix:nonFraction id="c73544369" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"><ix:nonFraction id="c73544370" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">174,900</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"><ix:nonFraction id="c73544371" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt"><ix:nonFraction id="c73544372" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">175,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73544373" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73544374" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73544375" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c73544376" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,214,139</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c73544377" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,214,139</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c73544378" contextRef="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,713</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(<ix:nonFraction id="c73544379" contextRef="i_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c73544380" contextRef="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">96,707,690</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(<ix:nonFraction id="c73544381" contextRef="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">43,565,217</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c73544382" contextRef="i_2020-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">34,252,271</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Treasury Stock </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of&#xa0;<em style="font: inherit;"> March 31, 2021</em>, and&#xa0;<em style="font: inherit;"> December 31, 2020</em>, there were <ix:nonFraction id="c73544297" contextRef="i_2021-03-31" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:numdotdecimal" decimals="INF">12,253,502</ix:nonFraction> shares of common stock held in treasury, at a cost of approximately $<ix:nonFraction id="c73544298" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="6" format="ixt:numdotdecimal" decimals="-5">18.9</ix:nonFraction> million, representing the purchase price on the date the shares were surrendered to the Company.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Open Market Sale Agreement</i></b>&#x2120;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> August 13, 2020, </em>we entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we <em style="font: inherit;"> may </em>offer and sell, from time to time at our sole discretion, shares of our common stock, par value $<ix:nonFraction id="c73544299" contextRef="i_2020-08-13" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> per share, having an aggregate offering price of up to $<ix:nonFraction id="c73544300" contextRef="i_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember" unitRef="USD" name="dyai:SaleOfStockAuthorizedOfferingAmount" scale="6" format="ixt:numdotdecimal" decimals="-7">50.0</ix:nonFraction>&#xa0;million through Jefferies as our sales agent or principal.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have <em style="font: inherit;">not</em> and are <em style="font: inherit;">not</em> obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies <em style="font: inherit;"> may </em>sell shares of our common stock by any method permitted by law deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will pay Jefferies a commission equal to <ix:nonFraction id="c73544306" contextRef="i_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember" unitRef="Pure" name="dyai:SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" scale="-2" format="ixt:numdotdecimal" decimals="2">3.0</ix:nonFraction>% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $<ix:nonFraction id="c73544307" contextRef="i_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember" unitRef="USD" name="dyai:SaleOfStockReimbursableLegalExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction>, in addition to certain ongoing disbursements of Jefferies&#x2019; counsel, if required. The sale agreement will terminate upon the sale of all $<ix:nonFraction id="c73544308" contextRef="d_2020-08-13_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember" unitRef="USD" name="dyai:SaleOfStockTerminationAmountUnderAgreement" scale="6" format="ixt:numdotdecimal" decimals="-7">50.0</ix:nonFraction>&#xa0;million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-<em style="font: inherit;">3</em> filed with the SEC on <em style="font: inherit;"> August 13, 2020 </em>and declared effective by the SEC on <em style="font: inherit;"> August 25, 2020 </em>and the accompanying Prospectus, as supplemented by a Prospectus Supplement. As of the date of this filing, there have been <em style="font: inherit;">no</em> sales made under the Open Market Sale Agreement&#x2120;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-03-31" name="us-gaap:SubsequentEventsTextBlock" id="c1856471" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">7:</em></b>&#xa0;&#xa0;&#xa0;&#xa0;<b>Subsequent Events </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management continues to actively monitor the COVID-<em style="font: inherit;">19</em> pandemic and its development, and the possible effects on the Company&#x2019;s financial condition, liquidity, operations, vendors, industry, and workforce.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through <em style="font: inherit;"> May 13, 2021</em>, the date the consolidated financial statements were available to be issued. Management is <em style="font: inherit;">not</em> aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="managements" title="managements" href="#"></a>Item 2. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Management</b>&#x2019;<b>s Discussion and Analysis of Financial Condition and Results of Operations</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>The following discussion and analysis of financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this Quarterly Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, assumptions and uncertainties. Important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis include, but not limited to those set forth in </i>&#x201c;<i>Item 1A. Risk Factors</i>&#x201d;<i> in this Quarterly Report. All forward-looking statements included in this Quarterly Report are based on information available to us as of the time we file this Quarterly Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Description of Business</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dyadic International, Inc. (&#x201c;Dyadic&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, or the &#x201c;Company&#x201d;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly three research organizations performing services under contract to Dyadic in the Netherlands, Finland and Israel. Over the past two plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the <i>Thermothelomyces heterothallica </i>(formerly known as&#xa0;<i>Myceliophthora thermophila</i>) fungus, which the Company named C1. The C1 technology is a&#xa0;robust and versatile fungal expression system for the development and production of enzymes and other proteins.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On December 31, 2015, the Company sold its industrial technology business to Danisco USA (&#x201c;Danisco&#x201d;), the industrial biosciences business of DuPont (NYSE: DD)&#xa0;(the &#x201c;DuPont Transaction&#x201d;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs and other biological products at flexible commercial scales.&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company and its C1 technology played an important role in the &#x20ac;20 million Zoonosis Anticipation Preparedness Initiative (&#x201c;ZAPI&#x201d;) program, which was a five-year research and development program sponsored by the European Union. ZAPI brought together experts in human and animal health to create new platforms and technologies that will facilitate a fast, coordinated, and practical response to new pandemic threats as soon as they emerge. The Company&#x2019;s C1 gene expression and recombinant protein production platform was selected by ZAPI as a production host of antigens for the Schmallenberg virus (&#x201c;SBV&#x201d;) and Rift Valley Fever virus (&#x201c;RVFV&#x201d;). The C1 expressed SBV antigen was produced at approximately 300 times greater yield than the SBV antigen expressed from insect (baculovirus) cells and was more stable. Additionally, the C1 SBV antigen was shown to be safe and effective to provide full protection to&#xa0;cattle, sheep, and mice.&#xa0;Based on these results, ZAPI has provided the Company with additional funding, in 2021, to produce both the SBV and RVFV antigens in order to perform expanded animal trials&#xa0;with the C1 expressed antigens which is expected to generate additional safety and efficacy data. In the first quarter of 2021, ZAPI expanded its program with Dyadic by providing additional funding to C1 research and development efforts as well as to conduct additional animal studies using the SBV and RVFV antigens produced from C1. Several positive outcomes have already originated from the ZAPI results, including several fully funded animal health projects and a number of COVID-19 vaccine collaborations, including Dyadic&#x2019;s proprietary receptor-binding domain (&#x201c;RBD&#x201d;) antigen of the SARS-CoV-2 spike protein, used in the production of the Company&#x2019;s proprietary COVID-19 DYAI-100 vaccine candidate. The C1 expressed SARS-CoV-2 RBD antigen has been&#xa0;developed and&#xa0;tested in various collaborations, including with three of the top infectious disease and coronavirus scientists who worked with Dyadic and C1 in the ZAPI consortium, the Israel Institute for Biological Research (&#x201c;IIBR&#x201d;), Medytox, Inc., and others. These activities have positioned the Company to determine its current path forward for an anticipated first-in-human Phase 1 clinical program of DYAI-100 which is anticipated to start in the second half of 2021.&#xa0;The main goal of the DYAI-100 Phase 1 clinical trial is to demonstrate that a protein produced from the Company&#x2019;s proprietary and patented C1-cells can be safely used in humans which we anticipate will help to accelerate the C1 technology platform&#x2019;s adoption, use and commercialization and also to serve as a proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based on a growing amount of safety, efficacy and productivity data from research and&#xa0;development programs within ZAPI, the IIBR and several&#xa0;internal and externally funded programs, we and a growing number of scientists globally believe that the C1 cell protein production platform can be used to speed the development, lower production costs, and improve the performance of biologic vaccines, drugs and other biological products which can be efficiently manufactured at flexible commercial scales more affordably. Based on these internally and externally funded C1-cell engineering programs, the number and types of potential vaccines, drugs and biologic products which may be developed and commercialized, continues to grow. Some examples of human and animal vaccines and drugs which have the potential to be produced from C1-cells are protein antigens, virus-like particles (&#x201c;VLPs&#x201d;), monoclonal antibodies (&#x201c;mAbs&#x201d;), Bi/Tri-specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies which are&#xa0;designed to leverage its C1 technology to&#xa0;develop innovative vaccines and drugs, biosimilars and/or biobetters.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b>Recent Developments </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In 2021, the Company continues to advance its internal research projects and expand its relationships with business and research partners in the biotech and pharmaceutical industry, academic and other institutions, as well as certain government agencies, as follows:&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;"><b><span style="text-decoration: underline; ">COVID-19 Initiatives:</span></b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Advancing the Company&#x2019;s proprietary COVID-19 vaccine candidate (C1 produced SARS-CoV-2-S-RBD antigen), DYAI-100, towards a first-in-human Phase 1 clinical trial:</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 54pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">DYAI-100 is supported by a strategic collaboration with, among other parties, the IIBR and leading infectious disease scientists from Erasmus Medical Centre, University Utrecht, TiHo Hannover (scientists who were involved in the ZAPI program) to develop a temperature stable, safe and effective COVID-19 vaccine candidate that can be rapidly manufactured, in large quantities, at low cost, using standard microbial fermenters that are readily available globally.</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 54pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In March 2021, the Company engaged CR2O, a contract research organization, to manage and support further preclinical and clinical development of DYAI-100.&#xa0;The animal GLP toxicology study began at the end of April 2021, the cGMP production of the C1 expressed SARS-CoV-2 RBD drug product has begun, and a first-in-human Phase 1 clinical trial is expected to begin by year-end.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 54pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">There are a number of benefits the Company expects to come from the DYAI-100 Phase 1 clinical trial, including demonstrating that certain C1 produced proteins can be produced under cGMP conditions and are safe and tolerated in humans, which will be required by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).&#xa0;Additionally, this will also serve as a proof of concept study for potential C1 manufactured next-generation monovalent and multivalent COVID-19 variant vaccine candidates that can be developed and manufactured rapidly, in large quantities, and more affordably.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In parallel with advancing the DYAI-100 vaccine candidate towards a Phase 1 clinical trial, the Company has already started to engineer several C1 cell lines to produce several SARS-CoV-2 variant antigens, and has successfully expressed the South African, Brazilian, and UK variant antigens at high productivity and stability. The Company and its collaborators are &#xa0;working to produce RBD antigen and full spike proteins for additional COVID-19 variants.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In March 2021, the Company expanded a vaccine development partnership with South Korea&#x2019;s Medytox Inc. to co-develop C1 enabled COVID-19 variant vaccines and/or boosters (e.g., tetravalent or quadrivalent COVID-19 vaccine candidates) to immunize people against two or more of the current and future COVID-19 variants in Korea and&#xa0;Southeast Asia.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In April 2021, the Company signed a separate fully funded research collaboration with CR2O to develop a COVID-19 antibody.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b><span style="text-decoration: underline; ">Human Health (Non-COVID) Collaborations:</span></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">In February 2021, the Company initiated a fully funded collaboration with TurtleTree Scientific to develop several recombinant protein growth factors, which have the potential to play a critical role in tissue development and healing, including regenerative therapies.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">In March 2021, the Company signed a research collaboration with a new research partner to develop an antigen.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">In April 2021, the Company expanded its collaboration with IDBiologics and started a new fully funded collaboration to develop a second antibody.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">Collaborating with Jiangsu Hengrui Medicine and two top pharmaceutical companies for proof of concept studies designed to improve the production of biologic drugs, including bispecific antibodies, of therapeutic interest. Interim results have demonstrated these biologic drugs were expressed from C1 and there are ongoing discussions for advancing some of these projects towards potential clinical development.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">Continued progress in several ongoing collaborations to develop potential therapeutic candidates of commercial potential, including expressing two new bispecific antibodies and advancing two other antibodies which are entering the second stages for applications in oncology and autoimmune disease.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; text-align: justify;">Conducting a feasibility study with the University of Oslo for a potential influenza vaccine. Interim results demonstrated that C1 can express hemagglutinin at a high level, and most importantly, that C1 hemagglutinin induced a high level response of neutralizing antibodies in a mice study.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b><span style="text-decoration: underline; ">Animal Health Collaborations:</span></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">In collaboration with a top global animal health company, initial studies have demonstrated production of two different antigens for a potential vaccine for an acute respiratory disease of birds. Interim results demonstrated that the antigens were effective at generating high antibody titers. An animal challenge study designed to evaluate protection against the acute respiratory disease is expected to start in June 2021.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">
     <td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 11pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 11pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">ZAPI held its Final Stakeholders Virtual Web Meeting on February 4-5, 2021, where positive results were reported from animal studies in mice, sheep, and cattle which evaluated the safety, efficacy, and protection of the C1 produced SBV&#xa0;antigen. The C1 platform was selected by ZAPI to produce recombinant antigens after demonstrating far greater antigen productivity from C1-cells than insect (baculovirus) cells, the next leading expression platform, for both SBV and RVFV. As previously disclosed, in the first quarter of 2021, ZAPI has provided the Company with additional funding to produce larger quantities of both the SBV and RVFV antigens&#xa0;to demonstrate commercial-scale viability of C1 produced SBV and RVFV antigens, and to further optimize the use of C1 to produce recombinant protein subunit nanoparticle vaccines. Preliminary results have been very encouraging and continues to further support C1&#x2019;s potential for use in developing nanoparticle vaccines in larger quantities at lower cost.<b> </b>Several positive outcomes have already originated from the ZAPI results, including several fully funded animal health projects and several SARS-CoV-2 vaccine collaborations, including Dyadic&#x2019;s RBD&#xa0;antigen of the SARS-CoV-2 spike protein.&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b><span style="text-decoration: underline; ">Corporate Highlights:</span></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company extended two non-exclusive research license agreements, including WuXi Biologics and an affiliate of a top pharma company, to continue their C1 research projects in a CDMO and manufacturing environment at their own facilities.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Hosted KOL Fireside Chat: &#x201c;The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges&#x201d;, which is available on the Investors section of the Company&#x2019;s website, which is available on the Investors section of the Company&#x2019;s website.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To date, the Company participated in several scientific conferences, including the recently held World Vaccine Conference, Protein Engineering and Cell Therapy Conference (PEGS) and the ZAPI Final Stakeholders Virtual Conference. ZAPI Stakeholders Final Conference speaker slides and webinar replay are now available on the IABS website&#xa0;via the following link:&#xa0;https://zapi-stakeholders-final-conference.iabs.org/conference-information.php?parag=slides</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Impact of COVID-19</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The outbreak of&#xa0;COVID-19 has led to adverse impacts on the U.S. and global economies and created uncertainty regarding the potential impact&#xa0;to the Company&#x2019;s employees, operations, and research projects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date, some of our employees are still working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV-2 variants and the actions taken and the level of success to contain or treat the SARS-CoV-2 virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business because of economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Open Market Sale Agreement</i></b>&#x2120;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On August 13, 2020, we entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have not and are not obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies may sell shares of our common stock by any method permitted by law deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies&#x2019; counsel, if required. The sale agreement will terminate upon the sale of all $50.0 million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-3 filed with the SEC on August 13, 2020 and declared effective by the SEC on August 25, 2020 and the accompanying Prospectus, as supplemented by a Prospectus Supplement. As of the date of this filing, there have been no sales made under the Open Market Sale Agreement&#x2120;.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Policies, Estimates, and Judgments </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Revenue Recognition</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Revenue related to research collaborations and agreements: </i>The Company typically&#xa0;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the input methods, revenue will be recognized on the basis of the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to grants: </i>The Company may receive grants&#xa0;from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to partially or fully fund the Company&#x2019;s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Milestone payments: </i>At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#x2019;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which sales-based royalties relate, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accrued Research and Development Expenses</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of accrued research and development expenses include amounts owed to contract research organizations, to service providers in connection with commercialization and development activities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have granted stock options and restricted stock to employees, directors and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and restricted stock and applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to the Company April 2019 uplisting to NASDAQ. We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option except in the case of our CEO, 5 or 10 years, and in the case of contractors, 2 or 3 years). The Company performs a review of assumptions used in the Black-Scholes option-pricing model on an annual basis. During the Company&#x2019;s annual review of its volatility assumption in 2018, the Company determined that it would be appropriate to use the Company&#x2019;s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company&#x2019;s business and capital structure. The change in assumption was effective January 1, 2018 and only impacts new options granted in 2018 and thereafter.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the options and restricted stock issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In connection with board member and employee terminations, the Company may modify certain terms to outstanding share-based awards. We have recorded charges related to these modifications based on the estimated fair value of the share-based options immediately prior to and immediately after the modification occurs, with any incremental value being charged to expense. We have used the Black-Scholes pricing model in this valuation process, and this requires management to use various assumptions and estimates. Future modifications to share-based compensation transactions may result in significant expenses being recorded in our consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounting for Income Taxes</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740 (&#x201c;Topic 740&#x201d;), &#x201c;Income Taxes&#x201d;. Under this method, income tax expense/(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#x2019;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In determining taxable income for the Company&#x2019;s consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#x2019;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is required to evaluate the provisions of Topic 740 related to the accounting for uncertainty in income taxes recognized in a company&#x2019;s financial statements. Topic 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#x201c;unrecognized benefits.&#x201d; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents a company&#x2019;s potential future obligation to the taxing authority for a tax position that was not recognized because of applying the provision of Topic 740.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Non-Marketable Investments</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do not have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which may include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company&#x2019;s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, may have no or limited revenues, may not be or may never become profitable, may not be able to secure additional funding or their technologies, services or products may not be successfully developed or introduced into the market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company bases its fair value estimates on assumptions it believes to be reasonable, but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Off-Balance Sheet Arrangements</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We do not have any off-balance sheet arrangements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Accounting Pronouncements </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">See Note 1 to the Consolidated Financial Statements for information about recent accounting pronouncements<i>.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Three Months Ended&#xa0;March 31, 2021 Compared to the Same Periods in&#xa0;2020 </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Revenue and Cost of Research and Development Revenue</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes the Company&#x2019;s revenue and cost of research and development revenue&#xa0;for the three months ended March 31, 2021 and 2020:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three</b> <b>Months</b> <b>Ended</b> <b>March 31,</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">460,520</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">315,372</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cost of research and development revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">390,762</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278,182</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The increase in revenue and cost of research and development revenue for the&#xa0;three months ended&#xa0;March 31, 2021, reflected the increased number of on-going research collaborations to&#xa0;eight compared to five collaborations for the same period a year ago.&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Research and Development Expenses</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development costs are expensed as incurred and primarily include salary and benefits of research personnel, third-party contract research organization services and supply costs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development expenses for the three months ended&#xa0;March 31, 2021&#xa0;increased to approximately $1,808,000&#xa0;compared to $755,000&#xa0;for the same period a year ago. The increase primarily reflected&#xa0;Phase 1 clinical trial cost of DYAI-100, our COVID-19 vaccine in the amount of&#xa0;$882,000 and an additional cost of $159,000 related to&#xa0;our other internal research&#xa0;projects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><b><i>General and Administrative Expenses</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">General and administrative expenses for the three months ended&#xa0;March 31, 2021, decreased 6.0% to approximately $1,554,000&#xa0;compared to $1,653,000&#xa0;for the same period a year ago. The decrease principally reflected&#xa0;reductions in travel and rent expenses of $65,000, insurance and other outside services of $47,000, other decrease of $30,000, offset by increase in legal expenses of $43,000.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Interest Income</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Interest income for the three months ended&#xa0;March 31, 2021 was approximately $26,000&#xa0;compared to $168,000&#xa0;for the same period a year ago. The decrease was primarily due to the lower balance&#xa0;of hold-to-maturity securities&#xa0;and less reinvestment&#xa0;as a result of the decrease in interest rate.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><b><i>Net Loss</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net loss for the three months ended&#xa0;March 31, 2021 was approximately $3,295,000&#xa0;compared to $2,214,000&#xa0;for the same period a year ago.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our primary source of cash has been the cash received from the DuPont Transaction in December 2015, interest income received from investment grade securities, and funding from our research collaboration agreements. The Company&#x2019;s liquidity was further improved with the receipt of an approximately $0.5 million tax refund in June 2019 and an approximately $0.5 million additional tax refund in July 2020 resulting from the elimination of corporate Alternative Minimum Tax (AMT) under the TCJA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our ability to achieve profitability depends on a number of factors, including our scientific results and our ability to continue to obtain funded research and development collaborations from industry and government programs, as well as sub-license agreements. We may continue to incur substantial operating losses even if we begin to generate revenues from research and development and licensing. Our primary future cash needs are expected to be for general operating activities, including our business development and research expenses, as well as additional costs as an SEC reporting and NASDAQ listed company.&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve (12) months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company may decide to fund all or part of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the C1 expression platform in humans. There is no assurance that external funding will be available at acceptable terms, if at all, and the Company may, therefore, self-fund these vital projects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On August 13, 2020, we entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock at an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal. This program adds to our financial flexibility to pursue additional opportunities that leverage the broad application potential of C1. However, as of the date of this filing, there have been no sales made under the Open Market Sale Agreement&#x2120;.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of&#xa0;March 31, 2021, cash and cash equivalents were approximately&#xa0;$13.1&#xa0;million compared to $20.6&#xa0;million as of&#xa0;December 31, 2020. The carrying value of investment grade securities, including accrued interest as of&#xa0;March 31, 2021 was approximately $14.3&#xa0;million compared to $8.6&#xa0;million as of&#xa0;December 31, 2020.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash used in operating activities for the&#xa0;three months ended March 31, 2021 of approximately $1.9&#xa0;million was principally attributable to a net loss of approximately $3.3&#xa0;million, partially offset by changes in operating assets and liabilities of approximately $0.9&#xa0;million, share-based compensation expenses of approximately $0.4&#xa0;million, and amortization of held-to-maturity securities of approximately $0.1&#xa0;million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash used in operating activities for the&#xa0;three months ended March 31, 2020 of approximately $2.0&#xa0;million was principally attributable to a net loss of approximately $2.2 million&#xa0;and changes in other operating assets and liabilities of approximately $0.3 million, offset by share-based compensation expense&#xa0;of approximately $0.4&#xa0;million, and amortization of held-to-maturity securities of approximately $0.1&#xa0;million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash used in investing activities for the&#xa0;three months ended March 31, 2021 was approximately $5.8&#xa0;million compared to a net cash provided by investing activity of&#xa0;$1.7&#xa0;million for the&#xa0;three months ended March 31, 2020. Cash flows from investing activities during the&#xa0;three months ended March 31, 2021 and 2020 were primarily related to proceeds from maturities and purchases of investment grade debt securities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash provided by&#xa0;financing activities for the&#xa0;three months ended March 31, 2020&#xa0;was approximately $116,000&#xa0;compared to $175,000&#xa0;for the three months ended March 31, 2020. Cash flows from financing activities during the three months ended March 31, 2021 and 2020 were primarily related to proceeds from exercise of options.</p>
  <div style="font-size: 10pt;">
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="quantitative" title="quantitative" href="#"></a>Item 3. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Quantitative and Qualitative Disclosures about Market Risk</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="controls" title="controls" href="#"></a>Item 4. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Controls and procedures</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. The term &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Changes in Internal Controls Over Financial Reporting</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There were no changes in our internal control over financial reporting that occurred during the&#xa0;three months ended March 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Inherent Limitation on Effectiveness of Controls</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="part2" title="part2" href="#"></a>PART II</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="legal" title="legal" href="#"></a>Item 1. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Legal Proceedings</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="risk" title="risk" href="#"></a>Item 1A. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Risk Factors</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There have been no changes to our risk factors from those disclosed in our Form 10-K for the&#xa0;2020 fiscal year filed on March&#xa0;30,&#xa0;2021.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b><a id="unregistered" title="unregistered" href="#"></a>Item 2. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b>Unregistered Sales of Equity Securities and Use of Proceeds</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="defaults" title="defaults" href="#"></a>Item 3. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Defaults Upon Senior Securities</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="minesafety" title="minesafety" href="#"></a>Item 4. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Mine Safety Disclosures</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="otherinfo" title="otherinfo" href="#"></a>Item 5. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Other Information</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 63pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><a id="exhibits" title="exhibits" href="#"></a>Item 6. </b></p> </td>
     <td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Exhibits</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr>
     <td style="width: 8%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 48%;">&#xa0;</td>
     <td style="width: 8%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td colspan="3" rowspan="1" style="width: 10%; text-align: center;">Incorporated by Reference</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 8%; border-bottom: thin solid rgb(0, 0, 0);">Exhibit No.</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 48%; border-bottom: thin solid rgb(0, 0, 0);">Description of Exhibit</td>
     <td style="width: 8%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);">Form</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; border-bottom: thin solid rgb(0, 0, 0); text-align: center;">Original No.</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 12%; border-bottom: thin solid rgb(0, 0, 0); text-align: center;">Date Filed</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 10%; border-bottom: thin solid rgb(0, 0, 0); text-align: center;">Filed Herewith</td>
    </tr>

    <tr>
     <td style="width: 8%; vertical-align: top;">1.1</td>
     <td style="width: 1%; vertical-align: top;">&#xa0;</td>
     <td style="width: 48%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000121380920000032/ex12jefferiesdyadic-sa.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Open Market Sale Agreement by and between the Company and Jeffries LLC, dated August 13, 2020</span></a></td>
     <td style="width: 8%; text-align: center;">S-3</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">1.2</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 12%; text-align: center;">August 13, 2020</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 8%; vertical-align: top;">10.1</td>
     <td style="width: 1%; vertical-align: top;">&#xa0;</td>
     <td style="width: 48%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774921009922/ex_238685.htm" style="-sec-extract:exhibit;">Dyadic International, Inc. 2021 Equity Inventive Award Plan</a></td>
     <td style="width: 8%; text-align: center;">DEF14A</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">10.1</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 12%; text-align: center;">April 27, 2021</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 8%; vertical-align: top;">31.1</td>
     <td style="width: 1%; vertical-align: top;">&#xa0;</td>
     <td style="width: 48%; vertical-align: top;"><a href="ex_237822.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Principal Executive Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td>
     <td style="width: 8%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 12%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="width: 8%; vertical-align: top;">31.2</td>
     <td style="width: 1%; vertical-align: top;">&#xa0;</td>
     <td style="width: 48%; vertical-align: top;"><a href="ex_237823.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Principal Financial Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td>
     <td style="width: 8%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 12%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="width: 8%; vertical-align: top;">32.1</td>
     <td style="width: 1%; vertical-align: top;">&#xa0;</td>
     <td style="width: 48%; vertical-align: top;"><a href="ex_237824.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Principal Executive Officer of Dyadic Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td>
     <td style="width: 8%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 12%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="width: 8%; vertical-align: top;">32.2</td>
     <td style="width: 1%; vertical-align: top;">&#xa0;</td>
     <td style="width: 48%; vertical-align: top;"><a href="ex_237825.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Principal Financial Officer of Dyadic Pursuant to18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td>
     <td style="width: 8%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 12%; text-align: center;">&#xa0;</td>
     <td style="width: 1%; text-align: center;">&#xa0;</td>
     <td style="width: 10%; text-align: center;">x</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr>
     <td style="width: 14%; vertical-align: top; text-align: center;"><b>Exhibit No.</b></td>
     <td style="width: 86%; vertical-align: top;"><b>Description</b></td>
    </tr>

    <tr>
     <td style="width: 14%; vertical-align: top; text-align: center;">101.INS</td>
     <td style="width: 86%; vertical-align: top;">Inline XBRL Instance Document</td>
    </tr>

    <tr>
     <td style="width: 14%; vertical-align: top; text-align: center;">101.SCH</td>
     <td style="width: 86%; vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document</td>
    </tr>

    <tr>
     <td style="width: 14%; vertical-align: top; text-align: center;">101.CAL</td>
     <td style="width: 86%; vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td>
    </tr>

    <tr>
     <td style="width: 14%; vertical-align: top; text-align: center;">101.DEF</td>
     <td style="width: 86%; vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document</td>
    </tr>

    <tr>
     <td style="width: 14%; vertical-align: top; text-align: center;">101.LAB</td>
     <td style="width: 86%; vertical-align: top;">Inline XBRL Taxonomy Extension Labels Linkbase Document</td>
    </tr>

    <tr>
     <td style="width: 14%; vertical-align: top; text-align: center;">101.PRE</td>
     <td style="width: 86%; vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td>
    </tr>

    <tr>
     <td style="width: 14%; vertical-align: top; text-align: center;">104</td>
     <td style="width: 86%; vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="signatures" title="signatures" href="#"></a>SIGNATURES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td colspan="9" style="vertical-align: middle; width: 40%;">&#xa0;</td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: bottom; width: 33%;">&#xa0;</td>
     <td colspan="6" style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DYADIC INTERNATIONAL, INC.</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: bottom; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 60%;">&#xa0;</td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: bottom; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 13, 2021</p> </td>
     <td colspan="3" style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p> </td>
     <td colspan="3" style="vertical-align: bottom; width: 60%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Mark A. Emalfarb</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: bottom; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mark A. Emalfarb</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: bottom; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: middle; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: middle; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: middle; width: 60%;">&#xa0;</td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: middle; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: middle; width: 60%;">&#xa0;</td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: bottom; width: 33%;">May 13, 2021</td>
     <td colspan="3" style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p> </td>
     <td colspan="3" style="vertical-align: bottom; width: 60%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Ping W. Rawson</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: middle; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ping W. Rawson</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: middle; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="vertical-align: middle; width: 33%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: middle; width: 7%;">&#xa0;</td>
     <td colspan="3" style="vertical-align: bottom; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex_237822.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/29/2021 1:12:24 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_237822.htm</title>

</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit</b>&nbsp;<b>31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Certification of Principal Executive Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>and Securities and Exchange Commission Release 34-46427</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Mark A. Emalfarb, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">1.</td>
			<td style="width: 94%; vertical-align: top;">I have reviewed this quarterly report on Form 10-Q of Dyadic International Inc.;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 94%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">2.</td>
			<td style="width: 94%; vertical-align: top;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 94%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">3.</td>
			<td style="width: 94%; vertical-align: top;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 94%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">4.</td>
			<td style="width: 94%; vertical-align: top;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and we have:</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 94%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">5.</td>
			<td style="width: 94%; vertical-align: top;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and we have:</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">a.</td>
			<td style="width: 88%; vertical-align: top;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">b.</td>
			<td style="width: 88%; vertical-align: top;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">c.</td>
			<td style="width: 88%; vertical-align: top;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">d.</td>
			<td style="width: 88%; vertical-align: top;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">6.</td>
			<td style="width: 94%; vertical-align: top;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">a.</td>
			<td style="width: 88%; vertical-align: top;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">a.</td>
			<td style="width: 88%; vertical-align: top;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 14%;">Date:</td>
			<td style="width: 86%;"><a data-tblloc="20x1" data-tblname="128711" data-tblv="40" id="led128711F20213201618944780368">May 13, 2021</a></td>
		</tr>
		<tr>
			<td style="width: 14%;">By:</td>
			<td style="width: 86%;">/s/&nbsp;&nbsp;&nbsp;Mark A. Emalfarb</td>
		</tr>
		<tr>
			<td style="width: 14%;">&nbsp;</td>
			<td style="width: 86%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 14%;">Name:</td>
			<td style="width: 86%;">Mark A. Emalfarb</td>
		</tr>
		<tr>
			<td style="width: 14%;">Title:</td>
			<td style="width: 86%;">Chief Executive Officer</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex_237823.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/29/2021 1:14:06 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_237823.htm</title>

</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit</b>&nbsp;<b>31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Certification of Principal Executive Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>and Securities and Exchange Commission Release 34-46427</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Ping W. Rawson, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">1.</td>
			<td style="width: 94%; vertical-align: top;">I have reviewed this quarterly report on Form 10-Q of Dyadic International Inc.;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 94%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">2.</td>
			<td style="width: 94%; vertical-align: top;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 94%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">3.</td>
			<td style="width: 94%; vertical-align: top;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 94%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">4.</td>
			<td style="width: 94%; vertical-align: top;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and we have:</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">a.</td>
			<td style="width: 88%; vertical-align: top;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">b.</td>
			<td style="width: 88%; vertical-align: top;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">c.</td>
			<td style="width: 88%; vertical-align: top;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">d.</td>
			<td style="width: 88%; vertical-align: top;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">5.</td>
			<td style="width: 94%; vertical-align: top;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">a.</td>
			<td style="width: 88%; vertical-align: top;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 88%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">b.</td>
			<td style="width: 88%; vertical-align: top;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 14%;">Date:</td>
			<td style="width: 86%;"><a data-tblloc="20x1" data-tblname="128711" data-tblv="40" id="led128711F20213201618944822536">May 13, 2021</a></td>
		</tr>
		<tr>
			<td style="width: 14%;">By:</td>
			<td style="width: 86%;">/s/&nbsp;&nbsp;&nbsp;Ping W. Rawson</td>
		</tr>
		<tr>
			<td style="width: 14%;">&nbsp;</td>
			<td style="width: 86%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 14%;">Name:</td>
			<td style="width: 86%;">Ping W. Rawson</td>
		</tr>
		<tr>
			<td style="width: 14%;">Title:</td>
			<td style="width: 86%;">Chief Financial Officer</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex_237824.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/29/2021 1:15:02 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_237824.htm</title>

</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the Quarterly Report of Dyadic International Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended <a data-tblloc="5x1" data-tblname="128711" data-tblv="40" id="led128711F20213201618944885845">March 31, 2021</a>&nbsp;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mark A. Emalfarb, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 14%;">Date:</td>
			<td style="width: 86%;"><a data-tblloc="20x1" data-tblname="128711" data-tblv="40" id="led128711F20213201618944857066">May 13, 2021</a></td>
		</tr>
		<tr>
			<td style="width: 14%;">By:</td>
			<td style="width: 86%;">/s/&nbsp;&nbsp;&nbsp;Mark A. Emalfarb</td>
		</tr>
		<tr>
			<td style="width: 14%;">&nbsp;</td>
			<td style="width: 86%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 14%;">Name:&nbsp;</td>
			<td style="width: 86%;">Mark A. Emalfarb</td>
		</tr>
		<tr>
			<td style="width: 14%;">Title:</td>
			<td style="width: 86%;">Chief Executive Officer</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex_237825.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/29/2021 1:15:36 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_237825.htm</title>

</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the Quarterly Report of Dyadic International Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended <a data-tblloc="5x1" data-tblname="128711" data-tblv="40" id="led128711F20213201618944923924">March 31, 2021</a>&nbsp;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Ping W. Rawson, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 14%;">Date:</td>
			<td style="width: 86%;"><a data-tblloc="20x1" data-tblname="128711" data-tblv="40" id="led128711F20213201618944955952">May 13, 2021</a></td>
		</tr>
		<tr>
			<td style="width: 14%;">By:</td>
			<td style="width: 86%;">/s/&nbsp;&nbsp;&nbsp;Ping W. Rawson</td>
		</tr>
		<tr>
			<td style="width: 14%;">&nbsp;</td>
			<td style="width: 86%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 14%;">Name:</td>
			<td style="width: 86%;">Ping W. Rawson</td>
		</tr>
		<tr>
			<td style="width: 14%;">Title:</td>
			<td style="width: 86%;">Chief Financial Officer</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>dyai-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:13PM UTC 2021-05-13--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dyai="http://www.dyadic.com/20210331" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dyadic.com/20210331">
  <xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.dyadic.com/20210331/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited-" roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-unaudited" roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-unaudited" roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies" roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-cash-cash-equivalent-and-investments-" roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies" roleURI="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-commitments-and-contingencies-" roleURI="http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-sharebased-compensation-" roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-shareholders-equity-" roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-subsequent-events-" roleURI="http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-cash-cash-equivalent-and-investments-tables" roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-sharebased-compensation-tables" roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 5 - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-shareholders-equity-tables" roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 6 - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-cash-cash-equivalent-and-investments-details-textual" roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" roleURI="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-sharebased-compensation-details-textual" roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 5 - Share-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-sharebased-compensation-stock-option-activity-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-shareholders-equity-details-textual" roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 6 - Shareholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dyai_AccountsPayablePolicyPolicyTextBlock" name="AccountsPayablePolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_AccruedExpensesPolicyPolicyTextBlock" name="AccruedExpensesPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_AccruedResearchAndDevelopmentInProcessCurrent" name="AccruedResearchAndDevelopmentInProcessCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_AlphazymeMember" name="AlphazymeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_BDIHoldingsMember" name="BDIHoldingsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_BDIMember" name="BDIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_CashCashEquivalentsAndInvestmentsFairValue" name="CashCashEquivalentsAndInvestmentsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_CollaborativeArrangementDurationOfAgreement" name="CollaborativeArrangementDurationOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_CollaborativeArrangementEquityInterestAcquired" name="CollaborativeArrangementEquityInterestAcquired" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" name="CollaborativeArrangementMaximumObligationForResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" name="CollaborativeArrangementMinimumObligationForResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_CollaborativeArrangementNumberOfSharesToBeReceived" name="CollaborativeArrangementNumberOfSharesToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="dyai_CollaborativeArrangementOutstandingCommitment" name="CollaborativeArrangementOutstandingCommitment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" name="CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" name="CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_CollaborativeArrangementRevenueSharingPercentage" name="CollaborativeArrangementRevenueSharingPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_CollaborativeArrangementVestingPercentages" name="CollaborativeArrangementVestingPercentages" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dyai_ConcentrationRiskNumberOfCustomers" name="ConcentrationRiskNumberOfCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ConcentrationRiskNumberOfSuppliers" name="ConcentrationRiskNumberOfSuppliers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ConsultantMember" name="ConsultantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ContractResearchOrganizationsMember" name="ContractResearchOrganizationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ContractorMember" name="ContractorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" name="DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent" name="DeferredTaxAssetsValuationAllowanceCoveragePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_EmployeesMember" name="EmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ExecutivesAndKeyPersonnelMember" name="ExecutivesAndKeyPersonnelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_IDBiologicsIncMember" name="IDBiologicsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ImpactOfCOVID19PolicyPolicyTextBlock" name="ImpactOfCOVID19PolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" name="NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_NovovetMember" name="NovovetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_NumberOfResearchOrganizations" name="NumberOfResearchOrganizations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_OneCROMember" name="OneCROMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_OwnershipPercentage" name="OwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" name="PrepaidResearchAndDevelopmentInProcessCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" name="ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" name="ResearchAndDevelopmentExpenseIncludingRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" name="ResearchAndDevelopmentExpenseOutsideContractedServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" name="ResearchAndDevelopmentExpensePersonnelRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentInProcessCurrent" name="ResearchAndDevelopmentInProcessCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_ResearchServicesAgreementMember" name="ResearchServicesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchServicesPurchased" name="ResearchServicesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_SaleOfStockAuthorizedOfferingAmount" name="SaleOfStockAuthorizedOfferingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" name="SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dyai_SaleOfStockReimbursableLegalExpenses" name="SaleOfStockReimbursableLegalExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_SaleOfStockTerminationAmountUnderAgreement" name="SaleOfStockTerminationAmountUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" name="ScheduleOfResearchAndDevelopmentCostsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ServiceAgreementToPerformResearchProjectMember" name="ServiceAgreementToPerformResearchProjectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ServiceFrameworkAgreementMember" name="ServiceFrameworkAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" name="SharebasedCompensationAwardTrancheTwoThroughFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ShortTermCorporateBondsMember" name="ShortTermCorporateBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_The2011PlanMember" name="The2011PlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ThreeCROsMember" name="ThreeCROsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_VLPbioMember" name="VLPbioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" name="statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables" name="statement-statement-note-2-cash-cash-equivalent-and-investments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" name="statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" name="statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details" name="statement-statement-note-5-sharebased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-5-sharebased-compensation-tables" name="statement-statement-note-5-sharebased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" name="statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-6-shareholders-equity-tables" name="statement-statement-note-6-shareholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>dyai-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:13PM UTC 2021-05-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" xlink:href="dyai-20210331.xsd#statement-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="dyai-20210331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidTaxes" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" xlink:href="dyai-20210331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" xlink:type="extended">
    <link:loc xlink:href="dyai-20210331.xsd#dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>dyai-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:13PM UTC 2021-05-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-" xlink:href="dyai-20210331.xsd#statement-note-7-subsequent-events-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-" xlink:href="dyai-20210331.xsd#statement-note-4-commitments-and-contingencies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-document-and-entity-information" xlink:href="dyai-20210331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="dyai-20210331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OneCROMember" xlink:label="dyai_OneCROMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="dyai_ContractResearchOrganizationsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="dyai_OneCROMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies" xlink:href="dyai-20210331.xsd#statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIHoldingsMember" xlink:label="dyai_BDIHoldingsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIMember" xlink:label="dyai_BDIMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_IDBiologicsIncMember" xlink:label="dyai_IDBiologicsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NovovetMember" xlink:label="dyai_NovovetMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchServicesAgreementMember" xlink:label="dyai_ResearchServicesAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceAgreementToPerformResearchProjectMember" xlink:label="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceFrameworkAgreementMember" xlink:label="dyai_ServiceFrameworkAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_VLPbioMember" xlink:label="dyai_VLPbioMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAxis" xlink:label="us-gaap_CapitalizedContractCostAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="us-gaap_CapitalizedContractCostDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="us-gaap_CapitalizedContractCostDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="us-gaap_CapitalizedContractCostDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="dyai_ResearchServicesAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_BDIHoldingsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_VLPbioMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedContractCostAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostDomain" xlink:to="dyai_ResearchServicesAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="us-gaap_CapitalizedContractCostDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostDomain" xlink:to="dyai_ServiceFrameworkAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_BDIMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="dyai_NovovetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_IDBiologicsIncMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_The2011PlanMember" xlink:label="dyai_The2011PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyai_The2011PlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_ContractorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_EmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-" xlink:href="dyai-20210331.xsd#statement-note-6-shareholders-equity-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OpenMarketSaleAgreementMember" xlink:label="dyai_OpenMarketSaleAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dyai_OpenMarketSaleAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" xlink:href="dyai-20210331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccountsPayablePolicyPolicyTextBlock" xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:label="dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables" xlink:href="dyai-20210331.xsd#statement-note-6-shareholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConcentrationRiskNumberOfCustomers" xlink:label="dyai_ConcentrationRiskNumberOfCustomers" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConcentrationRiskNumberOfSuppliers" xlink:label="dyai_ConcentrationRiskNumberOfSuppliers" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent" xlink:label="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NumberOfResearchOrganizations" xlink:label="dyai_NumberOfResearchOrganizations" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OneCROMember" xlink:label="dyai_OneCROMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchServicesPurchased" xlink:label="dyai_ResearchServicesPurchased" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="dyai_ContractResearchOrganizationsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="dyai_OneCROMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_NumberOfResearchOrganizations" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskNumberOfCustomers" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskNumberOfSuppliers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchServicesPurchased" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" xlink:label="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" xlink:href="dyai-20210331.xsd#statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIHoldingsMember" xlink:label="dyai_BDIHoldingsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIMember" xlink:label="dyai_BDIMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementDurationOfAgreement" xlink:label="dyai_CollaborativeArrangementDurationOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementEquityInterestAcquired" xlink:label="dyai_CollaborativeArrangementEquityInterestAcquired" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:label="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:label="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementNumberOfSharesToBeReceived" xlink:label="dyai_CollaborativeArrangementNumberOfSharesToBeReceived" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementOutstandingCommitment" xlink:label="dyai_CollaborativeArrangementOutstandingCommitment" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" xlink:label="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" xlink:label="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:label="dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementVestingPercentages" xlink:label="dyai_CollaborativeArrangementVestingPercentages" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_IDBiologicsIncMember" xlink:label="dyai_IDBiologicsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NovovetMember" xlink:label="dyai_NovovetMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OwnershipPercentage" xlink:label="dyai_OwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchServicesAgreementMember" xlink:label="dyai_ResearchServicesAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceAgreementToPerformResearchProjectMember" xlink:label="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceFrameworkAgreementMember" xlink:label="dyai_ServiceFrameworkAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_VLPbioMember" xlink:label="dyai_VLPbioMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAxis" xlink:label="us-gaap_CapitalizedContractCostAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="us-gaap_CapitalizedContractCostDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="us-gaap_CapitalizedContractCostDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="us-gaap_CapitalizedContractCostDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="dyai_ResearchServicesAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_BDIHoldingsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_VLPbioMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedContractCostAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostDomain" xlink:to="dyai_ResearchServicesAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="us-gaap_CapitalizedContractCostDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostDomain" xlink:to="dyai_ServiceFrameworkAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_BDIMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="dyai_NovovetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_IDBiologicsIncMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementDurationOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementEquityInterestAcquired" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementOutstandingCommitment" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementNumberOfSharesToBeReceived" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementVestingPercentages" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_The2011PlanMember" xlink:label="dyai_The2011PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyai_The2011PlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_ContractorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_EmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" xlink:href="dyai-20210331.xsd#statement-note-6-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OpenMarketSaleAgreementMember" xlink:label="dyai_OpenMarketSaleAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockAuthorizedOfferingAmount" xlink:label="dyai_SaleOfStockAuthorizedOfferingAmount" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" xlink:label="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockReimbursableLegalExpenses" xlink:label="dyai_SaleOfStockReimbursableLegalExpenses" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockTerminationAmountUnderAgreement" xlink:label="dyai_SaleOfStockTerminationAmountUnderAgreement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dyai_OpenMarketSaleAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SaleOfStockAuthorizedOfferingAmount" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SaleOfStockReimbursableLegalExpenses" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SaleOfStockTerminationAmountUnderAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" xlink:href="dyai-20210331.xsd#statement-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="dyai-20210331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidTaxes" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:href="dyai-20210331.xsd#statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" xlink:href="dyai-20210331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited" xlink:href="dyai-20210331.xsd#statement-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ShortTermCorporateBondsMember" xlink:label="dyai_ShortTermCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="dyai_ShortTermCorporateBondsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="dyai_ShortTermCorporateBondsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>dyai-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:13PM UTC 2021-05-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dyai-20210331.xsd#dyai_DocumentAndEntityInformation" xlink:label="dyai_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dyai_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DocumentAndEntityInformation" xlink:to="dyai_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dyai_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="dyai_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-significant-accounting-policies-policies" xlink:label="dyai_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-significant-accounting-policies-policies" xlink:to="dyai_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:label="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Cash, Cash Equivalent, and Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:to="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-5-sharebased-compensation-tables" xlink:label="dyai_statement-statement-note-5-sharebased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-5-sharebased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-5-sharebased-compensation-tables" xlink:to="dyai_statement-statement-note-5-sharebased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free interest rate, maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-6-shareholders-equity-tables" xlink:label="dyai_statement-statement-note-6-shareholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-6-shareholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Shareholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-6-shareholders-equity-tables" xlink:to="dyai_statement-statement-note-6-shareholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free interest rate, minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:label="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:to="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:label="dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:to="dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:label="dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Share-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:to="dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:label="dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:to="dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:label="dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:to="dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatements" xlink:label="dyai_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dyai_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NotesToFinancialStatements" xlink:to="dyai_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dyai_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="dyai_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life of options (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementDurationOfAgreement" xlink:label="dyai_CollaborativeArrangementDurationOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementDurationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementDurationOfAgreement</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementDurationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Duration Of Agreement (Year)</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementDurationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents duration of agreement for collaborative agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementDurationOfAgreement" xlink:to="dyai_CollaborativeArrangementDurationOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:label="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Minimum Obligation For Research and Development</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents minimum obligation for research and development for collaborative agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:to="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" xlink:label="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Payment for Research and Development Agreement</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents payment for research and development agreement for collaborate arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" xlink:to="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchServicesAgreementMember" xlink:label="dyai_ResearchServicesAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchServicesAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Services Agreement [Member]</link:label>
    <link:label xlink:label="dyai_ResearchServicesAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to research services agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchServicesAgreementMember" xlink:to="dyai_ResearchServicesAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementEquityInterestAcquired" xlink:label="dyai_CollaborativeArrangementEquityInterestAcquired" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementEquityInterestAcquired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementEquityInterestAcquired</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementEquityInterestAcquired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Equity Interest Acquired</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementEquityInterestAcquired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents equity interest acquired for collaborative agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementEquityInterestAcquired" xlink:to="dyai_CollaborativeArrangementEquityInterestAcquired-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIHoldingsMember" xlink:label="dyai_BDIHoldingsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_BDIHoldingsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BDI Holdings [Member]</link:label>
    <link:label xlink:label="dyai_BDIHoldingsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to BDI Holdings.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_BDIHoldingsMember" xlink:to="dyai_BDIHoldingsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investment securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:label="dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementRevenueSharingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementRevenueSharingPercentage</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementRevenueSharingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Revenue Sharing, Percentage</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementRevenueSharingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of revenue sharing for collaborate arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:to="dyai_CollaborativeArrangementRevenueSharingPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:label="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Obligation For Research and Development</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum obligation for research and development for collaborative agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:to="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="locator"/>
    <link:label xlink:label="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners</link:label>
    <link:label xlink:label="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:label xlink:label="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents ownership percentage by noncontrolling owners for noncontrolling interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementVestingPercentages" xlink:label="dyai_CollaborativeArrangementVestingPercentages" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementVestingPercentages-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementVestingPercentages</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementVestingPercentages-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Vesting Percentages</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementVestingPercentages-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting percentage for collaborative arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementVestingPercentages" xlink:to="dyai_CollaborativeArrangementVestingPercentages-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_IDBiologicsIncMember" xlink:label="dyai_IDBiologicsIncMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_IDBiologicsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ID Biologics Inc [Member]</link:label>
    <link:label xlink:label="dyai_IDBiologicsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents ID Biologics Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_IDBiologicsIncMember" xlink:to="dyai_IDBiologicsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementNumberOfSharesToBeReceived" xlink:label="dyai_CollaborativeArrangementNumberOfSharesToBeReceived" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementNumberOfSharesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementNumberOfSharesToBeReceived</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementNumberOfSharesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Shares To Be Received (in shares)</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementNumberOfSharesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of shares to be received for collaborative arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementNumberOfSharesToBeReceived" xlink:to="dyai_CollaborativeArrangementNumberOfSharesToBeReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" xlink:label="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Payment for Additional Development and Commercialization</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents payments for additional development and commercialization for collaborative arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" xlink:to="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceFrameworkAgreementMember" xlink:label="dyai_ServiceFrameworkAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ServiceFrameworkAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Framework Agreement [Member]</link:label>
    <link:label xlink:label="dyai_ServiceFrameworkAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to service framework agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ServiceFrameworkAgreementMember" xlink:to="dyai_ServiceFrameworkAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, exercisable (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalent, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NovovetMember" xlink:label="dyai_NovovetMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_NovovetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novovet [Member]</link:label>
    <link:label xlink:label="dyai_NovovetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to Novovet.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NovovetMember" xlink:to="dyai_NovovetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementOutstandingCommitment" xlink:label="dyai_CollaborativeArrangementOutstandingCommitment" xlink:type="locator"/>
    <link:label xlink:label="dyai_CollaborativeArrangementOutstandingCommitment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CollaborativeArrangementOutstandingCommitment</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementOutstandingCommitment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Outstanding Commitment</link:label>
    <link:label xlink:label="dyai_CollaborativeArrangementOutstandingCommitment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents outstanding commitment for collaborative.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CollaborativeArrangementOutstandingCommitment" xlink:to="dyai_CollaborativeArrangementOutstandingCommitment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, outstanding (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockCommonShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockCommonShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of held-to-maturity investment securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 39,807,659 and 39,747,659, outstanding shares - 27,554,157 and 27,494,157 as of March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canceled, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred research and development obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee wages and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_The2011PlanMember" xlink:label="dyai_The2011PlanMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_The2011PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2011 Plan [Member]</link:label>
    <link:label xlink:label="dyai_The2011PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding the 2011 plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_The2011PlanMember" xlink:to="dyai_The2011PlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ContractorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractor [Member]</link:label>
    <link:label xlink:label="dyai_ContractorMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to contractor.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ContractorMember" xlink:to="dyai_ContractorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_EquityMethodInvesteeNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award Tranche Two through Five [Member]</link:label>
    <link:label xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shares-based compensation award tranche two through five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_EmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees [Member]</link:label>
    <link:label xlink:label="dyai_EmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_EmployeesMember" xlink:to="dyai_EmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherPrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses - various</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ExecutivesAndKeyPersonnelMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executives and Key Personnel [Member]</link:label>
    <link:label xlink:label="dyai_ExecutivesAndKeyPersonnelMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents executives and key personnel.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ExecutivesAndKeyPersonnelMember" xlink:to="dyai_ExecutivesAndKeyPersonnelMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant [Member]</link:label>
    <link:label xlink:label="dyai_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to consultant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConsultantMember" xlink:to="dyai_ConsultantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange loss (gain), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableOtherCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsPayableOtherCurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableOtherCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockTerminationAmountUnderAgreement" xlink:label="dyai_SaleOfStockTerminationAmountUnderAgreement" xlink:type="locator"/>
    <link:label xlink:label="dyai_SaleOfStockTerminationAmountUnderAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_SaleOfStockTerminationAmountUnderAgreement</link:label>
    <link:label xlink:label="dyai_SaleOfStockTerminationAmountUnderAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Termination Amount Under Agreement</link:label>
    <link:label xlink:label="dyai_SaleOfStockTerminationAmountUnderAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents termination amount under agreement for sale of stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SaleOfStockTerminationAmountUnderAgreement" xlink:to="dyai_SaleOfStockTerminationAmountUnderAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OpenMarketSaleAgreementMember" xlink:label="dyai_OpenMarketSaleAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_OpenMarketSaleAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
    <link:label xlink:label="dyai_OpenMarketSaleAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to open market for sale agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_OpenMarketSaleAgreementMember" xlink:to="dyai_OpenMarketSaleAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockAuthorizedOfferingAmount" xlink:label="dyai_SaleOfStockAuthorizedOfferingAmount" xlink:type="locator"/>
    <link:label xlink:label="dyai_SaleOfStockAuthorizedOfferingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_SaleOfStockAuthorizedOfferingAmount</link:label>
    <link:label xlink:label="dyai_SaleOfStockAuthorizedOfferingAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Authorized Offering Amount</link:label>
    <link:label xlink:label="dyai_SaleOfStockAuthorizedOfferingAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents authorized offering amount of sale of stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SaleOfStockAuthorizedOfferingAmount" xlink:to="dyai_SaleOfStockAuthorizedOfferingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" xlink:label="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" xlink:type="locator"/>
    <link:label xlink:label="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare</link:label>
    <link:label xlink:label="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage of Commissions Paid of Gross Proceeds From Sale Of Each Share</link:label>
    <link:label xlink:label="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of commission paid on gross proceeds from sale of each share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" xlink:to="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockReimbursableLegalExpenses" xlink:label="dyai_SaleOfStockReimbursableLegalExpenses" xlink:type="locator"/>
    <link:label xlink:label="dyai_SaleOfStockReimbursableLegalExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_SaleOfStockReimbursableLegalExpenses</link:label>
    <link:label xlink:label="dyai_SaleOfStockReimbursableLegalExpenses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Reimbursable Legal Expenses</link:label>
    <link:label xlink:label="dyai_SaleOfStockReimbursableLegalExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents reimbursable legal expense for sale of stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SaleOfStockReimbursableLegalExpenses" xlink:to="dyai_SaleOfStockReimbursableLegalExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_VLPbioMember" xlink:label="dyai_VLPbioMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_VLPbioMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VL Pbio Member</link:label>
    <link:label xlink:label="dyai_VLPbioMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to VL Pbio.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_VLPbioMember" xlink:to="dyai_VLPbioMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Including Related Party</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents research and development expense including related party.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OwnershipPercentage" xlink:label="dyai_OwnershipPercentage" xlink:type="locator"/>
    <link:label xlink:label="dyai_OwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_OwnershipPercentage</link:label>
    <link:label xlink:label="dyai_OwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership Percentage</link:label>
    <link:label xlink:label="dyai_OwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of ownership.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_OwnershipPercentage" xlink:to="dyai_OwnershipPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term investment securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of held-to-maturity securities, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:label xlink:label="srt_DirectorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs of research and development revenue</link:label>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentOwnershipPercentage</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</link:label>
    <link:label xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development revenue</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, adjusted cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, adjusted cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</link:label>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Holding Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Holding Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent" xlink:label="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent" xlink:type="locator"/>
    <link:label xlink:label="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent</link:label>
    <link:label xlink:label="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance Coverage, Percent</link:label>
    <link:label xlink:label="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent after allocation of valuation allowance coverage of deferred tax asset attributable to deductible temporary differences and carryforwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent" xlink:to="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds, adjusted cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred research and development obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchServicesPurchased" xlink:label="dyai_ResearchServicesPurchased" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchServicesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ResearchServicesPurchased</link:label>
    <link:label xlink:label="dyai_ResearchServicesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Services Purchased</link:label>
    <link:label xlink:label="dyai_ResearchServicesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research services purchased during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchServicesPurchased" xlink:to="dyai_ResearchServicesPurchased-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ContractResearchOrganizationsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Research Organizations [Member]</link:label>
    <link:label xlink:label="dyai_ContractResearchOrganizationsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to contract research organizations, or to research services purchased from such organizations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ContractResearchOrganizationsMember" xlink:to="dyai_ContractResearchOrganizationsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:label="dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_ImpactOfCOVID19PolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of COVID-19, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="dyai_ImpactOfCOVID19PolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for impact of COVID-19.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:to="dyai_ImpactOfCOVID19PolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIMember" xlink:label="dyai_BDIMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_BDIMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BDI [Member]</link:label>
    <link:label xlink:label="dyai_BDIMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding Biotechnology Developments for Industry, S.L., a Spanish biotechnology company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_BDIMember" xlink:to="dyai_BDIMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConcentrationRiskNumberOfCustomers" xlink:label="dyai_ConcentrationRiskNumberOfCustomers" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ConcentrationRiskNumberOfCustomers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConcentrationRiskNumberOfCustomers" xlink:to="dyai_ConcentrationRiskNumberOfCustomers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentsAndCash</link:label>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, adjusted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableNet</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_AlphazymeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alphazyme [Member]</link:label>
    <link:label xlink:label="dyai_AlphazymeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to Alphazyme.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AlphazymeMember" xlink:to="dyai_AlphazymeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceAgreementToPerformResearchProjectMember" xlink:label="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ServiceAgreementToPerformResearchProjectMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Agreement to Perform Research Project [Member]</link:label>
    <link:label xlink:label="dyai_ServiceAgreementToPerformResearchProjectMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding a service agreement to perform a research project.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:to="dyai_ServiceAgreementToPerformResearchProjectMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:to="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonUsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ThreeCROsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three CROs [Member]</link:label>
    <link:label xlink:label="dyai_ThreeCROsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding three contract research organizations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ThreeCROsMember" xlink:to="dyai_ThreeCROsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAxis" xlink:label="us-gaap_CapitalizedContractCostAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalizedContractCostAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="us-gaap_CapitalizedContractCostAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="us-gaap_CapitalizedContractCostDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalizedContractCostDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostDomain" xlink:to="us-gaap_CapitalizedContractCostDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OneCROMember" xlink:label="dyai_OneCROMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_OneCROMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One CRO [Member]</link:label>
    <link:label xlink:label="dyai_OneCROMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding one contract research organization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_OneCROMember" xlink:to="dyai_OneCROMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByAssetClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccountsPayablePolicyPolicyTextBlock" xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for accounts payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:to="dyai_AccountsPayablePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for accrued expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:to="dyai_AccruedExpensesPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplierConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:label xlink:label="dyai_PrepaidResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Alphazyme</link:label>
    <link:label xlink:label="dyai_PrepaidResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the current amount of prepaid research and development in process as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:to="dyai_PrepaidResearchAndDevelopmentInProcessCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConcentrationRiskNumberOfSuppliers" xlink:label="dyai_ConcentrationRiskNumberOfSuppliers" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ConcentrationRiskNumberOfSuppliers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Suppliers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of suppliers accounting for 10% or more of the specified concentration risk benchmark.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConcentrationRiskNumberOfSuppliers" xlink:to="dyai_ConcentrationRiskNumberOfSuppliers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllowanceForDoubtfulAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TreasuryStockValue</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Ending Balance</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares held at cost - 12,253,502</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ResearchAndDevelopmentInProcessCurrent</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents current research and development in process.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:to="dyai_ResearchAndDevelopmentInProcessCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:label xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_AccruedResearchAndDevelopmentInProcessCurrent</link:label>
    <link:label xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents current accrued research and development in process.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:to="dyai_AccruedResearchAndDevelopmentInProcessCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProjectMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facilities, overhead and other</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents facilities, overhead and other for research and development expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personnel related costs</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents personnel related costs for research and development expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside contracted services</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents outside contracted services for research and development expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" xlink:label="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" xlink:type="locator"/>
    <link:label xlink:label="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase</link:label>
    <link:label xlink:label="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Premium Paid on Purchase</link:label>
    <link:label xlink:label="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents premium paid on purchase for debt securities held-to-maturity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" xlink:to="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Costs [Table Text Block]</link:label>
    <link:label xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:to="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ShortTermCorporateBondsMember" xlink:label="dyai_ShortTermCorporateBondsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ShortTermCorporateBondsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Corporate Bonds [Member]</link:label>
    <link:label xlink:label="dyai_ShortTermCorporateBondsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents short-term corporate bonds.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ShortTermCorporateBondsMember" xlink:to="dyai_ShortTermCorporateBondsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canceled, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:type="locator"/>
    <link:label xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CashCashEquivalentsAndInvestmentsFairValue</link:label>
    <link:label xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, fair value</link:label>
    <link:label xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents fair value of cash, cash equivalents and investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:to="dyai_CashCashEquivalentsAndInvestmentsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bonds, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateBondSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionGainLossRealized</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange loss (gain), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NumberOfResearchOrganizations" xlink:label="dyai_NumberOfResearchOrganizations" xlink:type="locator"/>
    <link:label xlink:label="dyai_NumberOfResearchOrganizations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_NumberOfResearchOrganizations</link:label>
    <link:label xlink:label="dyai_NumberOfResearchOrganizations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Research Organizations</link:label>
    <link:label xlink:label="dyai_NumberOfResearchOrganizations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of research organizations through which the entity operates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NumberOfResearchOrganizations" xlink:to="dyai_NumberOfResearchOrganizations-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>dyai-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:13PM UTC 2021-05-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-" xlink:href="dyai-20210331.xsd#statement-note-7-subsequent-events-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-" xlink:href="dyai-20210331.xsd#statement-note-4-commitments-and-contingencies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-document-and-entity-information" xlink:href="dyai-20210331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="dyai-20210331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OneCROMember" xlink:label="dyai_OneCROMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="dyai_ContractResearchOrganizationsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="dyai_OneCROMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies" xlink:href="dyai-20210331.xsd#statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIHoldingsMember" xlink:label="dyai_BDIHoldingsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIMember" xlink:label="dyai_BDIMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_IDBiologicsIncMember" xlink:label="dyai_IDBiologicsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NovovetMember" xlink:label="dyai_NovovetMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchServicesAgreementMember" xlink:label="dyai_ResearchServicesAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceAgreementToPerformResearchProjectMember" xlink:label="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceFrameworkAgreementMember" xlink:label="dyai_ServiceFrameworkAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_VLPbioMember" xlink:label="dyai_VLPbioMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAxis" xlink:label="us-gaap_CapitalizedContractCostAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="us-gaap_CapitalizedContractCostDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="us-gaap_CapitalizedContractCostDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="dyai_ResearchServicesAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_BDIHoldingsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_VLPbioMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedContractCostAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="dyai_ResearchServicesAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="dyai_ServiceFrameworkAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_BDIMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="dyai_NovovetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_IDBiologicsIncMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_The2011PlanMember" xlink:label="dyai_The2011PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dyai_The2011PlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_ContractorMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_EmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-" xlink:href="dyai-20210331.xsd#statement-note-6-shareholders-equity-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OpenMarketSaleAgreementMember" xlink:label="dyai_OpenMarketSaleAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dyai_OpenMarketSaleAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" xlink:href="dyai-20210331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccountsPayablePolicyPolicyTextBlock" xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:label="dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-significant-accounting-policies-policies" xlink:label="dyai_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_ImpactOfCOVID19PolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:label="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-5-sharebased-compensation-tables" xlink:label="dyai_statement-statement-note-5-sharebased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-5-sharebased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables" xlink:href="dyai-20210331.xsd#statement-note-6-shareholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-6-shareholders-equity-tables" xlink:label="dyai_statement-statement-note-6-shareholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-6-shareholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConcentrationRiskNumberOfCustomers" xlink:label="dyai_ConcentrationRiskNumberOfCustomers-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConcentrationRiskNumberOfSuppliers" xlink:label="dyai_ConcentrationRiskNumberOfSuppliers-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent" xlink:label="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NumberOfResearchOrganizations" xlink:label="dyai_NumberOfResearchOrganizations-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OneCROMember" xlink:label="dyai_OneCROMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchServicesPurchased" xlink:label="dyai_ResearchServicesPurchased-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="dyai_ContractResearchOrganizationsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="dyai_OneCROMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_NumberOfResearchOrganizations-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskNumberOfCustomers-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskNumberOfSuppliers-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchServicesPurchased-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase" xlink:label="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" xlink:href="dyai-20210331.xsd#statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIHoldingsMember" xlink:label="dyai_BDIHoldingsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_BDIMember" xlink:label="dyai_BDIMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementDurationOfAgreement" xlink:label="dyai_CollaborativeArrangementDurationOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementEquityInterestAcquired" xlink:label="dyai_CollaborativeArrangementEquityInterestAcquired-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:label="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:label="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementNumberOfSharesToBeReceived" xlink:label="dyai_CollaborativeArrangementNumberOfSharesToBeReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementOutstandingCommitment" xlink:label="dyai_CollaborativeArrangementOutstandingCommitment-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization" xlink:label="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement" xlink:label="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:label="dyai_CollaborativeArrangementRevenueSharingPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CollaborativeArrangementVestingPercentages" xlink:label="dyai_CollaborativeArrangementVestingPercentages-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_IDBiologicsIncMember" xlink:label="dyai_IDBiologicsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NovovetMember" xlink:label="dyai_NovovetMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OwnershipPercentage" xlink:label="dyai_OwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchServicesAgreementMember" xlink:label="dyai_ResearchServicesAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceAgreementToPerformResearchProjectMember" xlink:label="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ServiceFrameworkAgreementMember" xlink:label="dyai_ServiceFrameworkAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_VLPbioMember" xlink:label="dyai_VLPbioMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAxis" xlink:label="us-gaap_CapitalizedContractCostAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="us-gaap_CapitalizedContractCostDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="us-gaap_CapitalizedContractCostDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="dyai_ResearchServicesAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_BDIHoldingsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_VLPbioMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedContractCostAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="dyai_ResearchServicesAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="dyai_ServiceFrameworkAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="dyai_ServiceAgreementToPerformResearchProjectMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_BDIMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="dyai_NovovetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_IDBiologicsIncMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementDurationOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementEquityInterestAcquired-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementRevenueSharingPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementOutstandingCommitment-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementNumberOfSharesToBeReceived-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CollaborativeArrangementVestingPercentages-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_The2011PlanMember" xlink:label="dyai_The2011PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dyai_The2011PlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_ContractorMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_EmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:label="dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" xlink:href="dyai-20210331.xsd#statement-note-6-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_OpenMarketSaleAgreementMember" xlink:label="dyai_OpenMarketSaleAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockAuthorizedOfferingAmount" xlink:label="dyai_SaleOfStockAuthorizedOfferingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare" xlink:label="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockReimbursableLegalExpenses" xlink:label="dyai_SaleOfStockReimbursableLegalExpenses-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_SaleOfStockTerminationAmountUnderAgreement" xlink:label="dyai_SaleOfStockTerminationAmountUnderAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dyai_OpenMarketSaleAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SaleOfStockAuthorizedOfferingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SaleOfStockReimbursableLegalExpenses-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SaleOfStockTerminationAmountUnderAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" xlink:href="dyai-20210331.xsd#statement-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="dyai-20210331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidTaxes" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentInProcessCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_AccruedResearchAndDevelopmentInProcessCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:label="dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:href="dyai-20210331.xsd#statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:label="dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" xlink:href="dyai-20210331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="dyai_PrepaidResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited" xlink:href="dyai-20210331.xsd#statement-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:href="dyai-20210331.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-3" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:href="dyai-20210331.xsd#statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:label="dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:href="dyai-20210331.xsd#statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue-3" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_ShortTermCorporateBondsMember" xlink:label="dyai_ShortTermCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20210331.xsd#dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:label="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CashMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="dyai_ShortTermCorporateBondsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="dyai_ShortTermCorporateBondsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateBondSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CashCashEquivalentsAndInvestmentsFairValue-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>dyai-20200930_g1copy.jpg
<TEXT>
begin 644 dyai-20200930_g1copy.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_[0C 4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  >     $  0!X     0 !.$))300-       $    >#A"24T#\P
M    "           .$))300*       !   X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!0       0    !.$))300,      <P
M 0   $8    X    U   +F    <4 !@  ?_8_^  $$I&248  0(! $@ 2
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ . !& P$B  (1 0,1 ?_=  0 !?_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M?_<OTYURFV_H^;12TOMLH>UC!R7%I :N>_Q<]*ZCTS!RZ\_'?C/LM:YC7QJ
MV)T)7@B21KC'>E1XO8G5</$+_>?JI)?*J2>P/U4DOE5))3__V3A"24T$!@
M    !P &     0$ _^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT
M<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M             /;6  $     TRU(4" @
M                                   18W!R=    5     S9&5S8P
M 80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA9
M6@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(
M=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M   D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P
M!#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M           2<U)'0B!)14,V,3DV-BTR+C$
M                                         %A96B        #S40 !
M     1;,6%E:(                     !865H@        ;Z(  #CU   #
MD%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@
M                        9&5S8P         N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                         &1E<V,         +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                          !V:65W       3I/X %%\N !#/%  #[<P
M!!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                      */     G-I9R      0U)4(&-U<G8        $
M      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H
M &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4
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M^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X #D%D;V)E &1      ?_; (0
M @(" @(" @(" @," @(#! ," @,$!00$! 0$!08%!04%!04&!@<'" <'!@D)
M"@H)"0P,# P,# P,# P,# P,# $# P,%! 4)!@8)#0H)"@T/#@X.#@\/# P,
M# P/#PP,# P,# \,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M/4'(-0<=AF)#M*,A*='TU]I1F]E<V++CQ&<;R6!SVX1>[__2^M^K_P#.(_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>dyai20210331_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:dyai="http://www.dyadic.com/20210331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dyai-20210331.xsd" xlink:type="simple"/>
    <context id="d_2021-01-01_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-05-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="i_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:OneCROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:OneCROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:OneCROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_FairValueByAssetClassAxis-CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ShortTermCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_InvestmentTypeAxis-CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ShortTermCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_InvestmentTypeAxis-CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2017-06-30_2017-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-VLPbioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:VLPbioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i_2017-06-30_CapitalizedContractCostAxis-ResearchServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">dyai:ServiceFrameworkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="d_2017-06-30_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">dyai:ServiceFrameworkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-BDIMember_TypeOfArrangementAxis-ServiceAgreementToPerformResearchProjectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:BDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dyai:ServiceAgreementToPerformResearchProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2019-04-26_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-NovovetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:NovovetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-26</instant>
        </period>
    </context>
    <context id="d_2020-06-24_2020-06-24_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-24</startDate>
            <endDate>2020-06-24</endDate>
        </period>
    </context>
    <context id="i_2020-12-01_OwnershipAxis-AlphazymeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:AlphazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:IDBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-08</instant>
        </period>
    </context>
    <context id="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:IDBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-08</instant>
        </period>
    </context>
    <context id="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:IDBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-08</instant>
        </period>
    </context>
    <context id="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:IDBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-08</instant>
        </period>
    </context>
    <context id="i_2011-04-28_PlanNameAxis-The2011PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-04-28</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-01-01_PlanNameAxis-The2011PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="d_2021-04-16_2021-04-16_PlanNameAxis-The2011PlanMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_PlanNameAxis-The2011PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PlanNameAxis-The2011PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_OwnershipAxis-ContractorMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:ContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_OwnershipAxis-ContractorMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:ContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember_VestingAxis-SharebasedCompensationAwardTrancheTwoThroughFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyai:SharebasedCompensationAwardTrancheTwoThroughFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="d_2021-01-08_2021-01-08_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="d_2021-01-08_2021-01-08_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="d_2021-01-21_2021-01-21_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="d_2021-01-21_2021-01-21_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="d_2021-03-22_2021-03-22_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="d_2021-03-22_2021-03-22_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-08-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2020-08-13</instant>
        </period>
    </context>
    <context id="i_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dyai:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-13</instant>
        </period>
    </context>
    <context id="d_2020-08-13_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dyai:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-13</startDate>
            <endDate>2020-08-13</endDate>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2021-01-01_2021-03-31"
      id="thunderdome-EntityCentralIndexKey">0001213809</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2021-01-01_2021-03-31"
      id="thunderdome-EntityRegistrantName">DYADIC INTERNATIONAL INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2021-01-01_2021-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2021-01-01_2021-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2021-01-01_2021-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2021-01-01_2021-03-31">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-03-31"
      id="c73543538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2020-12-31"
      id="c73543539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543544"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543545"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543546"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543547"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-03-31"
      decimals="-3"
      id="c73543548"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-03-31"
      decimals="-3"
      id="c73543550"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c73543549"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c73543551"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543555"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543556"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543557"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543558"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543559"
      unitRef="Share">39807659</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543560"
      unitRef="Share">39747659</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543561"
      unitRef="Share">27554157</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543562"
      unitRef="Share">27494157</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543567"
      unitRef="Share">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543568"
      unitRef="Share">12253502</us-gaap:TreasuryStockCommonShares>
    <dyai:NumberOfResearchOrganizations
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543703"
      unitRef="Pure">3</dyai:NumberOfResearchOrganizations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543760"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c73543764"
      unitRef="Pure">8</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c73543765"
      unitRef="Pure">5</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c73543766"
      unitRef="Pure">7</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c73543767"
      unitRef="Pure">9</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfSuppliers
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"
      decimals="INF"
      id="c73543786"
      unitRef="Pure">3</dyai:ConcentrationRiskNumberOfSuppliers>
    <dyai:ConcentrationRiskNumberOfSuppliers
      contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"
      decimals="INF"
      id="c73543792"
      unitRef="Pure">1</dyai:ConcentrationRiskNumberOfSuppliers>
    <dyai:ConcentrationRiskNumberOfSuppliers
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"
      decimals="INF"
      id="c73543795"
      unitRef="Pure">1</dyai:ConcentrationRiskNumberOfSuppliers>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2021-03-31"
      decimals="-3"
      id="c73543806"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c73543807"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-03-31"
      decimals="-3"
      id="c73543846"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c73543847"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <dyai:DeferredTaxAssetsValuationAllowanceCoveragePercent
      contextRef="d_2020-01-01_2020-12-31"
      decimals="0"
      id="c73543851"
      unitRef="Pure">1</dyai:DeferredTaxAssetsValuationAllowanceCoveragePercent>
    <dyai:CollaborativeArrangementDurationOfAgreement contextRef="d_2017-06-30_2017-06-30" id="c73544044">P2Y</dyai:CollaborativeArrangementDurationOfAgreement>
    <dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment
      contextRef="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember"
      decimals="INF"
      id="c73544054"
      unitRef="USD">936000</dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment>
    <dyai:CollaborativeArrangementDurationOfAgreement
      contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember"
      id="c73544055">P2Y</dyai:CollaborativeArrangementDurationOfAgreement>
    <dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment
      contextRef="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember"
      decimals="-6"
      id="c73544058"
      unitRef="EUR">1000000</dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment>
    <dyai:CollaborativeArrangementMaximumObligationForResearchAndDevelopment
      contextRef="i_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember"
      decimals="-6"
      id="c73544061"
      unitRef="EUR">8000000.0</dyai:CollaborativeArrangementMaximumObligationForResearchAndDevelopment>
    <dyai:CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization
      contextRef="i_2017-06-30_CapitalizedContractCostAxis-ResearchServicesAgreementMember"
      decimals="-5"
      id="c73544064"
      unitRef="EUR">1500000</dyai:CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization>
    <dyai:CollaborativeArrangementDurationOfAgreement
      contextRef="d_2017-06-30_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember"
      id="c73544066">P2Y</dyai:CollaborativeArrangementDurationOfAgreement>
    <dyai:CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
      contextRef="d_2017-06-30_2017-06-30"
      decimals="-5"
      id="c73544074"
      unitRef="EUR">1100000</dyai:CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement>
    <dyai:CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
      contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember"
      decimals="-6"
      id="c73544049"
      unitRef="EUR">1000000.0</dyai:CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i_2020-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember"
      decimals="INF"
      id="c73544106"
      unitRef="USD">284709</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember"
      id="c73544184">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      id="c73544185">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      id="c73544186">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      id="c73544190">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_OwnershipAxis-ContractorMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      id="c73544194">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      id="c73544201">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember_VestingAxis-SharebasedCompensationAwardTrancheTwoThroughFiveMember"
      id="c73544202">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember"
      id="c73544205">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-EmployeesMember"
      id="c73544208">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-01-04_2021-01-04_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember"
      id="c73544211">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-01-08_2021-01-08_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember"
      id="c73544215">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-01-21_2021-01-21_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember"
      id="c73544218">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-03-22_2021-03-22_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ConsultantMember"
      id="c73544221">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544311"
      unitRef="Share">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i_2020-12-31"
      decimals="-5"
      id="c73544312"
      unitRef="USD">18900000</us-gaap:TreasuryStockValue>
    <dei:DocumentType contextRef="d_2021-01-01_2021-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2021-01-01_2021-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2021-01-01_2021-03-31">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2021-01-01_2021-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2021-01-01_2021-03-31">000-55264</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2021-01-01_2021-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2021-01-01_2021-03-31">45-0486747</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2021-01-01_2021-03-31">140 Intracoastal Pointe Drive, Suite 404</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2021-01-01_2021-03-31">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2021-01-01_2021-03-31">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2021-01-01_2021-03-31">33477</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2021-01-01_2021-03-31">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2021-01-01_2021-03-31">743-8333</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="d_2021-01-01_2021-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2021-01-01_2021-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2021-01-01_2021-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2021-01-01_2021-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2021-01-01_2021-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2021-01-01_2021-03-31">false</dei:EntityShellCompany>
    <dei:Security12bTitle contextRef="d_2021-01-01_2021-03-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2021-01-01_2021-03-31">DYAI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2021-01-01_2021-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2021-05-12" decimals="INF" unitRef="Share">27554157</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543508"
      unitRef="USD">13055558</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543509"
      unitRef="USD">20637045</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543510"
      unitRef="USD">14177441</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543511"
      unitRef="USD">8457452</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543512"
      unitRef="USD">157201</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543513"
      unitRef="USD">112247</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543514"
      unitRef="USD">384963</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543515"
      unitRef="USD">294199</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543516"
      unitRef="USD">216189</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543517"
      unitRef="USD">280555</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543518"
      unitRef="USD">27991352</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543519"
      unitRef="USD">29781498</us-gaap:AssetsCurrent>
    <dyai:PrepaidResearchAndDevelopmentInProcessCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543521"
      unitRef="USD">284709</dyai:PrepaidResearchAndDevelopmentInProcessCurrent>
    <dyai:PrepaidResearchAndDevelopmentInProcessCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543522"
      unitRef="USD">284709</dyai:PrepaidResearchAndDevelopmentInProcessCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543523"
      unitRef="USD">6151</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543524"
      unitRef="USD">6225</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543525"
      unitRef="USD">28282212</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543526"
      unitRef="USD">30072432</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543529"
      unitRef="USD">1473813</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543530"
      unitRef="USD">1013099</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543531"
      unitRef="USD">277668</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543532"
      unitRef="USD">489756</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543533"
      unitRef="USD">842248</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543534"
      unitRef="USD">123016</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543535"
      unitRef="USD">2593729</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543536"
      unitRef="USD">1625871</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockValue
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543542"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543543"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543553"
      unitRef="USD">39808</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543554"
      unitRef="USD">39748</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543563"
      unitRef="USD">98549890</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543564"
      unitRef="USD">98013079</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543565"
      unitRef="USD">18929915</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543566"
      unitRef="USD">18929915</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543569"
      unitRef="USD">-53971300</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543570"
      unitRef="USD">-50676351</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543571"
      unitRef="USD">25688483</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543572"
      unitRef="USD">28446561</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543573"
      unitRef="USD">28282212</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543574"
      unitRef="USD">30072432</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543580"
      unitRef="USD">460520</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543581"
      unitRef="USD">315372</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543583"
      unitRef="USD">390762</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543584"
      unitRef="USD">278182</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543585"
      unitRef="USD">1808098</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543586"
      unitRef="USD">755453</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543587"
      unitRef="USD">1554007</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543588"
      unitRef="USD">1653392</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543589"
      unitRef="USD">-28272</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543590"
      unitRef="USD">-10867</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543591"
      unitRef="USD">3781139</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543592"
      unitRef="USD">2697894</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543593"
      unitRef="USD">-3320619</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543594"
      unitRef="USD">-2382522</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543595"
      unitRef="USD">25670</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543596"
      unitRef="USD">168383</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543597"
      unitRef="USD">-3294949</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543598"
      unitRef="USD">-2214139</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543599"
      unitRef="USDPerShare">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543600"
      unitRef="USDPerShare">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543601"
      unitRef="Share">27533268</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543602"
      unitRef="Share">27452490</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73543617"
      unitRef="Share">39747659</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73543618"
      unitRef="USD">39748</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73543619"
      unitRef="Share">-12253502</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73543620"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73543621"
      unitRef="USD">98013079</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73543622"
      unitRef="USD">-50676351</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543623"
      unitRef="USD">28446561</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73543625"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73543627"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73543628"
      unitRef="USD">421071</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73543629"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543630"
      unitRef="USD">421071</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73543631"
      unitRef="Share">60000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73543632"
      unitRef="USD">60</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73543633"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73543634"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73543635"
      unitRef="USD">115740</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73543636"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543637"
      unitRef="USD">115800</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73543639"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73543641"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73543642"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73543643"
      unitRef="USD">-3294949</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543644"
      unitRef="USD">-3294949</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73543645"
      unitRef="Share">39807659</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73543646"
      unitRef="USD">39808</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73543647"
      unitRef="Share">-12253502</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73543648"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73543649"
      unitRef="USD">98549890</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73543650"
      unitRef="USD">-53971300</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543651"
      unitRef="USD">25688483</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543657"
      unitRef="USD">-3294949</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543658"
      unitRef="USD">-2214139</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543660"
      unitRef="USD">421071</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543661"
      unitRef="USD">426939</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543662"
      unitRef="USD">63951</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543663"
      unitRef="USD">107256</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543664"
      unitRef="USD">-28272</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543665"
      unitRef="USD">-10867</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543667"
      unitRef="USD">44954</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543668"
      unitRef="USD">-102565</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543669"
      unitRef="USD">131800</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543670"
      unitRef="USD">-35258</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543671"
      unitRef="USD">-64297</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543672"
      unitRef="USD">10529</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543673"
      unitRef="USD">480455</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543674"
      unitRef="USD">-292361</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543675"
      unitRef="USD">-212088</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543676"
      unitRef="USD">-326000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543677"
      unitRef="USD">719232</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543678"
      unitRef="USD">163799</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543679"
      unitRef="USD">-1906513</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543680"
      unitRef="USD">-1996345</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543682"
      unitRef="USD">11283940</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543683"
      unitRef="USD">11652385</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543684"
      unitRef="USD">5500000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543685"
      unitRef="USD">13350000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543686"
      unitRef="USD">-5783940</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543687"
      unitRef="USD">1697615</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543689"
      unitRef="USD">115800</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543690"
      unitRef="USD">175000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543691"
      unitRef="USD">115800</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543692"
      unitRef="USD">175000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543693"
      unitRef="USD">-6834</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543694"
      unitRef="USD">-2983</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543695"
      unitRef="USD">-7581487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543696"
      unitRef="USD">-126713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543697"
      unitRef="USD">20637045</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c73543698"
      unitRef="USD">4823544</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543699"
      unitRef="USD">13055558</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-03-31"
      decimals="INF"
      id="c73543700"
      unitRef="USD">4696831</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856453">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1:&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b&gt;Organization and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Dyadic International, Inc. (&#x201c;Dyadic&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, or the &#x201c;Company&#x201d;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office&#160;in the Netherlands and predominantly &lt;span style="-sec-ix-hidden:c73543703"&gt;three&lt;/span&gt; research organizations performing services in the Netherlands, Finland and Israel. Over the past &lt;em style="font: inherit;"&gt;two&lt;/em&gt; plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the &lt;i&gt;Thermothelomyces heterothallica &lt;/i&gt;(formerly known as &lt;i&gt;Myceliophthora thermophila&lt;/i&gt;) fungus, which the Company named &lt;em style="font: inherit;"&gt;C1.&lt;/em&gt; The &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; December 31, 2015, &lt;/em&gt;the Company sold its industrial technology business to Danisco USA (&#x201c;Danisco&#x201d;), the industrial biosciences business of DuPont (NYSE: DD)&#160;(the &#x201c;DuPont Transaction&#x201d;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic &lt;em style="font: inherit;"&gt; may &lt;/em&gt;owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs and other biological products at flexible commercial scales. Currently, the Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies to leverage its &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology to help develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. The Company is also working on several COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; related vaccine and antibody opportunities, including its proprietary COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; vaccine candidate, DYAI-&lt;em style="font: inherit;"&gt;100,&lt;/em&gt; towards a &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in-human Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; clinical trial.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Effective &lt;em style="font: inherit;"&gt; April 17, 2019, &lt;/em&gt;our common stock began trading on the NASDAQ Stock Market LLC&#x2019;s NASDAQ Capital Market, under the symbol &#x201c;DYAI&#x201d;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Impact of COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The outbreak of COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; has led to adverse impacts on the U.S. and global economies and created uncertainty regarding&#160;the potential impact to the Company&#x2019;s employees, operations, and research projects.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;To date, some of our employees are still working remotely. The extent to which the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;emerge concerning the severe acute respiratory syndrome coronavirus &lt;em style="font: inherit;"&gt;2&lt;/em&gt; (SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) and its&#160;variants and the actions taken and the level of success to contain or treat the SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic has subsided, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;continue to experience adverse impacts to its business because of economic recession or depression that has occurred or &lt;em style="font: inherit;"&gt; may &lt;/em&gt;occur in the future. Given the daily evolution of the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; able to accurately estimate the effects of the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; outbreak to our results of operations, financial condition, or liquidity.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months. However, in the event our financing needs for the foreseeable future are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; expression platform in humans. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that external funding will be available at acceptable terms, if at all, and the Company &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;therefore, self-fund these vital projects.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;Basis of Presentation &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt;&#160;included in our Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K which was filed with the SEC on &lt;em style="font: inherit;"&gt; March&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;b&gt;&lt;i&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented.&#160;The results of the Company&#x2019;s operations for any interim periods are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results of operations for any other interim period or for a full fiscal year.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Since concluding the DuPont Transaction, the Company has conducted business in &lt;span style="-sec-ix-hidden:c73543760"&gt;one&lt;/span&gt; operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Concentrations and Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#x201c;FDIC&#x201d;) and the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) insured limit on domestic currency and the Netherlands&#x2019; FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any losses in such accounts.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;, the Company&#x2019;s revenue was generated from&#160;&lt;span style="-sec-ix-hidden:c73543764"&gt;eight&lt;/span&gt; and&#160;&lt;span style="-sec-ix-hidden:c73543765"&gt;five&lt;/span&gt; customers, respectively.&#160;As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, the Company&#x2019;s accounts receivable was from&#160;&lt;span style="-sec-ix-hidden:c73543766"&gt;seven&lt;/span&gt; and &lt;span style="-sec-ix-hidden:c73543767"&gt;nine&lt;/span&gt;&#160;customers, respectively. The loss of business from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or a combination of the Company&#x2019;s customers could adversely affect its operations.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States.&#160;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, the Company had six&#160;customers outside of the United States (i.e. European and Asian customers) that accounted for approximately&#160;76.7%&#160;or&#160;$353,000&#160;of the revenue. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2020&lt;/em&gt;, the Company had&#160;three customers outside of the United States that accounted for approximately&#160;58.0% or $183,000&#160;of the revenue.&#160;As of&#160;the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, the Company had&#160;four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0%&#160;or $174,000&#160;of accounts receivable.&#160;As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, the Company had&#160;seven customers outside of the United States that accounted for approximately&#160;41.6% or&#160;$123,000 of accounts receivable.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company uses several contract research organizations (&#x201c;CROs&#x201d;) to conduct its research projects. As of and for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, &lt;span style="-sec-ix-hidden:c73543786"&gt;three&lt;/span&gt; CROs accounted for approximately $2,017,000 or 98.1%&#160;of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2020, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c73543792"&gt;one&lt;/span&gt; CRO accounted for approximately&#160;$855,000, or 100% of&#160;total research services we purchased. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, &lt;span style="-sec-ix-hidden:c73543795"&gt;one&lt;/span&gt; CRO accounted for approximately $690,000 or 68.1%&#160;of the accounts payable. The loss of this CRO or a combination of the Company&#x2019;s CROs could adversely affect its operations.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="margin-left: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="margin-left: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;"&gt;We treat highly liquid investments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Investment Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months or less, and long-term investment securities mature over &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#x2019;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company&#x2019;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, all of our money market funds were invested in U.S. Government money market funds. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any investment securities classified as trading as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; or&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#x2019;s best estimate of the amount of probable credit losses in the Company&#x2019;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months. There was &lt;span style="-sec-ix-hidden:c73543806"&gt;&lt;span style="-sec-ix-hidden:c73543807"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for doubtful accounts as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Accounts receivable consist of the following:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Billed receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;293,323&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;130,532&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unbilled receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,640&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;163,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;384,963&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;294,199&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;



   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Prepaid Expenses and Other Current Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;94,841&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;204,988&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid expenses - various&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;120,534&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;72,403&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;814&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,164&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;216,189&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;280,555&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Accounts payable consist of the following:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,337,755&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;904,572&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;93,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,987&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;84,031&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,473,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,013,099&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Employee wages and benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;175,210&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;447,881&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;42,006&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,508&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;60,452&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,367&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;277,668&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;489,756&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Revenue related to research collaborations and agreements: &lt;/i&gt;The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the &lt;em style="font: inherit;"&gt;5&lt;/em&gt;-step process outlined in ASC Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; (&#x201c;Topic &lt;em style="font: inherit;"&gt;606&#x201d;&lt;/em&gt;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; to measure the progress toward complete satisfaction of a performance obligation.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Under the input methods, revenue will be recognized on the basis of the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&lt;i&gt;Revenue related to grants: &lt;/i&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive grants&#160;from governments, agencies, and other private and &lt;em style="font: inherit;"&gt;not&lt;/em&gt;-for-profit organizations. These grants&#160;are intended to be used to partially or fully fund the Company&#x2019;s research collaborations, including opportunities arising in connection with COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; that the Company is pursuing with certain collaborators. However, most, if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; all, of such potential grant revenues, if received, is expected to be earmarked for &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties to advance the research required, including preclinical and clinical trials for SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; vaccines and/or antibodies candidates.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Revenue related to sublicensing agreements: &lt;/i&gt;If the sublicense to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Milestone payments: &lt;/i&gt;At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#x2019;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognized any milestone payment revenue resulting from any of its sublicensing arrangements.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Royalties: &lt;/i&gt;With respect to licenses deemed to be the predominant item to which the&lt;i&gt; &lt;/i&gt;sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognized any royalty revenue resulting from any of its sublicensing arrangements.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;We invoice customers based on our contractual arrangements with each customer, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. R&amp;amp;D costs are for the Company&#x2019;s internally funded pharmaceutical programs and other governmental and commercial projects.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; were as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outside contracted services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,659,194&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;613,790&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Personnel related costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;148,162&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;123,638&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Facilities, overhead and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;742&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,025&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,808,098&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;755,453&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Transaction Gain or Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into &lt;em style="font: inherit;"&gt;three&lt;/em&gt; levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&lt;i&gt;&#x2022;&lt;/i&gt;&lt;/td&gt;&lt;td style="width: 94%; vertical-align: top;"&gt;&lt;i&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/i&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&lt;i&gt;&#x2022;&lt;/i&gt;&lt;/td&gt;&lt;td style="width: 94%; vertical-align: top;"&gt;&lt;i&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/i&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&lt;i&gt;&#x2022;&lt;/i&gt;&lt;/td&gt;&lt;td style="width: 94%; vertical-align: top;"&gt;&lt;i&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/i&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company&#x2019;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#x2019;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party broker service for disclosure purposes.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"&gt;&lt;b&gt;&lt;i&gt;Non-Marketable Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company&#x2019;s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; or limited revenues, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be or &lt;em style="font: inherit;"&gt; may &lt;/em&gt;never become profitable, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be able to secure additional funding or their technologies, services or products &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be successfully developed or introduced into the market.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) was enacted on &lt;em style="font: inherit;"&gt; December 22, 2017 &lt;/em&gt;and became effective &lt;em style="font: inherit;"&gt; January 1, 2018. &lt;/em&gt;The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from &lt;em style="font: inherit;"&gt;35%&lt;/em&gt; to &lt;em style="font: inherit;"&gt;21%&lt;/em&gt; and repeal of the corporate alternative minimum tax (&#x201c;AMT&#x201d;). The TCJA&#x2019;s reduction in the U.S. statutory tax rate had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional impact on the consolidated financial statement for the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;For the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, there were &lt;span style="-sec-ix-hidden:c73543846"&gt;&lt;span style="-sec-ix-hidden:c73543847"&gt;no&lt;/span&gt;&lt;/span&gt; provision for income taxes and unrecognized tax benefits recorded. As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, deferred tax assets were approximately $10.2&#160;million and $9.4 million, respectively. Due to the Company&#x2019;s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#x2019; equity but are excluded from net income (loss) under GAAP. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separately present a statement of comprehensive income (loss) in its consolidated financial statements.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;We recognize all share-based payments to employees, consultants, and our board of directors (&#x201c;Board of Directors&#x201d;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;, the effect of the potential exercise of options to purchase 5,324,215&#160;and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which modifies the measurement of expected credit losses of certain financial instruments. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; will be effective for the Company beginning in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; to have a material impact on our consolidated financial positions, results of operations, and cash flows.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; December 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12,&lt;/em&gt;&#160;&lt;i&gt;Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Simplifying the Accounting for Income Taxes&lt;/i&gt;. The amendments of this update simplify the accounting for income taxes by removing certain exceptions&#160;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; on&#160;&lt;em style="font: inherit;"&gt; January 1, 2021, &lt;/em&gt;and&#160;adoption of ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; did&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either &lt;em style="font: inherit;"&gt;not&lt;/em&gt; applicable or &lt;em style="font: inherit;"&gt;not&lt;/em&gt; significant to our consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"/&gt;
   &lt;p style="text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0"&gt;&#160;&lt;/p&gt;


  </us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <dyai:ImpactOfCOVID19PolicyPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546953">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Impact of COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The outbreak of COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; has led to adverse impacts on the U.S. and global economies and created uncertainty regarding&#160;the potential impact to the Company&#x2019;s employees, operations, and research projects.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;To date, some of our employees are still working remotely. The extent to which the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;emerge concerning the severe acute respiratory syndrome coronavirus &lt;em style="font: inherit;"&gt;2&lt;/em&gt; (SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) and its&#160;variants and the actions taken and the level of success to contain or treat the SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic has subsided, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;continue to experience adverse impacts to its business because of economic recession or depression that has occurred or &lt;em style="font: inherit;"&gt; may &lt;/em&gt;occur in the future. Given the daily evolution of the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; able to accurately estimate the effects of the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; outbreak to our results of operations, financial condition, or liquidity.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months. However, in the event our financing needs for the foreseeable future are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; expression platform in humans. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that external funding will be available at acceptable terms, if at all, and the Company &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;therefore, self-fund these vital projects.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</dyai:ImpactOfCOVID19PolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546954">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;Basis of Presentation &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt;&#160;included in our Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K which was filed with the SEC on &lt;em style="font: inherit;"&gt; March&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;b&gt;&lt;i&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented.&#160;The results of the Company&#x2019;s operations for any interim periods are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results of operations for any other interim period or for a full fiscal year.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Since concluding the DuPont Transaction, the Company has conducted business in &lt;span style="-sec-ix-hidden:c73543760"&gt;one&lt;/span&gt; operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2021-01-01_2021-03-31" id="c73546955">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2021-01-01_2021-03-31" id="c73546956">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Concentrations and Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#x201c;FDIC&#x201d;) and the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) insured limit on domestic currency and the Netherlands&#x2019; FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any losses in such accounts.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;, the Company&#x2019;s revenue was generated from&#160;&lt;span style="-sec-ix-hidden:c73543764"&gt;eight&lt;/span&gt; and&#160;&lt;span style="-sec-ix-hidden:c73543765"&gt;five&lt;/span&gt; customers, respectively.&#160;As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, the Company&#x2019;s accounts receivable was from&#160;&lt;span style="-sec-ix-hidden:c73543766"&gt;seven&lt;/span&gt; and &lt;span style="-sec-ix-hidden:c73543767"&gt;nine&lt;/span&gt;&#160;customers, respectively. The loss of business from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or a combination of the Company&#x2019;s customers could adversely affect its operations.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States.&#160;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, the Company had six&#160;customers outside of the United States (i.e. European and Asian customers) that accounted for approximately&#160;76.7%&#160;or&#160;$353,000&#160;of the revenue. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2020&lt;/em&gt;, the Company had&#160;three customers outside of the United States that accounted for approximately&#160;58.0% or $183,000&#160;of the revenue.&#160;As of&#160;the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, the Company had&#160;four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0%&#160;or $174,000&#160;of accounts receivable.&#160;As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, the Company had&#160;seven customers outside of the United States that accounted for approximately&#160;41.6% or&#160;$123,000 of accounts receivable.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company uses several contract research organizations (&#x201c;CROs&#x201d;) to conduct its research projects. As of and for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, &lt;span style="-sec-ix-hidden:c73543786"&gt;three&lt;/span&gt; CROs accounted for approximately $2,017,000 or 98.1%&#160;of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2020, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c73543792"&gt;one&lt;/span&gt; CRO accounted for approximately&#160;$855,000, or 100% of&#160;total research services we purchased. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, &lt;span style="-sec-ix-hidden:c73543795"&gt;one&lt;/span&gt; CRO accounted for approximately $690,000 or 68.1%&#160;of the accounts payable. The loss of this CRO or a combination of the Company&#x2019;s CROs could adversely affect its operations.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c73543770"
      unitRef="Pure">6</dyai:ConcentrationRiskNumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="3"
      id="c73543771"
      unitRef="Pure">0.767</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c73543772"
      unitRef="USD">353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c73543774"
      unitRef="Pure">3</dyai:ConcentrationRiskNumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="2"
      id="c73543775"
      unitRef="Pure">0.580</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c73543776"
      unitRef="USD">183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c73543778"
      unitRef="Pure">4</dyai:ConcentrationRiskNumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="2"
      id="c73543779"
      unitRef="Pure">0.460</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c73543780"
      unitRef="USD">174000</us-gaap:AccountsReceivableNet>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c73543781"
      unitRef="Pure">7</dyai:ConcentrationRiskNumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="3"
      id="c73543782"
      unitRef="Pure">0.416</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c73543783"
      unitRef="USD">123000</us-gaap:AccountsReceivableNet>
    <dyai:ResearchServicesPurchased
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"
      decimals="INF"
      id="c73543787"
      unitRef="USD">2017000</dyai:ResearchServicesPurchased>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"
      decimals="3"
      id="c73543788"
      unitRef="Pure">0.981</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"
      decimals="INF"
      id="c73543789"
      unitRef="USD">1324000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-03-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"
      decimals="3"
      id="c73543790"
      unitRef="Pure">0.898</us-gaap:ConcentrationRiskPercentage1>
    <dyai:ResearchServicesPurchased
      contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember"
      decimals="INF"
      id="c73543793"
      unitRef="USD">855000</dyai:ResearchServicesPurchased>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-03-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember"
      decimals="0"
      id="c73543794"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember"
      decimals="INF"
      id="c73543796"
      unitRef="USD">690000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-OneCROMember"
      decimals="3"
      id="c73543797"
      unitRef="Pure">0.681</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546957">&lt;p style="margin-left: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;"&gt;We treat highly liquid investments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546958">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Investment Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months or less, and long-term investment securities mature over &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#x2019;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company&#x2019;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, all of our money market funds were invested in U.S. Government money market funds. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any investment securities classified as trading as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; or&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="d_2021-01-01_2021-03-31" id="c73546959">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#x2019;s best estimate of the amount of probable credit losses in the Company&#x2019;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months. There was &lt;span style="-sec-ix-hidden:c73543806"&gt;&lt;span style="-sec-ix-hidden:c73543807"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for doubtful accounts as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Accounts receivable consist of the following:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Billed receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;293,323&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;130,532&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unbilled receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,640&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;163,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;384,963&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;294,199&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
    </us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856454">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Billed receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;293,323&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;130,532&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unbilled receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,640&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;163,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;384,963&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;294,199&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="INF"
      id="c73543884"
      unitRef="USD">293323</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="INF"
      id="c73543885"
      unitRef="USD">130532</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="INF"
      id="c73543886"
      unitRef="USD">91640</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="INF"
      id="c73543887"
      unitRef="USD">163667</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543888"
      unitRef="USD">384963</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543889"
      unitRef="USD">294199</us-gaap:AccountsReceivableNetCurrent>
    <dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546960">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Prepaid Expenses and Other Current Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;94,841&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;204,988&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid expenses - various&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;120,534&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;72,403&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;814&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,164&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;216,189&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;280,555&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;</dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856455">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;94,841&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;204,988&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid expenses - various&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;120,534&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;72,403&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;814&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,164&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;216,189&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;280,555&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543892"
      unitRef="USD">94841</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543893"
      unitRef="USD">204988</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543894"
      unitRef="USD">120534</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543895"
      unitRef="USD">72403</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidTaxes
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543896"
      unitRef="USD">814</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543897"
      unitRef="USD">3164</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543898"
      unitRef="USD">216189</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543899"
      unitRef="USD">280555</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <dyai:AccountsPayablePolicyPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546963">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Accounts payable consist of the following:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,337,755&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;904,572&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;93,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,987&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;84,031&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,473,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,013,099&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;</dyai:AccountsPayablePolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856456">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,337,755&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;904,572&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;93,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,987&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;84,031&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,473,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,013,099&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <dyai:ResearchAndDevelopmentInProcessCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543902"
      unitRef="USD">1337755</dyai:ResearchAndDevelopmentInProcessCurrent>
    <dyai:ResearchAndDevelopmentInProcessCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543903"
      unitRef="USD">904572</dyai:ResearchAndDevelopmentInProcessCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543904"
      unitRef="USD">93071</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543905"
      unitRef="USD">24496</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543906"
      unitRef="USD">42987</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543907"
      unitRef="USD">84031</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543908"
      unitRef="USD">1473813</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543909"
      unitRef="USD">1013099</us-gaap:AccountsPayableCurrent>
    <dyai:AccruedExpensesPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546964">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Employee wages and benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;175,210&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;447,881&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;42,006&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,508&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;60,452&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,367&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;277,668&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;489,756&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;</dyai:AccruedExpensesPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856457">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;March 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Employee wages and benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;175,210&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;447,881&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;42,006&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,508&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;60,452&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,367&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;277,668&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;489,756&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543912"
      unitRef="USD">175210</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543913"
      unitRef="USD">447881</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <dyai:AccruedResearchAndDevelopmentInProcessCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543914"
      unitRef="USD">42006</dyai:AccruedResearchAndDevelopmentInProcessCurrent>
    <dyai:AccruedResearchAndDevelopmentInProcessCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543915"
      unitRef="USD">28508</dyai:AccruedResearchAndDevelopmentInProcessCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543916"
      unitRef="USD">60452</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543917"
      unitRef="USD">13367</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543918"
      unitRef="USD">277668</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73543919"
      unitRef="USD">489756</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546965">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Revenue related to research collaborations and agreements: &lt;/i&gt;The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the &lt;em style="font: inherit;"&gt;5&lt;/em&gt;-step process outlined in ASC Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; (&#x201c;Topic &lt;em style="font: inherit;"&gt;606&#x201d;&lt;/em&gt;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; to measure the progress toward complete satisfaction of a performance obligation.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Under the input methods, revenue will be recognized on the basis of the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&lt;i&gt;Revenue related to grants: &lt;/i&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive grants&#160;from governments, agencies, and other private and &lt;em style="font: inherit;"&gt;not&lt;/em&gt;-for-profit organizations. These grants&#160;are intended to be used to partially or fully fund the Company&#x2019;s research collaborations, including opportunities arising in connection with COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; that the Company is pursuing with certain collaborators. However, most, if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; all, of such potential grant revenues, if received, is expected to be earmarked for &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties to advance the research required, including preclinical and clinical trials for SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; vaccines and/or antibodies candidates.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Revenue related to sublicensing agreements: &lt;/i&gt;If the sublicense to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Milestone payments: &lt;/i&gt;At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#x2019;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognized any milestone payment revenue resulting from any of its sublicensing arrangements.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Royalties: &lt;/i&gt;With respect to licenses deemed to be the predominant item to which the&lt;i&gt; &lt;/i&gt;sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognized any royalty revenue resulting from any of its sublicensing arrangements.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;We invoice customers based on our contractual arrangements with each customer, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2021-01-01_2021-03-31" id="c73546966">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. R&amp;amp;D costs are for the Company&#x2019;s internally funded pharmaceutical programs and other governmental and commercial projects.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; were as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outside contracted services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,659,194&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;613,790&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Personnel related costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;148,162&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;123,638&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Facilities, overhead and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;742&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,025&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,808,098&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;755,453&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856458">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;(Unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outside contracted services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,659,194&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;613,790&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Personnel related costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;148,162&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;123,638&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Facilities, overhead and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;742&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,025&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,808,098&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;755,453&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock>
    <dyai:ResearchAndDevelopmentExpenseOutsideContractedServices
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543924"
      unitRef="USD">1659194</dyai:ResearchAndDevelopmentExpenseOutsideContractedServices>
    <dyai:ResearchAndDevelopmentExpenseOutsideContractedServices
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543925"
      unitRef="USD">613790</dyai:ResearchAndDevelopmentExpenseOutsideContractedServices>
    <dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543926"
      unitRef="USD">148162</dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts>
    <dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543927"
      unitRef="USD">123638</dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts>
    <dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543928"
      unitRef="USD">742</dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther>
    <dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543929"
      unitRef="USD">18025</dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther>
    <dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543930"
      unitRef="USD">1808098</dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty>
    <dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543931"
      unitRef="USD">755453</dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546967">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Transaction Gain or Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546968">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into &lt;em style="font: inherit;"&gt;three&lt;/em&gt; levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&lt;i&gt;&#x2022;&lt;/i&gt;&lt;/td&gt;&lt;td style="width: 94%; vertical-align: top;"&gt;&lt;i&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/i&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&lt;i&gt;&#x2022;&lt;/i&gt;&lt;/td&gt;&lt;td style="width: 94%; vertical-align: top;"&gt;&lt;i&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/i&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; vertical-align: top;"&gt;&lt;i&gt;&#x2022;&lt;/i&gt;&lt;/td&gt;&lt;td style="width: 94%; vertical-align: top;"&gt;&lt;i&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/i&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company&#x2019;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#x2019;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party broker service for disclosure purposes.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546969">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"&gt;&lt;b&gt;&lt;i&gt;Non-Marketable Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company&#x2019;s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; or limited revenues, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be or &lt;em style="font: inherit;"&gt; may &lt;/em&gt;never become profitable, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be able to secure additional funding or their technologies, services or products &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be successfully developed or introduced into the market.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546970">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) was enacted on &lt;em style="font: inherit;"&gt; December 22, 2017 &lt;/em&gt;and became effective &lt;em style="font: inherit;"&gt; January 1, 2018. &lt;/em&gt;The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from &lt;em style="font: inherit;"&gt;35%&lt;/em&gt; to &lt;em style="font: inherit;"&gt;21%&lt;/em&gt; and repeal of the corporate alternative minimum tax (&#x201c;AMT&#x201d;). The TCJA&#x2019;s reduction in the U.S. statutory tax rate had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional impact on the consolidated financial statement for the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;For the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, there were &lt;span style="-sec-ix-hidden:c73543846"&gt;&lt;span style="-sec-ix-hidden:c73543847"&gt;no&lt;/span&gt;&lt;/span&gt; provision for income taxes and unrecognized tax benefits recorded. As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, deferred tax assets were approximately $10.2&#160;million and $9.4 million, respectively. Due to the Company&#x2019;s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2021-03-31"
      decimals="-5"
      id="c73543848"
      unitRef="USD">10200000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2020-12-31"
      decimals="-5"
      id="c73543849"
      unitRef="USD">9400000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <dyai:DeferredTaxAssetsValuationAllowanceCoveragePercent
      contextRef="d_2021-01-01_2021-03-31"
      decimals="0"
      id="c73543850"
      unitRef="Pure">1</dyai:DeferredTaxAssetsValuationAllowanceCoveragePercent>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546971">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#x2019; equity but are excluded from net income (loss) under GAAP. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separately present a statement of comprehensive income (loss) in its consolidated financial statements.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2021-01-01_2021-03-31" id="c73546972">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;We recognize all share-based payments to employees, consultants, and our board of directors (&#x201c;Board of Directors&#x201d;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546973">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;, the effect of the potential exercise of options to purchase 5,324,215&#160;and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73543856"
      unitRef="Share">5324215</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73543857"
      unitRef="Share">4663390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-03-31" id="c73546974">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which modifies the measurement of expected credit losses of certain financial instruments. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; will be effective for the Company beginning in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; to have a material impact on our consolidated financial positions, results of operations, and cash flows.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; December 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12,&lt;/em&gt;&#160;&lt;i&gt;Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Simplifying the Accounting for Income Taxes&lt;/i&gt;. The amendments of this update simplify the accounting for income taxes by removing certain exceptions&#160;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; on&#160;&lt;em style="font: inherit;"&gt; January 1, 2021, &lt;/em&gt;and&#160;adoption of ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; did&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either &lt;em style="font: inherit;"&gt;not&lt;/em&gt; applicable or &lt;em style="font: inherit;"&gt;not&lt;/em&gt; significant to our consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856459">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2:&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b&gt;Cash, Cash Equivalent, and Investments &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company&#x2019;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company&#x2019;s cash, available-for-sale securities, and investment securities by major security type as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;March 31, 2021 (Unaudited)&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Adjusted Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,217,419&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,217,419&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Money Market Funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,838,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,838,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,055,558&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,055,558&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Short-Term Investment Securities &lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate Bonds &lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,161,252&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,658&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(17,847&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,177,441&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;27,216,810&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,658&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(17,847&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;27,232,999&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2020 (Audited)&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Adjusted Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;149,015&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;149,015&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Money Market Funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,488,030&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,488,030&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,637,045&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,637,045&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Short-Term Investment Securities &lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate Bonds &lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;8,473,461&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;22,473&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;(6,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;8,457,451&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,110,506&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,473&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(6,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,094,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;_________________&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Notes:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Definition of the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-level fair value hierarchy:&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Quoted prices (unadjusted) in active markets for identical assets or liabilities&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Other inputs that are directly or indirectly observable in the markets&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; - Inputs that are generally unobservable&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) Short-term investment securities will mature within &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months or less, from the applicable reporting date.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385&#160;for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company&#x2019;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the Company will be required to sell the investment before recovery of the investment&#x2019;s cost basis. As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consider any of its investments to be other-than-temporarily impaired.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="d_2021-01-01_2021-03-31"
      id="CE2D0B32-FB65-4AAE-A216-9572C0A689B9">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;March 31, 2021 (Unaudited)&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Adjusted Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,217,419&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,217,419&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Money Market Funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,838,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,838,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,055,558&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,055,558&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Short-Term Investment Securities &lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate Bonds &lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,161,252&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,658&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(17,847&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,177,441&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;27,216,810&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,658&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(17,847&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;27,232,999&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2020 (Audited)&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Adjusted Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;149,015&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;149,015&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Money Market Funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,488,030&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,488,030&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,637,045&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,637,045&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Short-Term Investment Securities &lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate Bonds &lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;8,473,461&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;22,473&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;(6,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;8,457,451&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,110,506&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,473&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(6,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,094,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-03-31_FairValueByAssetClassAxis-CashMember"
      decimals="INF"
      id="c73543971"
      unitRef="USD">1217419</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543974"
      unitRef="USD">1217419</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="INF"
      id="c73543976"
      unitRef="USD">11838139</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543979"
      unitRef="USD">11838139</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543981"
      unitRef="USD">13055558</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543984"
      unitRef="USD">13055558</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2021-03-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c73543987"
      unitRef="USD">14161252</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2021-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ShortTermCorporateBondsMember"
      decimals="INF"
      id="c73543988"
      unitRef="USD">1658</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2021-03-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c73543989"
      unitRef="USD">17847</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i_2021-03-31_InvestmentTypeAxis-CorporateBondSecuritiesMember"
      decimals="INF"
      id="c73543990"
      unitRef="USD">14177441</us-gaap:HeldToMaturitySecuritiesCurrent>
    <dyai:CashCashEquivalentsAndInvestmentsFairValue
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543992"
      unitRef="USD">27216810</dyai:CashCashEquivalentsAndInvestmentsFairValue>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543993"
      unitRef="USD">1658</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543994"
      unitRef="USD">17847</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:InvestmentsAndCash
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73543995"
      unitRef="USD">27232999</us-gaap:InvestmentsAndCash>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CashMember"
      decimals="INF"
      id="c73544018"
      unitRef="USD">149015</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544021"
      unitRef="USD">149015</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="INF"
      id="c73544023"
      unitRef="USD">20488030</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544026"
      unitRef="USD">20488030</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544028"
      unitRef="USD">20637045</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544031"
      unitRef="USD">20637045</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c73544034"
      unitRef="USD">8473461</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ShortTermCorporateBondsMember"
      decimals="INF"
      id="c73544035"
      unitRef="USD">22473</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c73544036"
      unitRef="USD">6463</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i_2020-12-31_InvestmentTypeAxis-CorporateBondSecuritiesMember"
      decimals="INF"
      id="c73544037"
      unitRef="USD">8457451</us-gaap:HeldToMaturitySecuritiesCurrent>
    <dyai:CashCashEquivalentsAndInvestmentsFairValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544039"
      unitRef="USD">29110506</dyai:CashCashEquivalentsAndInvestmentsFairValue>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544040"
      unitRef="USD">22473</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544041"
      unitRef="USD">6463</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:InvestmentsAndCash
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544042"
      unitRef="USD">29094496</us-gaap:InvestmentsAndCash>
    <dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase
      contextRef="d_2021-01-01_2021-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="INF"
      id="c73543941"
      unitRef="USD">283940</dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase>
    <dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase
      contextRef="d_2020-01-01_2020-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="INF"
      id="c73543942"
      unitRef="USD">196385</dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase>
    <dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase
      contextRef="d_2020-01-01_2020-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="INF"
      id="c73543945"
      unitRef="USD">282946</dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856462">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b&gt;Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-Held Companies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;BDI&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; June 30, 2017, &lt;/em&gt;the Company entered into a strategic Research Services Agreement (the &#x201c;RSA&#x201d;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#x201c;BDI Pharma&#x201d;), and a Service Framework Agreement (the &#x201c;SFA&#x201d;, and together with the RSA, the &#x201c;R&amp;amp;D Agreements&#x201d;), with VLP The Vaccines Company, S.L.U. (&#x201c;VLPbio&#x201d;), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#x201c;BDI Holdings&#x201d; and together with BDI Pharma and VLPbio, &#x201c;BDI&#x201d;).&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The R&amp;amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a &lt;span style="-sec-ix-hidden:c73544044"&gt;two&lt;/span&gt;-year period, with a focus on advancing Dyadic&#x2019;s proprietary &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#x2019;s previous &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#x2019;s proprietary &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Upon closing of the BDI transaction, the Company paid EUR &lt;em style="font: inherit;"&gt;&#x20ac;1.0&lt;/em&gt; million (the &#x201c;RSA Initial Payment&#x201d;) in cash to engage BDI to develop designated &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; based product candidates and further improve the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR &lt;span style="-sec-ix-hidden:c73544054"&gt;&#x20ac;936,000&lt;/span&gt; over &lt;span style="-sec-ix-hidden:c73544055"&gt;two&lt;/span&gt; years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI&#x2019;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR &lt;span style="-sec-ix-hidden:c73544058"&gt;&#x20ac;1&lt;/span&gt;&#160;million for a 50% share and EUR &lt;em style="font: inherit;"&gt;&#x20ac;&lt;span style="-sec-ix-hidden:c73544061"&gt;8.0&lt;/span&gt;&lt;/em&gt; million for a 75% share. If BDI does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR &lt;span style="-sec-ix-hidden:c73544064"&gt;&#x20ac;1.5&lt;/span&gt;&#160;million of the net income from Dyadic&#x2019;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1.0 million (the &#x201c;SFA Commitment&#x201d;) in contract research services specified by Dyadic over &lt;span style="-sec-ix-hidden:c73544066"&gt;two&lt;/span&gt; years since the closing of the BDI transaction.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company has concluded that BDI is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a Variable Interest Entity (&#x201c;VIE&#x201d;), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the primary beneficiary of BDI as Dyadic does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the power to control or direct the activities of BDI or its operations. As a result, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consolidate its investments in BDI, and the financial results of BDI are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the Company&#x2019;s consolidated financial results.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD &lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c73544074"&gt;$1.1&lt;/span&gt;&lt;/em&gt; million (EUR &lt;em style="font: inherit;"&gt;&#x20ac;1.0&lt;/em&gt; million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1.0 million paid by Dyadic were expensed as the related research services were performed by BDI. In &lt;em style="font: inherit;"&gt; June 2019, &lt;/em&gt;BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA in &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; February 18, 2021, &lt;/em&gt;the Company entered into a separate service agreement with BDI to perform a research&#160;project unrelated to the R&amp;amp;D Agreements.&#160;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, approximately&#160;$15,000 recorded in the cost of research and development revenue was associated with this new service agreement.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Novovet and Luina Bio&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;On &lt;em style="font: inherit;"&gt; April 26, 2019, &lt;/em&gt;the Company entered into a sub-license agreement (the &#x201c;Luina Bio Sub-License Agreement&#x201d;) with Luina Bio Pty Ltd. (&#x201c;Luina Bio&#x201d;) and Novovet Pty Ltd (&#x201c;Novovet&#x201d;). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on &lt;em style="font: inherit;"&gt; December 31, 2015, &lt;/em&gt;a worldwide sub-license to certain patent rights and know-how related to&#160;Dyadic&#x2019;s proprietary &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; gene expression platform&#160;for the exclusive and sole purpose of commercializing&#160;certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (&#x201c;Novovet Up-Front Consideration&#x201d;) in accordance with the terms of Novovet&#x2019;s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic&#x2019;s proprietary &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; gene expression platform.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have sufficient equity to finance its activities without additional financial support from &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party investors or lenders. However, the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the primary beneficiary of Novovet as Dyadic does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; control, over Novovet.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;To date Novovet has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; raised the capital required to move this opportunity forward, and therefore, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; transferred its &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet meet the revenue recognition criteria under ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology is completed and Novovet receives adequate financing required to commence its research and development activities.&#160;The Company intends to terminate the Luina Bio Sub-License Agreement in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; should Novovet be unable to raise the required funding.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Alphazyme&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;On &lt;em style="font: inherit;"&gt; May 5, 2019, &lt;/em&gt;the Company entered into a sub-license agreement (the &#x201c;Alphazyme Sub-License Agreement&#x201d;) with Alphazyme, LLC (&#x201c;Alphazyme&#x201d;). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on &lt;em style="font: inherit;"&gt; December 31, 2015, &lt;/em&gt;a sub-license to certain patent rights and know-how related to&#160;Dyadic&#x2019;s proprietary &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; gene expression platform&#160;for the purpose of commercializing&#160;certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; June 24, 2020, &lt;/em&gt;the Company entered into an Amended and Restated Non-Exclusive Sub-License Agreement (the &#x201c;Amended Sub-License Agreement&#x201d;) with Alphazyme.&#160;Pursuant to the Amended Sub-License Agreement and in consideration of Dyadic&#x2019;s transfer of its &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology, Alphazyme issued&#160;2.50% of the Class A shares of Alphazyme to Dyadic, and Dyadic became a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company has agreed to certain customary rights, covenants and obligations. In addition, and subject to achieving certain milestones, Alphazyme is obligated to pay a potential milestone payment and royalties, based on net sales, if any, which incorporate Dyadic&#x2019;s proprietary &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; gene expression platform.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; December 1, 2020, &lt;/em&gt;the Company entered into an Amended and Restated Limited Liability Company Agreement with Alphazyme (the &#x201c;Amended Alphazyme LLC Agreement&#x201d;) was entered into.&#160;Under the Amended Alphazyme LLC Agreement,&#160;Alphazyme obtained an additional capital contribution&#160;and Dyadic&#x2019;s ownership was diluted to 1.99%.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the primary beneficiary of Alphazyme as Dyadic does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consolidate its investment&#160;in Alphazyme. The Company reports&#160;its investment in Alphazyme under the cost method of accounting, given that it does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the ability to exercise significant influence or control,&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;For the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company recorded a gain of &lt;span style="-sec-ix-hidden:c73544106"&gt;$284,709&lt;/span&gt; from&#160;its investment in Alphazyme as a result of a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party additional capital contribution obtained by Alphazyme.&#160;As of &lt;em style="font: inherit;"&gt;March31,&lt;/em&gt;&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consider its&#160;investment in Alphazyme to be impaired.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"&gt;&lt;b&gt;&lt;i&gt;IDBiologics, Inc.&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; July 8, 2020, &lt;/em&gt;the Company entered into a Common Stock Purchase Agreement (the &#x201c;IDBiologics Agreement&#x201d;) with IDBiologics, Inc (&#x201c;IDBiologics&#x201d;). IDBiologics is a private biotechnology company focused on the development of human monoclonal antibodies for the treatment and prevention of serious infectious diseases. The Company was founded in &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; and seeded by Vanderbilt University Medical Center&#160;in response to the repeated threats of epidemics around the world, including Ebola in West Africa and Zika in the Americas. IDBiologics is developing a portfolio of monoclonal antibodies against SARS-CoV-&lt;em style="font: inherit;"&gt;2,&lt;/em&gt; influenza and Zika viruses.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Under the term of the IDBiologics Agreement, Dyadic agreed to receive 129,611 shares of IDBiologics&#x2019; common stock, which represent 0.37% of IDBiologics&#x2019; outstanding equity, in exchange for the services to be provided by Dyadic. Such services&#160;include the use of Dyadic&#x2019;s &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; technology to express a SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; monoclonal antibody which IDBiologics&#160;licensed from the Vanderbilt Vaccine Center. The shares of common stock of IDBiologics vested 50% upon the signing of the IDBiologics Agreement,&#160;25% will vest upon the completion of Step &lt;em style="font: inherit;"&gt;3&lt;/em&gt; of a feasibility study required by the IDBiologics Agreement, and 25% will vest at the end of the project.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company evaluated the nature of its equity interest in IDBiologics and determined that IDBiologics is a VIE due to the capital structure of the entity. However, the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the primary beneficiary of IDBiologics as Dyadic does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the power to control or direct the activities of IDBiologics that most significantly impact the VIE. As a result, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consolidate its investment in IDBiologics. Upon receipt its shares, Dyadic will account for the equity interest in IDBiologics under the cost method. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; revenue from the IDBiologics Agreement was recorded during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt;&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, because the amount of consideration received was immaterial.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dyai:CollaborativeArrangementEquityInterestAcquired
      contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember"
      decimals="3"
      id="c73544052"
      unitRef="Pure">0.161</dyai:CollaborativeArrangementEquityInterestAcquired>
    <dyai:CollaborativeArrangementEquityInterestAcquired
      contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-VLPbioMember"
      decimals="3"
      id="c73544053"
      unitRef="Pure">0.033</dyai:CollaborativeArrangementEquityInterestAcquired>
    <dyai:CollaborativeArrangementRevenueSharingPercentage
      contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember"
      decimals="1"
      id="c73544056"
      unitRef="Pure">0.50</dyai:CollaborativeArrangementRevenueSharingPercentage>
    <dyai:CollaborativeArrangementRevenueSharingPercentage
      contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c73544057"
      unitRef="Pure">0.75</dyai:CollaborativeArrangementRevenueSharingPercentage>
    <dyai:CollaborativeArrangementRevenueSharingPercentage
      contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MinimumMember"
      decimals="1"
      id="c73544059"
      unitRef="Pure">0.50</dyai:CollaborativeArrangementRevenueSharingPercentage>
    <dyai:CollaborativeArrangementRevenueSharingPercentage
      contextRef="d_2017-06-30_2017-06-30_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis-ResearchServicesAgreementMember_OwnershipAxis-BDIHoldingsMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c73544062"
      unitRef="Pure">0.75</dyai:CollaborativeArrangementRevenueSharingPercentage>
    <dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment
      contextRef="i_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember"
      decimals="-6"
      id="c73544065"
      unitRef="USD">1000000.0</dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment>
    <dyai:CollaborativeArrangementOutstandingCommitment
      contextRef="i_2017-06-30_CapitalizedContractCostAxis-ServiceFrameworkAgreementMember"
      decimals="-6"
      id="c73544075"
      unitRef="USD">1000000.0</dyai:CollaborativeArrangementOutstandingCommitment>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-BDIMember_TypeOfArrangementAxis-ServiceAgreementToPerformResearchProjectMember"
      decimals="INF"
      id="c73544078"
      unitRef="USD">15000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i_2019-04-26_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-NovovetMember"
      decimals="1"
      id="c73544081"
      unitRef="Pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i_2019-04-26_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-NovovetMember"
      decimals="1"
      id="c73544092"
      unitRef="Pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="d_2020-06-24_2020-06-24_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember"
      decimals="3"
      id="c73544099"
      unitRef="Pure">0.0250</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <dyai:OwnershipPercentage
      contextRef="i_2020-12-01_OwnershipAxis-AlphazymeMember"
      decimals="4"
      id="c73544101"
      unitRef="Pure">0.0199</dyai:OwnershipPercentage>
    <dyai:CollaborativeArrangementNumberOfSharesToBeReceived
      contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember"
      decimals="INF"
      id="c73544114"
      unitRef="Share">129611</dyai:CollaborativeArrangementNumberOfSharesToBeReceived>
    <dyai:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember"
      decimals="4"
      id="c73544115"
      unitRef="Pure">0.0037</dyai:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners>
    <dyai:CollaborativeArrangementVestingPercentages
      contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="1"
      id="c73544118"
      unitRef="Pure">0.50</dyai:CollaborativeArrangementVestingPercentages>
    <dyai:CollaborativeArrangementVestingPercentages
      contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      decimals="2"
      id="c73544119"
      unitRef="Pure">0.25</dyai:CollaborativeArrangementVestingPercentages>
    <dyai:CollaborativeArrangementVestingPercentages
      contextRef="i_2020-07-08_OwnershipAxis-IDBiologicsIncMember_VestingAxis-ShareBasedCompensationAwardTrancheThreeMember"
      decimals="2"
      id="c73544121"
      unitRef="Pure">0.25</dyai:CollaborativeArrangementVestingPercentages>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856463">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4:&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#x2019;s consolidated financial position, cash flows or results of operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856464">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5:&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Description of Equity Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Equity Incentive Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2011&lt;/em&gt; Plan&#x201d;) was adopted by the Company&#x2019;s Board of Directors on &lt;em style="font: inherit;"&gt; April 28, 2011 &lt;/em&gt;and approved by the Company&#x2019;s stockholders on &lt;em style="font: inherit;"&gt; June 15, 2011. &lt;/em&gt;The &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan serves as the successor to the Company&#x2019;s &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Stock Option Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2006&lt;/em&gt; Plan&#x201d;). Since the effective date of the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan, all equity awards were made from the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan, and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional awards will be granted under the &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; plan. Under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan, 3,000,000 shares of the Company&#x2019;s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Plan or are subject to awards under the &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Plan which are forfeited or lapse unexercised and which following the effective date are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; issued under the &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Plan. In accordance with the provisions of the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on &lt;em style="font: inherit;"&gt; January 1, 2019 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;At our &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Virtual Annual Meeting of Shareholders (&#x201c;Annual Meeting&#x201d;) to be held on &lt;em style="font: inherit;"&gt; June 11, 2021, &lt;/em&gt;shareholders will be asked to approve the Company&#x2019;s&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Equity Incentive Award Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2021&lt;/em&gt; Plan&#x201d;), which was adopted, subject to shareholder approval, by the Board of Directors on &lt;em style="font: inherit;"&gt; April 9, 2021. &lt;/em&gt;We are seeking&#160;stockholder approval of the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan to increase the number of shares available for the grant of stock options, restricted stock awards and other awards by&#160;3,000,000&#160;in addition to&#160;the number of shares remaining available for the grant of new awards under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt;&#160;Plan as of &lt;em style="font: inherit;"&gt; April 16, 2021. &lt;/em&gt;If this&#160;proposal is approved by our shareholders, the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan will become effective as of the date of the Annual Meeting and as of such date, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional awards will be&#160;granted under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan. If our shareholders do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; approve this proposal, the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; become effective and the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan will continue to be effective in&#160;accordance with its terms, until its expiration date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, the Company had 5,324,215 stock options outstanding and an additional 1,388,386&#160;shares of common stock available for grant under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, there were 4,638,390 stock options outstanding and 2,134,211 shares of common stock available for grant under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Stock Options &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan is &lt;span style="-sec-ix-hidden:c73544184"&gt;ten&lt;/span&gt; years except for certain options granted to the contractors which are &lt;span style="-sec-ix-hidden:c73544185"&gt;one&lt;/span&gt; or &lt;span style="-sec-ix-hidden:c73544186"&gt;three&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Risk-free interest rate&lt;/i&gt;. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Expected dividend yield&lt;/i&gt;. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently anticipate paying any in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;i&gt;Expected stock price volatility.&lt;/i&gt; The expected stock price volatility was calculated based on the Company&#x2019;s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company&#x2019;s historical volatility since &lt;em style="font: inherit;"&gt;2016,&lt;/em&gt; as the DuPont Transaction resulted in significant changes in the Company&#x2019;s business and capital structure.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&lt;i&gt;Expected life of option. &lt;/i&gt;The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., &lt;span style="-sec-ix-hidden:c73544190"&gt;5&lt;/span&gt; or 10 years) and certain contractors (i.e., 2 or &lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c73544194"&gt;3&lt;/span&gt;years&lt;/em&gt;).&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The assumptions used in the Black-Scholes option pricing model for stock options granted during the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt; are as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-Free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.13%-0.55%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;%&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected stock price volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;54.52%-56.07%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected life of options (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.00-6.25&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The following table summarizes the stock option activities during the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term (Years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,638,390&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.44&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.64&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;13,701,610&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;745,825&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised (2)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(60,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.93&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 13%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at March 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,324,215&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.84&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6.03&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,209,431&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 44%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at March 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,016,141&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,927,908&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;_________________&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Notes:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Represents the following stock options granted:&lt;/p&gt;
   &lt;table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Annual share-based compensation awards on &lt;em style="font: inherit;"&gt; January 4,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon &lt;span style="-sec-ix-hidden:c73544201"&gt;one&lt;/span&gt; year anniversary, or vesting&#160;annually in equal installments over &lt;span style="-sec-ix-hidden:c73544202"&gt;four&lt;/span&gt; years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon &lt;span style="-sec-ix-hidden:c73544205"&gt;one&lt;/span&gt; year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over &lt;span style="-sec-ix-hidden:c73544208"&gt;four&lt;/span&gt; years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon &lt;span style="-sec-ix-hidden:c73544211"&gt;one&lt;/span&gt; year anniversary.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;One-time award on &lt;em style="font: inherit;"&gt; January 8,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in &lt;span style="-sec-ix-hidden:c73544215"&gt;one&lt;/span&gt; year from the grant date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;One-time award on &lt;em style="font: inherit;"&gt; January 21, 2021, &lt;/em&gt;7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in &lt;span style="-sec-ix-hidden:c73544218"&gt;one&lt;/span&gt; year from the grant date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;One-time award on &lt;em style="font: inherit;"&gt; March 22, 2021, &lt;/em&gt;30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in &lt;span style="-sec-ix-hidden:c73544221"&gt;one&lt;/span&gt; year from the grant date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) Represents the following stock options exercised:&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Compensation Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact on the Company&#x2019;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Total non-cash stock option compensation expense was allocated among the following expense categories:&#160;&#160;&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;377,052&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;380,251&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;44,019&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,688&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;421,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;426,939&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2011-04-28_PlanNameAxis-The2011PlanMember"
      decimals="INF"
      id="c73544158"
      unitRef="Share">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2019-01-01_2019-01-01_PlanNameAxis-The2011PlanMember"
      decimals="INF"
      id="c73544164"
      unitRef="Share">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2021-04-16_2021-04-16_PlanNameAxis-The2011PlanMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c73545121"
      unitRef="Share">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-03-31_PlanNameAxis-The2011PlanMember"
      decimals="INF"
      id="c73544177"
      unitRef="Share">5324215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-03-31_PlanNameAxis-The2011PlanMember"
      decimals="INF"
      id="c73544178"
      unitRef="Share">1388386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31_PlanNameAxis-The2011PlanMember"
      decimals="INF"
      id="c73544180"
      unitRef="Share">4638390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2020-12-31_PlanNameAxis-The2011PlanMember"
      decimals="INF"
      id="c73544181"
      unitRef="Share">2134211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2011PlanMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      id="c73544191">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_OwnershipAxis-ContractorMember_PlanNameAxis-The2011PlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      id="c73544192">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856465">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-Free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.13%-0.55%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;%&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected stock price volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;54.52%-56.07%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected life of options (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.00-6.25&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2021-01-01_2021-03-31"
      decimals="4"
      id="c73544227"
      unitRef="Pure">0.0013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2021-01-01_2021-03-31"
      decimals="4"
      id="c73544229"
      unitRef="Pure">0.0055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="d_2021-01-01_2021-03-31"
      decimals="4"
      id="c73544233"
      unitRef="Pure">0.5452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2021-01-01_2021-03-31"
      decimals="4"
      id="c73544235"
      unitRef="Pure">0.5607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-03-31_RangeAxis-MinimumMember"
      id="c73544236">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-03-31_RangeAxis-MaximumMember"
      id="c73544238">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856466">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term (Years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,638,390&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.44&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.64&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;13,701,610&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;745,825&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised (2)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(60,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.93&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 13%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at March 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,324,215&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.84&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6.03&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,209,431&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 44%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at March 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,016,141&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,927,908&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544251"
      unitRef="Share">4638390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544252"
      unitRef="USDPerShare">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2020-01-01_2020-12-31" id="c73544253">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544254"
      unitRef="USD">13701610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544255"
      unitRef="Share">745825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544256"
      unitRef="USDPerShare">5.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544259"
      unitRef="Share">60000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544260"
      unitRef="USDPerShare">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544263"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544264"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544267"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544268"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73544271"
      unitRef="Share">5324215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73544272"
      unitRef="USDPerShare">2.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2021-01-01_2021-03-31" id="c73544273">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73544274"
      unitRef="USD">14209431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73544275"
      unitRef="Share">4016141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73544276"
      unitRef="USDPerShare">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2021-01-01_2021-03-31" id="c73544277">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73544278"
      unitRef="USD">12927908</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      decimals="INF"
      id="c73544199"
      unitRef="Share">417500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      decimals="INF"
      id="c73544200"
      unitRef="USDPerShare">5.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c73544203"
      unitRef="Share">227500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c73544204"
      unitRef="USDPerShare">5.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-EmployeesMember"
      decimals="INF"
      id="c73544206"
      unitRef="Share">23325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-EmployeesMember"
      decimals="INF"
      id="c73544207"
      unitRef="USDPerShare">5.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c73544209"
      unitRef="Share">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c73544210"
      unitRef="USDPerShare">5.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-08_2021-01-08_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c73544213"
      unitRef="Share">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-08_2021-01-08_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c73544214"
      unitRef="USDPerShare">5.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-21_2021-01-21_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c73544216"
      unitRef="Share">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-21_2021-01-21_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c73544217"
      unitRef="USDPerShare">5.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-03-22_2021-03-22_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c73544219"
      unitRef="Share">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-03-22_2021-03-22_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c73544220"
      unitRef="USDPerShare">6.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544223"
      unitRef="Share">60000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544224"
      unitRef="USDPerShare">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856467">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;377,052&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;380,251&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;44,019&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,688&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;421,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;426,939&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c73544283"
      unitRef="USD">377052</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c73544284"
      unitRef="USD">380251</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="c73544285"
      unitRef="USD">44019</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="c73544286"
      unitRef="USD">46688</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544287"
      unitRef="USD">421071</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73544288"
      unitRef="USD">426939</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856468">
   &lt;b&gt;Note &lt;em style="font: inherit;"&gt;6:&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;
   &lt;b&gt;Shareholders&lt;/b&gt;&#x2019;
   &lt;b&gt; Equity&lt;/b&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Issuances of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, there were 60,000 shares of the Company&#x2019;s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.93 per share. For the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2020&lt;/em&gt;, there were 100,000 shares of the Company&#x2019;s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.78 per share.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:54pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Changes in Stockholders Equity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31, 2021 (Unaudited)&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Common Stock&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Treasury Stock&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Additional Paid-In Capital&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accumulated Deficit&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;January 1, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;39,748&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(18,929,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;98,013,079&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(50,676,351&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,446,561&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;421,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;421,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;60&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;115,740&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;115,800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,294,949&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,294,949&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;March 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;39,808&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;(18,929,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;98,549,890&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;(53,971,300&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;25,688,483&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31, 2020 (Unaudited)&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Common Stock&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Treasury Stock&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Additional Paid-In Capital&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accumulated Deficit&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;January 1, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;39,613&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(18,929,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;96,105,851&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(41,351,078&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;35,864,471&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;426,939&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;426,939&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%"&gt;Stock issued&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;174,900&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;175,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,214,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,214,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;March 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;39,713&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;(18,929,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;96,707,690&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;(43,565,217&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;34,252,271&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Treasury Stock &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2021&lt;/em&gt;, and&#160;&lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Open Market Sale Agreement&lt;/i&gt;&lt;/b&gt;&#x2120;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;On &lt;em style="font: inherit;"&gt; August 13, 2020, &lt;/em&gt;we entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0&#160;million through Jefferies as our sales agent or principal.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;We have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; and are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell shares of our common stock by any method permitted by law deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule &lt;em style="font: inherit;"&gt;415&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) under the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies&#x2019; counsel, if required. The sale agreement will terminate upon the sale of all $50.0&#160;million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; filed with the SEC on &lt;em style="font: inherit;"&gt; August 13, 2020 &lt;/em&gt;and declared effective by the SEC on &lt;em style="font: inherit;"&gt; August 25, 2020 &lt;/em&gt;and the accompanying Prospectus, as supplemented by a Prospectus Supplement. As of the date of this filing, there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; sales made under the Open Market Sale Agreement&#x2120;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544291"
      unitRef="Share">60000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544292"
      unitRef="USDPerShare">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544294"
      unitRef="Share">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73544295"
      unitRef="USDPerShare">1.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="d_2021-01-01_2021-03-31"
      id="CDEAAB20-0B0C-47BA-8DE6-95401D676DA8">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31, 2021 (Unaudited)&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Common Stock&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Treasury Stock&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Additional Paid-In Capital&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accumulated Deficit&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;January 1, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;39,748&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(18,929,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;98,013,079&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(50,676,351&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,446,561&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;421,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;421,071&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;60&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;115,740&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;115,800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,294,949&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,294,949&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;March 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;39,808&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;(18,929,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;98,549,890&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;(53,971,300&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;25,688,483&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended March 31, 2020 (Unaudited)&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Common Stock&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Treasury Stock&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Additional Paid-In Capital&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accumulated Deficit&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;January 1, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;39,613&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(18,929,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;96,105,851&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(41,351,078&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;35,864,471&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;426,939&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;426,939&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%"&gt;Stock issued&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;174,900&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt"&gt;175,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,214,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,214,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;March 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;39,713&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;(18,929,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;96,707,690&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;(43,565,217&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;34,252,271&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544323"
      unitRef="USD">39748</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544324"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544325"
      unitRef="USD">98013079</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544326"
      unitRef="USD">-50676351</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c73544327"
      unitRef="USD">28446561</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544328"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544329"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544330"
      unitRef="USD">421071</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544331"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544332"
      unitRef="USD">421071</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544333"
      unitRef="USD">60</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544334"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544335"
      unitRef="USD">115740</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544336"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544337"
      unitRef="USD">115800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544338"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544339"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544340"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544341"
      unitRef="USD">-3294949</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c73544342"
      unitRef="USD">-3294949</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544343"
      unitRef="USD">39808</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544344"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544345"
      unitRef="USD">98549890</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544346"
      unitRef="USD">-53971300</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73544347"
      unitRef="USD">25688483</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544358"
      unitRef="USD">39613</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544359"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544360"
      unitRef="USD">96105851</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544361"
      unitRef="USD">-41351078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c73544362"
      unitRef="USD">35864471</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544363"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544364"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544365"
      unitRef="USD">426939</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544366"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73544367"
      unitRef="USD">426939</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544368"
      unitRef="USD">100</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544369"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544370"
      unitRef="USD">174900</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544371"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73544372"
      unitRef="USD">175000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544373"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544374"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544375"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544376"
      unitRef="USD">-2214139</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c73544377"
      unitRef="USD">-2214139</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c73544378"
      unitRef="USD">39713</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c73544379"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c73544380"
      unitRef="USD">96707690</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c73544381"
      unitRef="USD">-43565217</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31"
      decimals="INF"
      id="c73544382"
      unitRef="USD">34252271</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c73544297"
      unitRef="Share">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i_2021-03-31"
      decimals="-5"
      id="c73544298"
      unitRef="USD">18900000</us-gaap:TreasuryStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-08-13"
      decimals="INF"
      id="c73544299"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <dyai:SaleOfStockAuthorizedOfferingAmount
      contextRef="i_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember"
      decimals="-7"
      id="c73544300"
      unitRef="USD">50000000.0</dyai:SaleOfStockAuthorizedOfferingAmount>
    <dyai:SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare
      contextRef="i_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember"
      decimals="2"
      id="c73544306"
      unitRef="Pure">0.030</dyai:SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare>
    <dyai:SaleOfStockReimbursableLegalExpenses
      contextRef="i_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember"
      decimals="INF"
      id="c73544307"
      unitRef="USD">50000</dyai:SaleOfStockReimbursableLegalExpenses>
    <dyai:SaleOfStockTerminationAmountUnderAgreement
      contextRef="d_2020-08-13_2020-08-13_SubsidiarySaleOfStockAxis-OpenMarketSaleAgreementMember"
      decimals="-7"
      id="c73544308"
      unitRef="USD">50000000.0</dyai:SaleOfStockTerminationAmountUnderAgreement>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2021-01-01_2021-03-31" id="c1856471">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7:&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b&gt;Subsequent Events &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Management continues to actively monitor the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic and its development, and the possible effects on the Company&#x2019;s financial condition, liquidity, operations, vendors, industry, and workforce.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through &lt;em style="font: inherit;"&gt; May 13, 2021&lt;/em&gt;, the date the consolidated financial statements were available to be issued. Management is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c73544255"
          xlink:label="c73544255"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73544256"
          xlink:label="c73544256"
          xlink:type="locator"/>
        <link:footnote id="fe854cce7-7819-4440-b61b-0330189eab0a" xlink:label="fe854cce7-7819-4440-b61b-0330189eab0a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Represents the following stock options granted:




Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary.




One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date.


One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date.


One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544255"
          xlink:to="fe854cce7-7819-4440-b61b-0330189eab0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544256"
          xlink:to="fe854cce7-7819-4440-b61b-0330189eab0a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c73544259"
          xlink:label="c73544259"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73544260"
          xlink:label="c73544260"
          xlink:type="locator"/>
        <link:footnote id="f1a568bde-b180-41e5-8730-f648b8c1a213" xlink:label="f1a568bde-b180-41e5-8730-f648b8c1a213" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Represents the following stock options exercised:




A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544259"
          xlink:to="f1a568bde-b180-41e5-8730-f648b8c1a213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544260"
          xlink:to="f1a568bde-b180-41e5-8730-f648b8c1a213"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c73543987"
          xlink:label="c73543987"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73544035"
          xlink:label="c73544035"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73544037"
          xlink:label="c73544037"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73543989"
          xlink:label="c73543989"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73544036"
          xlink:label="c73544036"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73543988"
          xlink:label="c73543988"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73544034"
          xlink:label="c73544034"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c73543990"
          xlink:label="c73543990"
          xlink:type="locator"/>
        <link:footnote id="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0" xlink:label="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the three months ended March 31, 2021 and 2020, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended  December 31, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73543987"
          xlink:to="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544035"
          xlink:to="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544037"
          xlink:to="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73543989"
          xlink:to="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544036"
          xlink:to="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73543988"
          xlink:to="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544034"
          xlink:to="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73543990"
          xlink:to="fbcbd66c0-c485-48e9-a373-fb19cf6f67b0"
          xlink:type="arc"/>
        <link:footnote id="fd641e60f-9c4a-4be0-b3fc-9172db74071d" xlink:label="fd641e60f-9c4a-4be0-b3fc-9172db74071d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73543987"
          xlink:to="fd641e60f-9c4a-4be0-b3fc-9172db74071d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544035"
          xlink:to="fd641e60f-9c4a-4be0-b3fc-9172db74071d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544037"
          xlink:to="fd641e60f-9c4a-4be0-b3fc-9172db74071d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73543989"
          xlink:to="fd641e60f-9c4a-4be0-b3fc-9172db74071d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544036"
          xlink:to="fd641e60f-9c4a-4be0-b3fc-9172db74071d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73543988"
          xlink:to="fd641e60f-9c4a-4be0-b3fc-9172db74071d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73544034"
          xlink:to="fd641e60f-9c4a-4be0-b3fc-9172db74071d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c73543990"
          xlink:to="fd641e60f-9c4a-4be0-b3fc-9172db74071d"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650986667512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DYADIC INTERNATIONAL INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-55264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0486747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">140 Intracoastal Pointe Drive, Suite 404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">743-8333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DYAI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,554,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650988067928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,055,558<span></span>
</td>
<td class="nump">$ 20,637,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">14,177,441<span></span>
</td>
<td class="nump">8,457,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">157,201<span></span>
</td>
<td class="nump">112,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">384,963<span></span>
</td>
<td class="nump">294,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">216,189<span></span>
</td>
<td class="nump">280,555<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">27,991,352<span></span>
</td>
<td class="nump">29,781,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_PrepaidResearchAndDevelopmentInProcessCurrent', window );">Investment in Alphazyme</a></td>
<td class="nump">284,709<span></span>
</td>
<td class="nump">284,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,151<span></span>
</td>
<td class="nump">6,225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,282,212<span></span>
</td>
<td class="nump">30,072,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,473,813<span></span>
</td>
<td class="nump">1,013,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">277,668<span></span>
</td>
<td class="nump">489,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred research and development obligations</a></td>
<td class="nump">842,248<span></span>
</td>
<td class="nump">123,016<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,593,729<span></span>
</td>
<td class="nump">1,625,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 39,807,659 and 39,747,659, outstanding shares - 27,554,157 and 27,494,157 as of March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">39,808<span></span>
</td>
<td class="nump">39,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">98,549,890<span></span>
</td>
<td class="nump">98,013,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, shares held at cost - 12,253,502</a></td>
<td class="num">(18,929,915)<span></span>
</td>
<td class="num">(18,929,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(53,971,300)<span></span>
</td>
<td class="num">(50,676,351)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">25,688,483<span></span>
</td>
<td class="nump">28,446,561<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 28,282,212<span></span>
</td>
<td class="nump">$ 30,072,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_PrepaidResearchAndDevelopmentInProcessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current amount of prepaid research and development in process as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_PrepaidResearchAndDevelopmentInProcessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140651069955000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">39,807,659<span></span>
</td>
<td class="nump">39,747,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,554,157<span></span>
</td>
<td class="nump">27,494,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">12,253,502<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140651065275016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Research and development revenue</a></td>
<td class="nump">$ 460,520<span></span>
</td>
<td class="nump">$ 315,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of research and development revenue</a></td>
<td class="nump">390,762<span></span>
</td>
<td class="nump">278,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,808,098<span></span>
</td>
<td class="nump">755,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,554,007<span></span>
</td>
<td class="nump">1,653,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency exchange loss (gain), net</a></td>
<td class="nump">28,272<span></span>
</td>
<td class="nump">10,867<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">3,781,139<span></span>
</td>
<td class="nump">2,697,894<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,320,619)<span></span>
</td>
<td class="num">(2,382,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">25,670<span></span>
</td>
<td class="nump">168,383<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,294,949)<span></span>
</td>
<td class="num">$ (2,214,139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">27,533,268<span></span>
</td>
<td class="nump">27,452,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650988067928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 39,613<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">$ 96,105,851<span></span>
</td>
<td class="num">$ (41,351,078)<span></span>
</td>
<td class="nump">$ 35,864,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">426,939<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">426,939<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,214,139)<span></span>
</td>
<td class="num">(2,214,139)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 39,713<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">96,707,690<span></span>
</td>
<td class="num">(43,565,217)<span></span>
</td>
<td class="nump">34,252,271<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">39,747,659<span></span>
</td>
<td class="num">(12,253,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 39,748<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">98,013,079<span></span>
</td>
<td class="num">(50,676,351)<span></span>
</td>
<td class="nump">28,446,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">421,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 421,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">115,740<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 115,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,294,949)<span></span>
</td>
<td class="num">(3,294,949)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">39,807,659<span></span>
</td>
<td class="num">(12,253,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 39,808<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">$ 98,549,890<span></span>
</td>
<td class="num">$ (53,971,300)<span></span>
</td>
<td class="nump">$ 25,688,483<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the following stock options exercised:




A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140651063034504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,294,949)<span></span>
</td>
<td class="num">$ (2,214,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">421,071<span></span>
</td>
<td class="nump">426,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of held-to-maturity securities, net</a></td>
<td class="nump">63,951<span></span>
</td>
<td class="nump">107,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange loss (gain), net</a></td>
<td class="nump">28,272<span></span>
</td>
<td class="nump">10,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(44,954)<span></span>
</td>
<td class="nump">102,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(131,800)<span></span>
</td>
<td class="nump">35,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">64,297<span></span>
</td>
<td class="num">(10,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">480,455<span></span>
</td>
<td class="num">(292,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(212,088)<span></span>
</td>
<td class="num">(326,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred research and development obligation</a></td>
<td class="nump">719,232<span></span>
</td>
<td class="nump">163,799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,906,513)<span></span>
</td>
<td class="num">(1,996,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of held-to-maturity investment securities</a></td>
<td class="num">(11,283,940)<span></span>
</td>
<td class="num">(11,652,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Proceeds from maturities of investment securities</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">13,350,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(5,783,940)<span></span>
</td>
<td class="nump">1,697,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">115,800<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">115,800<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(6,834)<span></span>
</td>
<td class="num">(2,983)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(7,581,487)<span></span>
</td>
<td class="num">(126,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">20,637,045<span></span>
</td>
<td class="nump">4,823,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 13,055,558<span></span>
</td>
<td class="nump">$ 4,696,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650984972920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Business Description and Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1:</em></b>&#160;&#160;&#160;&#160;<b>Organization and Summary of Significant Accounting Policies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Description of Business</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office&#160;in the Netherlands and predominantly <span style="-sec-ix-hidden:c73543703">three</span> research organizations performing services in the Netherlands, Finland and Israel. Over the past <em style="font: inherit;">two</em> plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to <em style="font: inherit;">third</em> parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the <i>Thermothelomyces heterothallica </i>(formerly known as <i>Myceliophthora thermophila</i>) fungus, which the Company named <em style="font: inherit;">C1.</em> The <em style="font: inherit;">C1</em> technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> December 31, 2015, </em>the Company sold its industrial technology business to Danisco USA (&#8220;Danisco&#8221;), the industrial biosciences business of DuPont (NYSE: DD)&#160;(the &#8220;DuPont Transaction&#8221;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the <em style="font: inherit;">C1</em> technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the <em style="font: inherit;">C1</em> technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic <em style="font: inherit;"> may </em>owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary <em style="font: inherit;">C1</em> technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs and other biological products at flexible commercial scales. Currently, the Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies to leverage its <em style="font: inherit;">C1</em> technology to help develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. The Company is also working on several COVID-<em style="font: inherit;">19</em> related vaccine and antibody opportunities, including its proprietary COVID-<em style="font: inherit;">19</em> vaccine candidate, DYAI-<em style="font: inherit;">100,</em> towards a <em style="font: inherit;">first</em>-in-human Phase <em style="font: inherit;">1</em> clinical trial.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Effective <em style="font: inherit;"> April 17, 2019, </em>our common stock began trading on the NASDAQ Stock Market LLC&#8217;s NASDAQ Capital Market, under the symbol &#8220;DYAI&#8221;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Impact of COVID-<em style="font: inherit;">19</em></i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The outbreak of COVID-<em style="font: inherit;">19</em> has led to adverse impacts on the U.S. and global economies and created uncertainty regarding&#160;the potential impact to the Company&#8217;s employees, operations, and research projects.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date, some of our employees are still working remotely. The extent to which the COVID-<em style="font: inherit;">19</em> pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that <em style="font: inherit;"> may </em>emerge concerning the severe acute respiratory syndrome coronavirus <em style="font: inherit;">2</em> (SARS-CoV-<em style="font: inherit;">2</em>) and its&#160;variants and the actions taken and the level of success to contain or treat the SARS-CoV-<em style="font: inherit;">2</em> virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or <em style="font: inherit;">third</em>-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-<em style="font: inherit;">19</em> pandemic has subsided, the Company <em style="font: inherit;"> may </em>continue to experience adverse impacts to its business because of economic recession or depression that has occurred or <em style="font: inherit;"> may </em>occur in the future. Given the daily evolution of the COVID-<em style="font: inherit;">19</em> outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are <em style="font: inherit;">not</em> able to accurately estimate the effects of the COVID-<em style="font: inherit;">19</em> outbreak to our results of operations, financial condition, or liquidity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. However, in the event our financing needs for the foreseeable future are <em style="font: inherit;">not</em> able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company <em style="font: inherit;"> may </em>decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the <em style="font: inherit;">C1</em> expression platform in humans. There is <em style="font: inherit;">no</em> assurance that external funding will be available at acceptable terms, if at all, and the Company <em style="font: inherit;"> may, </em>therefore, self-fund these vital projects.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Basis of Presentation </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em>&#160;included in our Form <em style="font: inherit;">10</em>-K which was filed with the SEC on <em style="font: inherit;"> March&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021.</em><b><i> </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented.&#160;The results of the Company&#8217;s operations for any interim periods are <em style="font: inherit;">not</em> necessarily indicative of the results of operations for any other interim period or for a full fiscal year.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Since concluding the DuPont Transaction, the Company has conducted business in <span style="-sec-ix-hidden:c73543760">one</span> operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands&#8217; FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company&#8217;s revenue was generated from&#160;<span style="-sec-ix-hidden:c73543764">eight</span> and&#160;<span style="-sec-ix-hidden:c73543765">five</span> customers, respectively.&#160;As of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>, the Company&#8217;s accounts receivable was from&#160;<span style="-sec-ix-hidden:c73543766">seven</span> and <span style="-sec-ix-hidden:c73543767">nine</span>&#160;customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company&#8217;s customers could adversely affect its operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States.&#160;For the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2021</em>, the Company had six&#160;customers outside of the United States (i.e. European and Asian customers) that accounted for approximately&#160;76.7%&#160;or&#160;$353,000&#160;of the revenue. For the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2020</em>, the Company had&#160;three customers outside of the United States that accounted for approximately&#160;58.0% or $183,000&#160;of the revenue.&#160;As of&#160;the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2021</em>, the Company had&#160;four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0%&#160;or $174,000&#160;of accounts receivable.&#160;As of&#160;<em style="font: inherit;"> December 31, 2020</em>, the Company had&#160;seven customers outside of the United States that accounted for approximately&#160;41.6% or&#160;$123,000 of accounts receivable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses several contract research organizations (&#8220;CROs&#8221;) to conduct its research projects. As of and for the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2021</em>, <span style="-sec-ix-hidden:c73543786">three</span> CROs accounted for approximately $2,017,000 or 98.1%&#160;of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020, </em><span style="-sec-ix-hidden:c73543792">one</span> CRO accounted for approximately&#160;$855,000, or 100% of&#160;total research services we purchased. As of&#160;<em style="font: inherit;"> December 31, 2020</em>, <span style="-sec-ix-hidden:c73543795">one</span> CRO accounted for approximately $690,000 or 68.1%&#160;of the accounts payable. The loss of this CRO or a combination of the Company&#8217;s CROs could adversely affect its operations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="margin-left: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b><i/></b></p>
   <p style="margin-left: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">We treat highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Investment Securities</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months or less, and long-term investment securities mature over <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#8217;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company&#8217;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>, all of our money market funds were invested in U.S. Government money market funds. The Company did <em style="font: inherit;">not</em> have any investment securities classified as trading as of&#160;<em style="font: inherit;"> March 31, 2021</em> or&#160;<em style="font: inherit;"> December 31, 2020</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Receivable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. There was <span style="-sec-ix-hidden:c73543806"><span style="-sec-ix-hidden:c73543807">no</span></span> allowance for doubtful accounts as of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">293,323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,532</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">163,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">384,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">294,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>



   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Prepaid Expenses and Other Current Assets</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94,841</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">204,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">216,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,555</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Payable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts payable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,337,755</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">904,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,987</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,473,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,013,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accrued expenses consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">447,881</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,452</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,367</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">277,668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">489,756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Revenue Recognition </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has <em style="font: inherit;">no</em> pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from <em style="font: inherit;">third</em>-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which <em style="font: inherit;"> may </em>include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to research collaborations and agreements: </i>The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the <em style="font: inherit;">5</em>-step process outlined in ASC Topic <em style="font: inherit;">606</em> (&#8220;Topic <em style="font: inherit;">606&#8221;</em>): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic <em style="font: inherit;">606</em> to measure the progress toward complete satisfaction of a performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the input methods, revenue will be recognized on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and <em style="font: inherit;">third</em>-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to grants: </i>The Company <em style="font: inherit;"> may </em>receive grants&#160;from governments, agencies, and other private and <em style="font: inherit;">not</em>-for-profit organizations. These grants&#160;are intended to be used to partially or fully fund the Company&#8217;s research collaborations, including opportunities arising in connection with COVID-<em style="font: inherit;">19</em> that the Company is pursuing with certain collaborators. However, most, if <em style="font: inherit;">not</em> all, of such potential grant revenues, if received, is expected to be earmarked for <em style="font: inherit;">third</em> parties to advance the research required, including preclinical and clinical trials for SARS-CoV-<em style="font: inherit;">2</em> vaccines and/or antibodies candidates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Milestone payments: </i>At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has <em style="font: inherit;">not</em> recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which the<i> </i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <em style="font: inherit;">not</em> recognized any royalty revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We invoice customers based on our contractual arrangements with each customer, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are <em style="font: inherit;">not</em> required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of <em style="font: inherit;">one</em> year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Research and Development Costs </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are for the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,659,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">613,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">148,162</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">123,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,808,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">755,453</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Foreign Currency Transaction Gain or Loss</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Fair Value Measurements</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into <em style="font: inherit;">three</em> levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 3%; vertical-align: top;">&#160;</td><td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">1</em></i> &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr><td style="width: 3%; vertical-align: top;">&#160;</td><td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">2</em></i> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr><td style="width: 3%; vertical-align: top;">&#160;</td><td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">3</em></i> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</td></tr>
</tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company&#8217;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#8217;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the <em style="font: inherit;">third</em>-party broker service for disclosure purposes.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Non-Marketable Investments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do <em style="font: inherit;">not</em> have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes <em style="font: inherit;"> may </em>include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which <em style="font: inherit;"> may </em>include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company&#8217;s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, <em style="font: inherit;"> may </em>have <em style="font: inherit;">no</em> or limited revenues, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be or <em style="font: inherit;"> may </em>never become profitable, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to secure additional funding or their technologies, services or products <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be successfully developed or introduced into the market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) was enacted on <em style="font: inherit;"> December 22, 2017 </em>and became effective <em style="font: inherit;"> January 1, 2018. </em>The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from <em style="font: inherit;">35%</em> to <em style="font: inherit;">21%</em> and repeal of the corporate alternative minimum tax (&#8220;AMT&#8221;). The TCJA&#8217;s reduction in the U.S. statutory tax rate had <em style="font: inherit;">no</em> additional impact on the consolidated financial statement for the year ended&#160;<em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, there were <span style="-sec-ix-hidden:c73543846"><span style="-sec-ix-hidden:c73543847">no</span></span> provision for income taxes and unrecognized tax benefits recorded. As of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>, deferred tax assets were approximately $10.2&#160;million and $9.4 million, respectively. Due to the Company&#8217;s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Comprehensive Income (Loss)</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under GAAP. The Company does <em style="font: inherit;">not</em> have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does <em style="font: inherit;">not</em> separately present a statement of comprehensive income (loss) in its consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We recognize all share-based payments to employees, consultants, and our board of directors (&#8220;Board of Directors&#8221;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the effect of the potential exercise of options to purchase 5,324,215&#160;and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><b><i/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b>&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which modifies the measurement of expected credit losses of certain financial instruments. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will be effective for the Company beginning in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> The Company does <em style="font: inherit;">not</em> expect ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> to have a material impact on our consolidated financial positions, results of operations, and cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em>&#160;<i>Income Taxes (Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes</i>. The amendments of this update simplify the accounting for income taxes by removing certain exceptions&#160;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> on&#160;<em style="font: inherit;"> January 1, 2021, </em>and&#160;adoption of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> did&#160;<em style="font: inherit;">not</em> have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either <em style="font: inherit;">not</em> applicable or <em style="font: inherit;">not</em> significant to our consolidated financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"/>
   <p style="text-indent: 9pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650980756888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Cash, Cash Equivalent, and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2:</em></b>&#160;&#160;&#160;&#160;<b>Cash, Cash Equivalent, and Investments </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company&#8217;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company&#8217;s cash, available-for-sale securities, and investment securities by major security type as of&#160;<em style="font: inherit;"> March 31, 2021</em>, and&#160;<em style="font: inherit;"> December 31, 2020</em>:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2021 (Unaudited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 10%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,217,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,217,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,838,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,838,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,055,558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,055,558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,161,252</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(17,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,177,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,216,810</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(17,847</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,232,999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020 (Audited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,488,030</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,488,030</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,637,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,637,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">8,473,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">22,473</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(6,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">8,457,451</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,110,506</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,473</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,094,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_________________</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">1</em>) Definition of the <em style="font: inherit;">three</em>-level fair value hierarchy:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#8226;</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">1</em> - Quoted prices (unadjusted) in active markets for identical assets or liabilities</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#8226;</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">2</em> - Other inputs that are directly or indirectly observable in the markets</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#8226;</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">3</em> - Inputs that are generally unobservable</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">2</em>) Short-term investment securities will mature within <em style="font: inherit;">12</em> months or less, from the applicable reporting date.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">3</em>) The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385&#160;for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended&#160;<em style="font: inherit;"> December 31, 2020</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than <em style="font: inherit;">not</em> the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. As of&#160;<em style="font: inherit;"> March 31, 2021</em>, the Company does <em style="font: inherit;">not</em> consider any of its investments to be other-than-temporarily impaired.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650984952024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3:</em></b>&#160;&#160;&#160;&#160;<b>Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-Held Companies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>BDI&#160;</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> June 30, 2017, </em>the Company entered into a strategic Research Services Agreement (the &#8220;RSA&#8221;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#8220;BDI Pharma&#8221;), and a Service Framework Agreement (the &#8220;SFA&#8221;, and together with the RSA, the &#8220;R&amp;D Agreements&#8221;), with VLP The Vaccines Company, S.L.U. (&#8220;VLPbio&#8221;), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#8220;BDI Holdings&#8221; and together with BDI Pharma and VLPbio, &#8220;BDI&#8221;).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a <span style="-sec-ix-hidden:c73544044">two</span>-year period, with a focus on advancing Dyadic&#8217;s proprietary <em style="font: inherit;">C1</em> technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#8217;s previous <em style="font: inherit;">C1</em> gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#8217;s proprietary <em style="font: inherit;">C1</em> technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Upon closing of the BDI transaction, the Company paid EUR <em style="font: inherit;">&#8364;1.0</em> million (the &#8220;RSA Initial Payment&#8221;) in cash to engage BDI to develop designated <em style="font: inherit;">C1</em> based product candidates and further improve the <em style="font: inherit;">C1</em> manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR <span style="-sec-ix-hidden:c73544054">&#8364;936,000</span> over <span style="-sec-ix-hidden:c73544055">two</span> years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI&#8217;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR <span style="-sec-ix-hidden:c73544058">&#8364;1</span>&#160;million for a 50% share and EUR <em style="font: inherit;">&#8364;<span style="-sec-ix-hidden:c73544061">8.0</span></em> million for a 75% share. If BDI does <em style="font: inherit;">not</em> enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR <span style="-sec-ix-hidden:c73544064">&#8364;1.5</span>&#160;million of the net income from Dyadic&#8217;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1.0 million (the &#8220;SFA Commitment&#8221;) in contract research services specified by Dyadic over <span style="-sec-ix-hidden:c73544066">two</span> years since the closing of the BDI transaction.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has concluded that BDI is <em style="font: inherit;">not</em> a Variable Interest Entity (&#8220;VIE&#8221;), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is <em style="font: inherit;">not</em> the primary beneficiary of BDI as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of BDI or its operations. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investments in BDI, and the financial results of BDI are <em style="font: inherit;">not</em> included in the Company&#8217;s consolidated financial results.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD <em style="font: inherit;"><span style="-sec-ix-hidden:c73544074">$1.1</span></em> million (EUR <em style="font: inherit;">&#8364;1.0</em> million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1.0 million paid by Dyadic were expensed as the related research services were performed by BDI. In <em style="font: inherit;"> June 2019, </em>BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA in <em style="font: inherit;">2019.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> February 18, 2021, </em>the Company entered into a separate service agreement with BDI to perform a research&#160;project unrelated to the R&amp;D Agreements.&#160;For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, approximately&#160;$15,000 recorded in the cost of research and development revenue was associated with this new service agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Novovet and Luina Bio&#160;</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> April 26, 2019, </em>the Company entered into a sub-license agreement (the &#8220;Luina Bio Sub-License Agreement&#8221;) with Luina Bio Pty Ltd. (&#8220;Luina Bio&#8221;) and Novovet Pty Ltd (&#8220;Novovet&#8221;). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on <em style="font: inherit;"> December 31, 2015, </em>a worldwide sub-license to certain patent rights and know-how related to&#160;Dyadic&#8217;s proprietary <em style="font: inherit;">C1</em> gene expression platform&#160;for the exclusive and sole purpose of commercializing&#160;certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (&#8220;Novovet Up-Front Consideration&#8221;) in accordance with the terms of Novovet&#8217;s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic&#8217;s proprietary <em style="font: inherit;">C1</em> gene expression platform.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does <em style="font: inherit;">not</em> have sufficient equity to finance its activities without additional financial support from <em style="font: inherit;">third</em> party investors or lenders. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of Novovet as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will <em style="font: inherit;">not</em> consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but <em style="font: inherit;">not</em> control, over Novovet.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date Novovet has <em style="font: inherit;">not</em> raised the capital required to move this opportunity forward, and therefore, the Company has <em style="font: inherit;">not</em> transferred its <em style="font: inherit;">C1</em> technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does <em style="font: inherit;">not</em> yet meet the revenue recognition criteria under ASC <em style="font: inherit;">606.</em> The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its <em style="font: inherit;">C1</em> technology is completed and Novovet receives adequate financing required to commence its research and development activities.&#160;The Company intends to terminate the Luina Bio Sub-License Agreement in <em style="font: inherit;">2021</em> should Novovet be unable to raise the required funding.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Alphazyme&#160;</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> May 5, 2019, </em>the Company entered into a sub-license agreement (the &#8220;Alphazyme Sub-License Agreement&#8221;) with Alphazyme, LLC (&#8220;Alphazyme&#8221;). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on <em style="font: inherit;"> December 31, 2015, </em>a sub-license to certain patent rights and know-how related to&#160;Dyadic&#8217;s proprietary <em style="font: inherit;">C1</em> gene expression platform&#160;for the purpose of commercializing&#160;certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> June 24, 2020, </em>the Company entered into an Amended and Restated Non-Exclusive Sub-License Agreement (the &#8220;Amended Sub-License Agreement&#8221;) with Alphazyme.&#160;Pursuant to the Amended Sub-License Agreement and in consideration of Dyadic&#8217;s transfer of its <em style="font: inherit;">C1</em> technology, Alphazyme issued&#160;2.50% of the Class A shares of Alphazyme to Dyadic, and Dyadic became a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company has agreed to certain customary rights, covenants and obligations. In addition, and subject to achieving certain milestones, Alphazyme is obligated to pay a potential milestone payment and royalties, based on net sales, if any, which incorporate Dyadic&#8217;s proprietary <em style="font: inherit;">C1</em> gene expression platform.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> December 1, 2020, </em>the Company entered into an Amended and Restated Limited Liability Company Agreement with Alphazyme (the &#8220;Amended Alphazyme LLC Agreement&#8221;) was entered into.&#160;Under the Amended Alphazyme LLC Agreement,&#160;Alphazyme obtained an additional capital contribution&#160;and Dyadic&#8217;s ownership was diluted to 1.99%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of Alphazyme as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investment&#160;in Alphazyme. The Company reports&#160;its investment in Alphazyme under the cost method of accounting, given that it does <em style="font: inherit;">not</em> have the ability to exercise significant influence or control,</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company recorded a gain of <span style="-sec-ix-hidden:c73544106">$284,709</span> from&#160;its investment in Alphazyme as a result of a <em style="font: inherit;">third</em>-party additional capital contribution obtained by Alphazyme.&#160;As of <em style="font: inherit;">March31,</em>&#160;<em style="font: inherit;">2021</em>, the Company does <em style="font: inherit;">not</em> consider its&#160;investment in Alphazyme to be impaired.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>IDBiologics, Inc.</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> July 8, 2020, </em>the Company entered into a Common Stock Purchase Agreement (the &#8220;IDBiologics Agreement&#8221;) with IDBiologics, Inc (&#8220;IDBiologics&#8221;). IDBiologics is a private biotechnology company focused on the development of human monoclonal antibodies for the treatment and prevention of serious infectious diseases. The Company was founded in <em style="font: inherit;">2017</em> and seeded by Vanderbilt University Medical Center&#160;in response to the repeated threats of epidemics around the world, including Ebola in West Africa and Zika in the Americas. IDBiologics is developing a portfolio of monoclonal antibodies against SARS-CoV-<em style="font: inherit;">2,</em> influenza and Zika viruses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under the term of the IDBiologics Agreement, Dyadic agreed to receive 129,611 shares of IDBiologics&#8217; common stock, which represent 0.37% of IDBiologics&#8217; outstanding equity, in exchange for the services to be provided by Dyadic. Such services&#160;include the use of Dyadic&#8217;s <em style="font: inherit;">C1</em> technology to express a SARS-CoV-<em style="font: inherit;">2</em> monoclonal antibody which IDBiologics&#160;licensed from the Vanderbilt Vaccine Center. The shares of common stock of IDBiologics vested 50% upon the signing of the IDBiologics Agreement,&#160;25% will vest upon the completion of Step <em style="font: inherit;">3</em> of a feasibility study required by the IDBiologics Agreement, and 25% will vest at the end of the project.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company evaluated the nature of its equity interest in IDBiologics and determined that IDBiologics is a VIE due to the capital structure of the entity. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of IDBiologics as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of IDBiologics that most significantly impact the VIE. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investment in IDBiologics. Upon receipt its shares, Dyadic will account for the equity interest in IDBiologics under the cost method. <em style="font: inherit;">No</em> revenue from the IDBiologics Agreement was recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March&#160;</em><em style="font: inherit;">31,</em>&#160;<em style="font: inherit;">2021</em>, because the amount of consideration received was immaterial.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650984932616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4:</em></b>&#160;&#160;&#160;&#160;<b>Commitments and Contingencies</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are <em style="font: inherit;">not</em> currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of <em style="font: inherit;">one</em> or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#8217;s consolidated financial position, cash flows or results of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650980833576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5:</em></b>&#160;&#160;&#160;&#160;<b>Share-Based Compensation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Description of Equity Plans</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The <em style="font: inherit;">2011</em> Equity Incentive Plan (the <em style="font: inherit;">&#8220;2011</em> Plan&#8221;) was adopted by the Company&#8217;s Board of Directors on <em style="font: inherit;"> April 28, 2011 </em>and approved by the Company&#8217;s stockholders on <em style="font: inherit;"> June 15, 2011. </em>The <em style="font: inherit;">2011</em> Plan serves as the successor to the Company&#8217;s <em style="font: inherit;">2006</em> Stock Option Plan (the <em style="font: inherit;">&#8220;2006</em> Plan&#8221;). Since the effective date of the <em style="font: inherit;">2011</em> Plan, all equity awards were made from the <em style="font: inherit;">2011</em> Plan, and <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2006</em> plan. Under the <em style="font: inherit;">2011</em> Plan, 3,000,000 shares of the Company&#8217;s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the <em style="font: inherit;">2006</em> Plan or are subject to awards under the <em style="font: inherit;">2006</em> Plan which are forfeited or lapse unexercised and which following the effective date are <em style="font: inherit;">not</em> issued under the <em style="font: inherit;">2006</em> Plan. In accordance with the provisions of the <em style="font: inherit;">2011</em> Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on <em style="font: inherit;"> January 1, 2019 </em>and <em style="font: inherit;">2020.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">At our <em style="font: inherit;">2021</em> Virtual Annual Meeting of Shareholders (&#8220;Annual Meeting&#8221;) to be held on <em style="font: inherit;"> June 11, 2021, </em>shareholders will be asked to approve the Company&#8217;s&#160;<em style="font: inherit;">2021</em> Equity Incentive Award Plan (the <em style="font: inherit;">&#8220;2021</em> Plan&#8221;), which was adopted, subject to shareholder approval, by the Board of Directors on <em style="font: inherit;"> April 9, 2021. </em>We are seeking&#160;stockholder approval of the <em style="font: inherit;">2021</em> Plan to increase the number of shares available for the grant of stock options, restricted stock awards and other awards by&#160;3,000,000&#160;in addition to&#160;the number of shares remaining available for the grant of new awards under the <em style="font: inherit;">2011</em>&#160;Plan as of <em style="font: inherit;"> April 16, 2021. </em>If this&#160;proposal is approved by our shareholders, the <em style="font: inherit;">2021</em> Plan will become effective as of the date of the Annual Meeting and as of such date, <em style="font: inherit;">no</em> additional awards will be&#160;granted under the <em style="font: inherit;">2011</em> Plan. If our shareholders do <em style="font: inherit;">not</em> approve this proposal, the <em style="font: inherit;">2021</em> Plan will <em style="font: inherit;">not</em> become effective and the <em style="font: inherit;">2011</em> Plan will continue to be effective in&#160;accordance with its terms, until its expiration date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of&#160;<em style="font: inherit;"> March 31, 2021</em>, the Company had 5,324,215 stock options outstanding and an additional 1,388,386&#160;shares of common stock available for grant under the <em style="font: inherit;">2011</em> Plan. As of&#160;<em style="font: inherit;"> December 31, 2020</em>, there were 4,638,390 stock options outstanding and 2,134,211 shares of common stock available for grant under the <em style="font: inherit;">2011</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock Options </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company&#8217;s <em style="font: inherit;">2011</em> Plan is <span style="-sec-ix-hidden:c73544184">ten</span> years except for certain options granted to the contractors which are <span style="-sec-ix-hidden:c73544185">one</span> or <span style="-sec-ix-hidden:c73544186">three</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Risk-free interest rate</i>. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected dividend yield</i>. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does <em style="font: inherit;">not</em> currently anticipate paying any in the foreseeable future.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected stock price volatility.</i> The expected stock price volatility was calculated based on the Company&#8217;s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company&#8217;s historical volatility since <em style="font: inherit;">2016,</em> as the DuPont Transaction resulted in significant changes in the Company&#8217;s business and capital structure.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Expected life of option. </i>The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., <span style="-sec-ix-hidden:c73544190">5</span> or 10 years) and certain contractors (i.e., 2 or <em style="font: inherit;"><span style="-sec-ix-hidden:c73544194">3</span>years</em>).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The assumptions used in the Black-Scholes option pricing model for stock options granted during the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em> are as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.13%-0.55%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;%</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54.52%-56.07%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.00-6.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes the stock option activities during the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term (Years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,638,390</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,701,610</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">745,825</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(60,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,324,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.03</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,209,431</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 44%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 10%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 11%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 13%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 10%;">&#160;</td><td style="width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,016,141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,927,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">_________________</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">1</em>) Represents the following stock options granted:</p>
   <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8226;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Annual share-based compensation awards on <em style="font: inherit;"> January 4,&#160;</em><em style="font: inherit;">2021</em>, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon <span style="-sec-ix-hidden:c73544201">one</span> year anniversary, or vesting&#160;annually in equal installments over <span style="-sec-ix-hidden:c73544202">four</span> years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon <span style="-sec-ix-hidden:c73544205">one</span> year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over <span style="-sec-ix-hidden:c73544208">four</span> years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon <span style="-sec-ix-hidden:c73544211">one</span> year anniversary.</p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8226;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> January 8,&#160;</em><em style="font: inherit;">2021</em>, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in <span style="-sec-ix-hidden:c73544215">one</span> year from the grant date.</p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8226;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> January 21, 2021, </em>7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in <span style="-sec-ix-hidden:c73544218">one</span> year from the grant date.</p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8226;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> March 22, 2021, </em>30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in <span style="-sec-ix-hidden:c73544221">one</span> year from the grant date.</p> </td></tr>
</tbody></table>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 27pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">2</em>) Represents the following stock options exercised:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">&#8226;</p> </td><td> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Compensation Expenses</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had <em style="font: inherit;">no</em> impact on the Company&#8217;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Total non-cash stock option compensation expense was allocated among the following expense categories:&#160;&#160;&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">377,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">380,251</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,019</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,688</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650985218520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <b>Note <em style="font: inherit;">6:</em></b>&#160;&#160;&#160;&#160;
   <b>Shareholders</b>&#8217;
   <b> Equity</b>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Issuances of Common Stock</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, there were 60,000 shares of the Company&#8217;s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.93 per share. For the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020</em>, there were 100,000 shares of the Company&#8217;s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.78 per share.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:54pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Changes in Stockholders Equity</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2021 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">98,013,079</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(50,676,351</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,446,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock issued</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,294,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,294,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">39,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">98,549,890</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(53,971,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">25,688,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2020 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,105,851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(41,351,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,864,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%">Stock issued</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">174,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt">175,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,214,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,214,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">39,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">96,707,690</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(43,565,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">34,252,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Treasury Stock </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of&#160;<em style="font: inherit;"> March 31, 2021</em>, and&#160;<em style="font: inherit;"> December 31, 2020</em>, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Open Market Sale Agreement</i></b>&#8480;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> August 13, 2020, </em>we entered into an Open Market Sale Agreement&#8480; with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we <em style="font: inherit;"> may </em>offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0&#160;million through Jefferies as our sales agent or principal.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have <em style="font: inherit;">not</em> and are <em style="font: inherit;">not</em> obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies <em style="font: inherit;"> may </em>sell shares of our common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies&#8217; counsel, if required. The sale agreement will terminate upon the sale of all $50.0&#160;million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-<em style="font: inherit;">3</em> filed with the SEC on <em style="font: inherit;"> August 13, 2020 </em>and declared effective by the SEC on <em style="font: inherit;"> August 25, 2020 </em>and the accompanying Prospectus, as supplemented by a Prospectus Supplement. As of the date of this filing, there have been <em style="font: inherit;">no</em> sales made under the Open Market Sale Agreement&#8480;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650980687768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">7:</em></b>&#160;&#160;&#160;&#160;<b>Subsequent Events </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management continues to actively monitor the COVID-<em style="font: inherit;">19</em> pandemic and its development, and the possible effects on the Company&#8217;s financial condition, liquidity, operations, vendors, industry, and workforce.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through <em style="font: inherit;"> May 13, 2021</em>, the date the consolidated financial statements were available to be issued. Management is <em style="font: inherit;">not</em> aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650985935928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ImpactOfCOVID19PolicyPolicyTextBlock', window );">Impact of COVID-19, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Impact of COVID-<em style="font: inherit;">19</em></i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The outbreak of COVID-<em style="font: inherit;">19</em> has led to adverse impacts on the U.S. and global economies and created uncertainty regarding&#160;the potential impact to the Company&#8217;s employees, operations, and research projects.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date, some of our employees are still working remotely. The extent to which the COVID-<em style="font: inherit;">19</em> pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that <em style="font: inherit;"> may </em>emerge concerning the severe acute respiratory syndrome coronavirus <em style="font: inherit;">2</em> (SARS-CoV-<em style="font: inherit;">2</em>) and its&#160;variants and the actions taken and the level of success to contain or treat the SARS-CoV-<em style="font: inherit;">2</em> virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or <em style="font: inherit;">third</em>-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-<em style="font: inherit;">19</em> pandemic has subsided, the Company <em style="font: inherit;"> may </em>continue to experience adverse impacts to its business because of economic recession or depression that has occurred or <em style="font: inherit;"> may </em>occur in the future. Given the daily evolution of the COVID-<em style="font: inherit;">19</em> outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are <em style="font: inherit;">not</em> able to accurately estimate the effects of the COVID-<em style="font: inherit;">19</em> outbreak to our results of operations, financial condition, or liquidity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. However, in the event our financing needs for the foreseeable future are <em style="font: inherit;">not</em> able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company <em style="font: inherit;"> may </em>decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the <em style="font: inherit;">C1</em> expression platform in humans. There is <em style="font: inherit;">no</em> assurance that external funding will be available at acceptable terms, if at all, and the Company <em style="font: inherit;"> may, </em>therefore, self-fund these vital projects.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Basis of Presentation </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em>&#160;included in our Form <em style="font: inherit;">10</em>-K which was filed with the SEC on <em style="font: inherit;"> March&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021.</em><b><i> </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented.&#160;The results of the Company&#8217;s operations for any interim periods are <em style="font: inherit;">not</em> necessarily indicative of the results of operations for any other interim period or for a full fiscal year.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Since concluding the DuPont Transaction, the Company has conducted business in <span style="-sec-ix-hidden:c73543760">one</span> operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands&#8217; FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company&#8217;s revenue was generated from&#160;<span style="-sec-ix-hidden:c73543764">eight</span> and&#160;<span style="-sec-ix-hidden:c73543765">five</span> customers, respectively.&#160;As of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>, the Company&#8217;s accounts receivable was from&#160;<span style="-sec-ix-hidden:c73543766">seven</span> and <span style="-sec-ix-hidden:c73543767">nine</span>&#160;customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company&#8217;s customers could adversely affect its operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States.&#160;For the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2021</em>, the Company had six&#160;customers outside of the United States (i.e. European and Asian customers) that accounted for approximately&#160;76.7%&#160;or&#160;$353,000&#160;of the revenue. For the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2020</em>, the Company had&#160;three customers outside of the United States that accounted for approximately&#160;58.0% or $183,000&#160;of the revenue.&#160;As of&#160;the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2021</em>, the Company had&#160;four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0%&#160;or $174,000&#160;of accounts receivable.&#160;As of&#160;<em style="font: inherit;"> December 31, 2020</em>, the Company had&#160;seven customers outside of the United States that accounted for approximately&#160;41.6% or&#160;$123,000 of accounts receivable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses several contract research organizations (&#8220;CROs&#8221;) to conduct its research projects. As of and for the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2021</em>, <span style="-sec-ix-hidden:c73543786">three</span> CROs accounted for approximately $2,017,000 or 98.1%&#160;of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020, </em><span style="-sec-ix-hidden:c73543792">one</span> CRO accounted for approximately&#160;$855,000, or 100% of&#160;total research services we purchased. As of&#160;<em style="font: inherit;"> December 31, 2020</em>, <span style="-sec-ix-hidden:c73543795">one</span> CRO accounted for approximately $690,000 or 68.1%&#160;of the accounts payable. The loss of this CRO or a combination of the Company&#8217;s CROs could adversely affect its operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="margin-left: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">We treat highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Investment Securities</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months or less, and long-term investment securities mature over <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#8217;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company&#8217;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>, all of our money market funds were invested in U.S. Government money market funds. The Company did <em style="font: inherit;">not</em> have any investment securities classified as trading as of&#160;<em style="font: inherit;"> March 31, 2021</em> or&#160;<em style="font: inherit;"> December 31, 2020</em>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Receivable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. There was <span style="-sec-ix-hidden:c73543806"><span style="-sec-ix-hidden:c73543807">no</span></span> allowance for doubtful accounts as of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">293,323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,532</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">163,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">384,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">294,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Prepaid Expenses and Other Current Assets</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94,841</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">204,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">216,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,555</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_AccountsPayablePolicyPolicyTextBlock', window );">Accounts Payable, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Payable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts payable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,337,755</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">904,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,987</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,473,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,013,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_AccruedExpensesPolicyPolicyTextBlock', window );">Accrued Expenses, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accrued expenses consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">447,881</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,452</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,367</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">277,668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">489,756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contract with Customer [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Revenue Recognition </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has <em style="font: inherit;">no</em> pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from <em style="font: inherit;">third</em>-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which <em style="font: inherit;"> may </em>include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to research collaborations and agreements: </i>The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the <em style="font: inherit;">5</em>-step process outlined in ASC Topic <em style="font: inherit;">606</em> (&#8220;Topic <em style="font: inherit;">606&#8221;</em>): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic <em style="font: inherit;">606</em> to measure the progress toward complete satisfaction of a performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the input methods, revenue will be recognized on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and <em style="font: inherit;">third</em>-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to grants: </i>The Company <em style="font: inherit;"> may </em>receive grants&#160;from governments, agencies, and other private and <em style="font: inherit;">not</em>-for-profit organizations. These grants&#160;are intended to be used to partially or fully fund the Company&#8217;s research collaborations, including opportunities arising in connection with COVID-<em style="font: inherit;">19</em> that the Company is pursuing with certain collaborators. However, most, if <em style="font: inherit;">not</em> all, of such potential grant revenues, if received, is expected to be earmarked for <em style="font: inherit;">third</em> parties to advance the research required, including preclinical and clinical trials for SARS-CoV-<em style="font: inherit;">2</em> vaccines and/or antibodies candidates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Milestone payments: </i>At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has <em style="font: inherit;">not</em> recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which the<i> </i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <em style="font: inherit;">not</em> recognized any royalty revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We invoice customers based on our contractual arrangements with each customer, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are <em style="font: inherit;">not</em> required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of <em style="font: inherit;">one</em> year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Research and Development Costs </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are for the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,659,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">613,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">148,162</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">123,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,808,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">755,453</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Foreign Currency Transaction Gain or Loss</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Fair Value Measurements</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into <em style="font: inherit;">three</em> levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 3%; vertical-align: top;">&#160;</td><td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">1</em></i> &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr><td style="width: 3%; vertical-align: top;">&#160;</td><td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">2</em></i> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr><td style="width: 3%; vertical-align: top;">&#160;</td><td style="width: 3%; vertical-align: top;"><i>&#8226;</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">3</em></i> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</td></tr>
</tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company&#8217;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#8217;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the <em style="font: inherit;">third</em>-party broker service for disclosure purposes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock', window );">Equity Securities without Readily Determinable Fair Value [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Non-Marketable Investments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do <em style="font: inherit;">not</em> have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes <em style="font: inherit;"> may </em>include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which <em style="font: inherit;"> may </em>include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company&#8217;s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, <em style="font: inherit;"> may </em>have <em style="font: inherit;">no</em> or limited revenues, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be or <em style="font: inherit;"> may </em>never become profitable, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to secure additional funding or their technologies, services or products <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be successfully developed or introduced into the market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) was enacted on <em style="font: inherit;"> December 22, 2017 </em>and became effective <em style="font: inherit;"> January 1, 2018. </em>The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from <em style="font: inherit;">35%</em> to <em style="font: inherit;">21%</em> and repeal of the corporate alternative minimum tax (&#8220;AMT&#8221;). The TCJA&#8217;s reduction in the U.S. statutory tax rate had <em style="font: inherit;">no</em> additional impact on the consolidated financial statement for the year ended&#160;<em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, there were <span style="-sec-ix-hidden:c73543846"><span style="-sec-ix-hidden:c73543847">no</span></span> provision for income taxes and unrecognized tax benefits recorded. As of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>, deferred tax assets were approximately $10.2&#160;million and $9.4 million, respectively. Due to the Company&#8217;s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of&#160;<em style="font: inherit;"> March 31, 2021</em> and&#160;<em style="font: inherit;"> December 31, 2020</em>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Comprehensive Income (Loss)</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under GAAP. The Company does <em style="font: inherit;">not</em> have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does <em style="font: inherit;">not</em> separately present a statement of comprehensive income (loss) in its consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We recognize all share-based payments to employees, consultants, and our board of directors (&#8220;Board of Directors&#8221;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the effect of the potential exercise of options to purchase 5,324,215&#160;and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b>&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which modifies the measurement of expected credit losses of certain financial instruments. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will be effective for the Company beginning in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> The Company does <em style="font: inherit;">not</em> expect ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> to have a material impact on our consolidated financial positions, results of operations, and cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em>&#160;<i>Income Taxes (Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes</i>. The amendments of this update simplify the accounting for income taxes by removing certain exceptions&#160;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> on&#160;<em style="font: inherit;"> January 1, 2021, </em>and&#160;adoption of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> did&#160;<em style="font: inherit;">not</em> have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either <em style="font: inherit;">not</em> applicable or <em style="font: inherit;">not</em> significant to our consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_AccountsPayablePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_AccountsPayablePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_AccruedExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_AccruedExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ImpactOfCOVID19PolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for impact of COVID-19.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ImpactOfCOVID19PolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650980576456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">293,323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,532</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">163,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">384,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">294,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94,841</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">204,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">216,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,555</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,337,755</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">904,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,987</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,473,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,013,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">447,881</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,452</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,367</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">277,668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">489,756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock', window );">Schedule of Research and Development Costs [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,659,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">613,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">148,162</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">123,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,808,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">755,453</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650984948920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Cash, Cash Equivalent, and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash, Cash Equivalents and Investments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2021 (Unaudited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 10%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,217,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,217,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,838,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,838,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,055,558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,055,558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,161,252</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(17,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,177,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,216,810</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(17,847</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,232,999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020 (Audited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,488,030</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,488,030</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,637,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,637,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">8,473,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">22,473</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(6,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">8,457,451</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,110,506</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,473</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,094,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140651063353032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.13%-0.55%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;%</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54.52%-56.07%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.00-6.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term (Years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,638,390</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,701,610</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">745,825</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(60,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,324,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.03</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,209,431</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 44%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 10%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 11%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 13%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 10%;">&#160;</td><td style="width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,016,141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,927,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">377,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">380,251</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,019</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,688</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650984948920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Stockholders Equity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2021 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">98,013,079</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(50,676,351</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,446,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock issued</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,294,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,294,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">39,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">98,549,890</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(53,971,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">25,688,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2020 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,105,851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(41,351,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,864,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%">Stock issued</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">174,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt">175,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,214,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,214,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">39,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">96,707,690</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(43,565,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">34,252,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140651065319704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_NumberOfResearchOrganizations', window );">Number of Research Organizations</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax, Total</a></td>
<td class="nump">$ 460,520<span></span>
</td>
<td class="nump">$ 315,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets, Net, Total</a></td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent', window );">Deferred Tax Assets, Valuation Allowance Coverage, Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares</a></td>
<td class="nump">5,324,215<span></span>
</td>
<td class="nump">4,663,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">76.70%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax, Total</a></td>
<td class="nump">$ 353,000<span></span>
</td>
<td class="nump">$ 183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Contract Research Organizations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">98.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfSuppliers', window );">Concentration Risk, Number of Suppliers</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Three CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchServicesPurchased', window );">Research Services Purchased</a></td>
<td class="nump">$ 2,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | One CRO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchServicesPurchased', window );">Research Services Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfSuppliers', window );">Concentration Risk, Number of Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Accounts Payable [Member] | Three CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">89.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable, Total</a></td>
<td class="nump">$ 1,324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Accounts Payable [Member] | One CRO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ConcentrationRiskNumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ConcentrationRiskNumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ConcentrationRiskNumberOfSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of suppliers accounting for 10% or more of the specified concentration risk benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ConcentrationRiskNumberOfSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent after allocation of valuation allowance coverage of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_NumberOfResearchOrganizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of research organizations through which the entity operates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_NumberOfResearchOrganizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchServicesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research services purchased during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchServicesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=dyai_ContractResearchOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=dyai_ContractResearchOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=dyai_ThreeCROsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=dyai_ThreeCROsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=dyai_OneCROMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=dyai_OneCROMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650978900552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 384,963<span></span>
</td>
<td class="nump">$ 294,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">293,323<span></span>
</td>
<td class="nump">130,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 91,640<span></span>
</td>
<td class="nump">$ 163,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650979175432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 94,841<span></span>
</td>
<td class="nump">$ 204,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses - various</a></td>
<td class="nump">120,534<span></span>
</td>
<td class="nump">72,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid Expense and Other Assets, Current</a></td>
<td class="nump">$ 216,189<span></span>
</td>
<td class="nump">$ 280,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650979156312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentInProcessCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 1,337,755<span></span>
</td>
<td class="nump">$ 904,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal expenses</a></td>
<td class="nump">93,071<span></span>
</td>
<td class="nump">24,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">42,987<span></span>
</td>
<td class="nump">84,031<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current, Total</a></td>
<td class="nump">$ 1,473,813<span></span>
</td>
<td class="nump">$ 1,013,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentInProcessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents current research and development in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentInProcessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650978899352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee wages and benefits</a></td>
<td class="nump">$ 175,210<span></span>
</td>
<td class="nump">$ 447,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_AccruedResearchAndDevelopmentInProcessCurrent', window );">Research and development expenses</a></td>
<td class="nump">42,006<span></span>
</td>
<td class="nump">28,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">60,452<span></span>
</td>
<td class="nump">13,367<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current, Total</a></td>
<td class="nump">$ 277,668<span></span>
</td>
<td class="nump">$ 489,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_AccruedResearchAndDevelopmentInProcessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents current accrued research and development in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_AccruedResearchAndDevelopmentInProcessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650979185880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices', window );">Outside contracted services</a></td>
<td class="nump">$ 1,659,194<span></span>
</td>
<td class="nump">$ 613,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts', window );">Personnel related costs</a></td>
<td class="nump">148,162<span></span>
</td>
<td class="nump">123,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther', window );">Facilities, overhead and other</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">18,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty', window );">Research And Development Expense, Including Related Party</a></td>
<td class="nump">$ 1,808,098<span></span>
</td>
<td class="nump">$ 755,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents facilities, overhead and other for research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents research and development expense including related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents outside contracted services for research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseOutsideContractedServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents personnel related costs for research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650985108280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Cash, Cash Equivalent, and Investments (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase', window );">Debt Securities, Held-to-maturity, Premium Paid on Purchase</a></td>
<td class="nump">$ 283,940<span></span>
</td>
<td class="nump">$ 196,385<span></span>
</td>
<td class="nump">$ 282,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents premium paid on purchase for debt securities held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140651062834808">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,055,558<span></span>
</td>
<td class="nump">$ 20,637,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, adjusted cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,217,419<span></span>
</td>
<td class="nump">149,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money Market Funds, adjusted cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,838,139<span></span>
</td>
<td class="nump">20,488,030<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, adjusted cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,055,558<span></span>
</td>
<td class="nump">20,637,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross Unrealized Holding Gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">22,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross Unrealized Holding Losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,847)<span></span>
</td>
<td class="num">(6,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,177,441<span></span>
</td>
<td class="nump">8,457,452<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CashCashEquivalentsAndInvestmentsFairValue', window );">Total, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,216,810<span></span>
</td>
<td class="nump">29,110,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,232,999<span></span>
</td>
<td class="nump">29,094,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">14,177,441<span></span>
</td>
<td class="nump">8,457,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Short-term Corporate Bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross Unrealized Holding Gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">22,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember', window );">Cash [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,217,419<span></span>
</td>
<td class="nump">149,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,838,139<span></span>
</td>
<td class="nump">20,488,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=dyai_ShortTermCorporateBondsMember', window );">Short-term Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Corporate Bonds, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">14,161,252<span></span>
</td>
<td class="nump">8,473,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross Unrealized Holding Losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (17,847)<span></span>
</td>
<td class="num">$ (6,463)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the three months ended March 31, 2021 and 2020, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended  December 31, 2020.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CashCashEquivalentsAndInvestmentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents fair value of cash, cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CashCashEquivalentsAndInvestmentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=dyai_ShortTermCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=dyai_ShortTermCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=dyai_ShortTermCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=dyai_ShortTermCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650983007960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Jun. 24, 2020</div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 01, 2020</div></th>
<th class="th">
<div>Jul. 08, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 26, 2019</div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementDurationOfAgreement', window );">Collaborative Arrangement, Duration Of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement', window );">Collaborative Arrangement, Payment for Research and Development Agreement | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390,762<span></span>
</td>
<td class="nump">$ 278,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember', window );">Novovet [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember', window );">Alphazyme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of Stock, Percentage of Ownership after Transaction</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity Securities without Readily Determinable Fair Value, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dyai_ServiceAgreementToPerformResearchProjectMember', window );">Service Agreement to Perform Research Project [Member] | BDI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=dyai_ResearchServicesAgreementMember', window );">Research Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization', window );">Collaborative Arrangement, Payment for Additional Development and Commercialization | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=dyai_ServiceFrameworkAgreementMember', window );">Service Framework Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementDurationOfAgreement', window );">Collaborative Arrangement, Duration Of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment', window );">Collaborative Arrangement, Minimum Obligation For Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementOutstandingCommitment', window );">Collaborative Arrangement, Outstanding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=dyai_AlphazymeMember', window );">Alphazyme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_OwnershipPercentage', window );">Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=dyai_IDBiologicsIncMember', window );">ID Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementNumberOfSharesToBeReceived', window );">Collaborative Arrangement, Number of Shares To Be Received (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=dyai_IDBiologicsIncMember', window );">ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementVestingPercentages', window );">Collaborative Arrangement, Vesting Percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=dyai_IDBiologicsIncMember', window );">ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementVestingPercentages', window );">Collaborative Arrangement, Vesting Percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=dyai_IDBiologicsIncMember', window );">ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementVestingPercentages', window );">Collaborative Arrangement, Vesting Percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">Research Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement', window );">Collaborative Arrangement, Payment for Research and Development Agreement | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">Research Services Agreement [Member] | BDI Holdings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementDurationOfAgreement', window );">Collaborative Arrangement, Duration Of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementEquityInterestAcquired', window );">Collaborative Arrangement, Equity Interest Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment', window );">Collaborative Arrangement, Minimum Obligation For Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment', window );">Collaborative Arrangement, Maximum Obligation For Research and Development | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">Research Services Agreement [Member] | BDI Holdings [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment', window );">Collaborative Arrangement, Minimum Obligation For Research and Development | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementRevenueSharingPercentage', window );">Collaborative Arrangement, Revenue Sharing, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">Research Services Agreement [Member] | BDI Holdings [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementRevenueSharingPercentage', window );">Collaborative Arrangement, Revenue Sharing, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">Research Services Agreement [Member] | VL Pbio Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementEquityInterestAcquired', window );">Collaborative Arrangement, Equity Interest Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementDurationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents duration of agreement for collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementDurationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementEquityInterestAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents equity interest acquired for collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementEquityInterestAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum obligation for research and development for collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents minimum obligation for research and development for collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementNumberOfSharesToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares to be received for collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementNumberOfSharesToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementOutstandingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents outstanding commitment for collaborative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementOutstandingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments for additional development and commercialization for collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payment for research and development agreement for collaborate arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementRevenueSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of revenue sharing for collaborate arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementRevenueSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementVestingPercentages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents vesting percentage for collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementVestingPercentages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents ownership percentage by noncontrolling owners for noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dyai_ServiceAgreementToPerformResearchProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dyai_ServiceAgreementToPerformResearchProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_BDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_BDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=dyai_ResearchServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=dyai_ResearchServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=dyai_ServiceFrameworkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=dyai_ServiceFrameworkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_AlphazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_AlphazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_IDBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_IDBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_BDIHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_BDIHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_VLPbioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_VLPbioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650974632968">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Share-based Compensation (Details Textual) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Jan. 21, 2021</div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Jan. 04, 2021</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 28, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,324,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,638,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,825<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember', window );">Executives and Key Personnel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">227,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_EmployeesMember', window );">Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 5.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Employees [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Consultant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Share-based Compensation Award Tranche Two through Five [Member] | Executives and Key Personnel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,324,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,638,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,386<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,134,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member] | Contractor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member] | Chief Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Contractor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Chief Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember', window );">The 2011 Plan [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the following stock options granted:




Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary.




One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date.


One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date.


One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the following stock options exercised:




A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dyai_The2011PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dyai_The2011PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_ContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_ContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650985916792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-Free interest rate, minimum</a></td>
<td class="nump">0.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-Free interest rate, maximum</a></td>
<td class="nump">0.55%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">54.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">56.07%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (Year)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (Year)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140651063011672">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Share-based Compensation - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,638,390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, outstanding (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 10 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,209,431<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,701,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">745,825<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(60,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,324,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,638,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,016,141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, exercisable (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 1 month 2 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,927,908<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the following stock options granted:




Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary.




One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date.


One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date.


One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the following stock options exercised:




A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650978280392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 421,071<span></span>
</td>
<td class="nump">$ 426,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">377,052<span></span>
</td>
<td class="nump">380,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 44,019<span></span>
</td>
<td class="nump">$ 46,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650985707528">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Shareholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2020</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,929,915<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,929,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dyai_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SaleOfStockAuthorizedOfferingAmount', window );">Sale of Stock, Authorized Offering Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare', window );">Sale of Stock, Percentage of Commissions Paid of Gross Proceeds From Sale Of Each Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SaleOfStockReimbursableLegalExpenses', window );">Sale of Stock, Reimbursable Legal Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SaleOfStockTerminationAmountUnderAgreement', window );">Sale of Stock, Termination Amount Under Agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the following stock options exercised:




A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SaleOfStockAuthorizedOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents authorized offering amount of sale of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SaleOfStockAuthorizedOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of commission paid on gross proceeds from sale of each share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SaleOfStockReimbursableLegalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents reimbursable legal expense for sale of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SaleOfStockReimbursableLegalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SaleOfStockTerminationAmountUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents termination amount under agreement for sale of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SaleOfStockTerminationAmountUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dyai_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dyai_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650988072408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">$ 28,446,561<span></span>
</td>
<td class="nump">$ 35,864,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">421,071<span></span>
</td>
<td class="nump">426,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued</a></td>
<td class="nump">115,800<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,294,949)<span></span>
</td>
<td class="num">(2,214,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">25,688,483<span></span>
</td>
<td class="nump">34,252,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">39,748<span></span>
</td>
<td class="nump">39,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">39,808<span></span>
</td>
<td class="nump">39,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">(18,929,915)<span></span>
</td>
<td class="num">(18,929,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">(18,929,915)<span></span>
</td>
<td class="num">(18,929,915)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">98,013,079<span></span>
</td>
<td class="nump">96,105,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">421,071<span></span>
</td>
<td class="nump">426,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued</a></td>
<td class="nump">115,740<span></span>
</td>
<td class="nump">174,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">98,549,890<span></span>
</td>
<td class="nump">96,707,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">(50,676,351)<span></span>
</td>
<td class="num">(41,351,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,294,949)<span></span>
</td>
<td class="num">(2,214,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">$ (53,971,300)<span></span>
</td>
<td class="num">$ (43,565,217)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +N K5('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "[@*U2YHOF->\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NFG9#E&7"]-.("$Q"<0M2KPMHFFBQ*C=V].&K1."!^ 8^\_G
MSY);'83V$9^C#QC)8KH;7=<GH<.&G8B" $CZA$ZE<DKT4_/@HU,T/>,1@M(?
MZHA05]4:')(RBA3,P"(L1"9;HX6.J,C'"][H!1\^8Y=A1@-VZ+"G!+SDP.0\
M,9S'KH4;8(811I>^"V@68J[^B<T=8)?DF.R2&H:A')J<FW;@\/;T^)+7+6R?
M2/4:IU_)"CH'W+#KY-?F8;O?,5E7-2^J5<&;/5^+:B7N^?OL^L/O)NR\L0?[
MCXVO@K*%7W<AOP!02P,$%     @ NX"M4IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M&/+XNNLXT&)OWQAMA-:BM)<[1B$!8P#WMP*4M1F8EU#M2\?5OU!+ P04
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M<_ #  " #   &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)V7;6_;-A"
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MY08H]V=#^QO!-M71Q!,3@N75Y9J2A)8*(-\O&1/O-VJ YH1N_"]02P,$%
M  @ NX"M4EF]T&:A!0  OA0  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6R56-MNVS@0_17"V(<$J&N1N@=)@,1ML7UH$33H[C,MC6UN)=$EZ5SZ]3N4
M%,F5*"5M@)J2A^29,\,Y8UX^2O5#[P$,>2J+2E\M]L8<+E8KG>VAY/J]/$"%
MWVRE*KG!1[5;Z8,"GM>3RF+%/"]:E5Q4B^O+^MV=NKZ41U.("NX4T<>RY.KY
M%@KY>+6@BY<7W\1N;^R+U?7E@>_@'LSWPYW"IU6W2BY*J+20%5&PO5K<T(LU
MB^V$VN(? 8_Z9$RL*QLI?]B'S_G5PK.(H(#,V"4X?CS &HK"KH0X?K:++KH]
M[<33\<OJGVKGT9D-U["6Q;\B-_NK1;(@.6SYL3#?Y./?T#H4VO4R6>CZ?_+8
MV,;1@F1';6393D8$I:B:3_[4$G$R ==Q3V#M!#:<$$Q,\-L)?NUH@ZQVZP,W
M_/I2R4>BK#6N9@<U-_5L]$94-HSW1N&W N>9Z[6LM"Q$S@WDY-[@!\;(:"*W
M9,WUGGS".&MR]KWBQUR@S3E9DN_W'\C97^>7*X, [#*KK-WLMMF,36SFDR^R
M,GM-/E8YY+_/7R'P#CU[07_+9A?\PM5[XM-WA'F,.O"LWS[=FX'C=V3Z]7K^
M%)F6L6W-V%;)DN!A4]R(:M=DJS "],PV0;=-4&\33&SS%4]W(;5V!:"9&=4S
M[1%^N%[Z+ WP[W+U<,J,PY Q&E"_-_P-7-B!"V<YN,G_PZQMDLA(/.F9K#)1
M *E:U/:M'6>6K*/&M!.5DZF+&:JB#DTT2]6]D=F/I3WG.<EDB<5/\[I\P),=
M@XO"9L7PA)F 42^F P)=9E$Z15_< 8YG =^44AGQJP&)AW /1;XT<HD%ZZB$
M>28:,CM ?MY9&ET.Q"-DD9^&0_QC*W22A9$;?]+A3V;Q8VW%REEAZ5(*JNP9
MB<[VO-I!$_NS'2K+^23R9(2))2QF ^1C*^HE4>P&GG; T_FS6Z/4@V34&C"/
M>9630O"-*%Y-3.KUA=>;9>IS94"!-O:(@'C@F\*9C>TJI]XN@R -@P$I#COJ
M83A#-RWT1"#H?$9FF3S:T_P*3CK&27V:>-X0Z-C0#UF83.!D/4XVB_-.P8&+
M_.5D-U&39@^J34;3AM.)GHW/3,#2>(A];+:D7L@F#CWMA8/Z;R/YP)\G&?;'
M%2?Q@C <@AS;+5G*_(A.H.QUA\X+#Z)41^@I=J(,'+M3YB7)$*;#T&>1=Y(P
MO\/L%8B&LS _P!8PX#EFK :NLGV="CD\8--ZL,I$Y*80N[K&.ET(1\ABB@0.
MZY##CD9^G$YE0R]:=%ZUOKY%'IW(QZ*TI*D7A=0?8G=:II$?3!6,7L%H_$==
MD*@>L,R]N0NBO=30>:VY.V)LN3WJ+J%LMJW#W6NFD[2QGBPI98F?!J/:Y32-
M0N8G4[3U^D/35^J7S #REK36#=$X]W9?TA' ,/0\;UR%QX;4]T-O\OBQ7MC8
MO+!UV7O6IN\Y.2CY(+#E)YOG-Z1#V_D[A"^,75%Q6-(HC2,Z$1/6:Q^C?Y3*
M6U%Q[&;?FLJL%R_VFGB=!A^>0&5"@PV]/-@RY69HK$:4AF/%==G%X72D>]5B
M\ZK51?HTOJ]SU*(?RY0;O<-N#GVO9FQ>S3YNMY 9RW'7HV*1!9*UG2 VX-8Y
M)W:'=D6)/^S)7&8L3?P)Y+W L7F!L[SGD"G XF?EH8Z!U;AZ #^/V*85]A>8
M$_M8M99QF- @&78[+DO*HIA..= +')L7N/448,(-V<!.5)5-( P-"I^0N=./
ML8(Q#^77"X8-D<,R2)@?!L&$'[W4L?E?:[-^@.T_9SV(1[_!J>^%^&_8*SDL
M@RC%C!NV=*N3FZ 2U*Z^(-.D;BZ;:Y7N;7<)=U-?/0W>W]*+=7.5UB_3W.Q]
MX0KCHTD!6US2>Q\CKZJY+&L>C#S4]TT;:8PLZ^$>> [*&N#W6RG-RX/=H+NR
MO/X?4$L#!!0    ( +N K5)FD_W\ZA,  ! W   8    >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&ULK5MK<]NVMOTK&-]SSJ0SM*R7;3FO&=M)SG6G;7SBM/UP
MYGZ 2$A"0Q(J05I1?_U=>P,@09FVTVFG32*1>.SGV@] KW>F^F(W2M7B:Y&7
M]LW1IJZW+T].;+I1A;0CLU4EWJQ,5<@:7ZOUB=U62F8\J<A/IN/QV4DA=7GT
M]C4_NZW>OC9-G>M2W5;"-D4AJ_V5RLWNS='D*#SXI->;FAZ<O'V]E6MUI^J?
MM[<5OIVTJV2Z4*75IA256KTYNIR\O)K3>![PBU8[&WT6Q,G2F"_TY29[<S0F
M@E2NTII6D/CG7EVK/*>%0,;O?LVC=DN:&'\.JW]@WL'+4EIU;?)?=59OWAPM
MCD2F5K+)ZT]F][_*\W-*ZZ4FM_RWV+FQ9Q='(FUL;0H_&104NG3_RJ]>#M&$
MQ?B1"5,_8<ITNXV8RG>REF]?5V8G*AJ-U>@#L\JS09PN22EW=86W&O/JMS^9
M6HF).!8?J[4L]1_2R:K,Q)U3DS K<:?7I5[I5):UN$Q3TY2U+M?BUN0ZU<J^
M/JE!":UWDOI=K]RNTT=VG8D?35EOK'A?9BKKSS\!!RT;T\#&U?3)!7^4U4C,
M)HF8CJ>3)]:;M6*9\7JS)\1B16W$!UW*,M4R%W>UK!7,L;9/K#]OUY_S^O-'
MUK]J+)Y8*]XIFU9ZVTI]0+SBOY_5UUI<Y2;]\G]#LGYR*_+JEW8K4_7F"&YK
M576OCKS:7_X5K?=(Q_".I;W,="INREI5):\L\P1?TY%X\:__64RGXU=N"'^9
MO$J$?[I3AT\:>_C$-%7[R%2BWJCPYMH46UGN_=OOA+9"BG5NEM#=4H/?=%.:
MW*SW8IO+FN!,I&X*NW4F="F^;[8:5"?B0VXJG4DX8[T10,"*^; TAK;\N<2P
MS)F$3;"/Q8<\QT-( B)38>!/"G]7.21K6;S00&8*LJDZWV-$I92H=P:?=)6)
MSQA;&,S(3;%/(>*- C5X(+%V*L6/>)AKL]W4&U-)V@##MQN=2W$]&>&/^%A"
M+:DJEJKR[C Y3>@%_B_D7ERNL"!3]JZYA0N*SY4LK62$3/BY%Z/82"N62I5B
M90!#8-8XCI:TOP0>IJJI050.5C/@5+5/A-VJE"TF!W.0P*JIB$:ABVUE[LEX
M2 9RN\WW](66PXMMI55--N?(G%SP_^-Q(E:ZLC70Z?UJI1B]Q24&YV)RSIQ=
MP*I ;%J3^5U__.7FW3%-A10%PL\2,>K+P1LC,B@*A)J"-(5AE5#%-C=[!6G+
M2@E;ZSSG2$(45@KJ4/E^Q(O""^'^A J[C4XW3ESMXB3>*?_GE.D?T1]\+$U-
M__RJL":$0RY#>W_5EITJE7;#PN$/ZO=&W\N<L":!'.^5K1EX2*:96M;"JK2I
M=*W9^##+6VA8:(502V2RU#/%A :64@D3A]9*I6"3< ,FI#/Q$=&XA)FI>YHH
MZP%"M\;J%C$Z^HB\Z-NZDMB[(Q7.!-$NE<#CWQOH@4@L*/'H44!@L?18XKEC
M(\HUI)+I>@\)XE/EL)@Y )&YDC 58K0DL*QW*@?]DRD+GG0 RRH-?4K^#,9=
M20L<P<!;@LZR=D!)QB!3CQXTOBEEDS$DI 81K;3ND\4R9' 9+#F$$=N&$5)M
MFF.>=P7I]N?M8D]D(>/Q;F/(K\RNQ(*V65I(0U9L QMYKYRW F"VL&-&,UJP
MRK"O<CCV\^AN)-:JA*!I(;Q66R).=HS#O4#F-@?K :O_?7EYVX)J\%](;)G#
MEAL:20\KM6YR#Y*>_KM.\S3B_==T(\LU\U5HRUE=V./N_76[!5:2%0M%4P31
M120\,&<J(A1@IZI:LL&YS#28X\J8NJ3HEFF;YL8V4!PTCR$.E$CB3CS/*B@2
M:Z=6<IA"US1GVU2VD0X1; - &!3'2%S"[&UD:."KDL?8@8RY[@#8346\(I7%
MN\,;*6;4AW1CCD.F6 @QBT B*_[3R J"!/>?6'P$/I31 F,/@\44H(NGR*;
MS6SLTJD18C<KU&QUZ8-](4ND["2EI+7= 6\(&GQ>U,C%*5$7T!+PX;?&(U[B
MH9:@&=M*KTD,AVU5M!G$ A4GO 6PCDR_!%/6DH<S.(B5U)78Q@Y,2V$C0(XV
M0$'_3F5.FOB&G/[0#\E )^>O;)P.\/KEON4S+$CD$O#<:7(^D!;[^;=$7K*W
M)B5I!2@D=9H2J8=E2;P''!>4?3#%SNM;WK":5=\@] &,(&\/ &LC-3-6RR\(
M@NW&9*R_-=G:K<6A0G*@9FZ<JQ*Z% 0N+')K5>WFY5HN==Z! X(BD]DY+4T
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M!J(O-%W09L,&VE\T9W\#4$L#!!0    ( +N K5+_ $H?^04  'X.   8
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M-\@ENV48G-8,RR>[AP[N"F&Q,(J!W@N3RQ90W@9*<=*84C:>,4]VK%D)%<B
MBC.K/9.FIO"<4+3&ZMKHK>;-$M)UC1%(ZKI>12VC2&(#6S$WD$Q3EW58-!K4
M)_3<:6I''R[88*0=<RV":XI($C*^K6/'E/V2-B3%)2'>;K':[1'@!'RYNHA@
MBIFHJ7G=3FZPP;(OI,V_1;2!G*):BS,?='N4 ?_LQ#M#?@X#>JJJ0OQ-:."A
MO!8KV'Y](CLB3R=APN.HI2]:7RLDW=;_4Z^G$%^JV--N5S/(B2-:(&2BDIX
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M5\)C01=$M"Q ^S-#'Y+M"SM87SE/_@%02P,$%     @ NX"M4F&MJ\$H @
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M;NAQCIH9:'^EJ!MT'WS \-P__3]02P,$%     @ NX"M4NGN)!A%!0  = P
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M.%?'5K>/'C_RP6 8]%GD$'<R^1TLG6/H>"&5[Y.!\-#59LMQHS]V'3):RME
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M<Y)%6FWC9.>T S]J Y0;D6ZKITNR>(;*3KNSR-N0!*G)D.%LQAS"X3D'FBZ
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MC_KMCU+O^$/ZE2Y+G?$EU4=E02_@.7WMZ'\0@/H_K?#N_P%02P,$%     @
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MFU@0DDG_Q<@Z(K*?(>)_8MX;XUTQ_U1O*O6""'L:$YH&N4")2V$]VMF(16%
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MBZX$U$Z!OB\5O?/MP@7H)N_9OU!+ P04    " "[@*U2_,8 !V4#   <"
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M#25+*O0 =7_%N=R?Z =4>Y-7_P)02P,$%     @ NX"M4G]?2/YA @  /@8
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M,"-_<9=<5J!5=Z^(EVA%*D9*DF.FT%V>\PU3A%5HR2G)"4BM[E<E6N)7O*:
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MO:J=&-FX<E])@\W##2ML[Z"L >X7$DN^F]@.TO]AI/\ 4$L#!!0    ( +N
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MI#' ]J40^NG&O* ]=YS^!U!+ P04    " "[@*U21^M&@9X&  "@(   &0
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MQCZ+FRN^4FF2L\\"R5664;&Y8RE?7W=P9SOP)9DOE!X8W%PMZ9P],O5U^5G
MW:"R$B<9RV7"<R38[+ISBR\_$%\#S(R_$[:6C6ND77GB_%G?_!%?=SS-B*4L
M4MH$A3\O;,K25%L"'C]*HYUJ30UL7F^M?S#.@S-/5+(I3[\EL5I<=\8=%+,9
M7:7J"U__SDJ'0FTOXJDTO]&ZF#N"R=%**IZ58&"0)7GQE_XLA6@ QEX+@)0
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MA!; ]PN.UXUBH0V4-^[1?U!+ P04    " "[@*U2YV#GAZ $   ,%0  &0
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "[@*U2Z$LO33(#   %%P
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M]#:+PY)WZNW\H[9N[GFN<?]W4NW'=^V\_;1\WEQ\*A/.&HX.C[]02P,$%
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M:XI"UA2%K"D*6=/_).N'ULN__O76KDDM57/P9]W_S=D74$L! A0#%     @
MNX"M4@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "[@*U2YHOF->\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " "[@*U2.B&HR_\$  "M$P  &
M    @('"&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MNX"M4EF]T&:A!0  OA0  !@              ("!]Q\  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +N K5)FD_W\ZA,  ! W   8
M          " @<XE  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " "[@*U2\H4D1F %  #=#   &               @('N.0  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ NX"M4O\ 2A_Y!0  ?@X
M !@              ("!A#\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( +N K5)AK:O!* (  -4$   9              " @;-%  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ NX"M4N;)GZWE
M!@  ^@\  !D              ("!$D@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " "[@*U2Z>XD&$4%  !T#   &0
M@($N3P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +N
MK5*:01[0;0(  $4%   9              " @:I4  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ NX"M4IVC;>:,%   9D$  !D
M         ("!3E<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " "[@*U2*PRB9$L$  "%"P  &0              @($1;   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +N K5+\Q@ '90,  !P(
M   9              " @9-P  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ NX"M4@I3<NWS P  & D  !D              ("!+W0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "[@*U2-B[G
M;& #   ;"   &0              @(%9>   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( +N K5)(5\\V 08  *<<   9
M  " @?![  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MNX"M4G]?2/YA @  /@8  !D              ("!*((  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " "[@*U2HXEZ[GP"  !/!@  &0
M            @(' A   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( +N K5+]GI$5? (  "\&   9              " @7.'  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ NX"M4I?E<".1 @
M/ 8  !D              ("!)HH  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " "[@*U2"G$5(=<"   5!P  &0              @('N
MC   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +N K5($
MY(^\A0(  "4&   9              " @?R/  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ NX"M4NGWOR(N!0  @Q0  !D
M     ("!N)(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +N K5(VV!W.G (  /T&   9              "
M@0&Q  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ NX"M
M4N]Y[8N7!   ?0\  !D              ("!U+,  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " "[@*U2YV#GAZ $   ,%0  &0
M        @(&BN   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( +N K5)ZC%_4/ ,  ) 3   -              "  7F]  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ NX"M4I>*NQS     $P(   L
M ( !X,   %]R96QS+RYR96QS4$L! A0#%     @ NX"M4NA++TTR P  !1<
M  \              ( !R<$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M +N K5+@/0E7: $  $H4   :              "  2C%  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +N K5(<F@E=C $  .<4   3
M              "  <C&  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     I
- "D %@L  (7(      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>277</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-</Role>
      <ShortName>Note 2 - Cash, Cash Equivalent, and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies</Role>
      <ShortName>Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-</Role>
      <ShortName>Note 4 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-</Role>
      <ShortName>Note 5 - Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-</Role>
      <ShortName>Note 6 - Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-</Role>
      <ShortName>Note 7 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables</Role>
      <ShortName>Note 2 - Cash, Cash Equivalent, and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 5 - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables</Role>
      <ShortName>Note 5 - Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 6 - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables</Role>
      <ShortName>Note 6 - Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual</Role>
      <ShortName>Note 2 - Cash, Cash Equivalent, and Investments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details</Role>
      <ShortName>Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual</Role>
      <ShortName>Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 5 - Share-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual</Role>
      <ShortName>Note 5 - Share-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details</Role>
      <ShortName>Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 5 - Share-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details</Role>
      <ShortName>Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 6 - Shareholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual</Role>
      <ShortName>Note 6 - Shareholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dyai20210331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details</Role>
      <ShortName>Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="dyai20210331_10q.htm">dyai20210331_10q.htm</File>
    <File>dyai-20210331.xsd</File>
    <File>dyai-20210331_cal.xml</File>
    <File>dyai-20210331_def.xml</File>
    <File>dyai-20210331_lab.xml</File>
    <File>dyai-20210331_pre.xml</File>
    <File>ex_237822.htm</File>
    <File>ex_237823.htm</File>
    <File>ex_237824.htm</File>
    <File>ex_237825.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dyai-20200930_g1copy.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>52
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dyai20210331_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 123,
   "dts": {
    "calculationLink": {
     "local": [
      "dyai-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dyai-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "dyai20210331_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dyai-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dyai-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dyai-20210331.xsd"
     ],
     "remote": [
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 350,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 41,
    "http://www.dyadic.com/20210331": 18,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 65
   },
   "keyCustom": 35,
   "keyStandard": 242,
   "memberCustom": 20,
   "memberStandard": 29,
   "nsprefix": "dyai",
   "nsuri": "http://www.dyadic.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.dyadic.com/20210331/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 4 - Commitments and Contingencies",
     "role": "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-",
     "shortName": "Note 4 - Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 5 - Share-based Compensation",
     "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
     "shortName": "Note 5 - Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 6 - Shareholders' Equity",
     "role": "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
     "shortName": "Note 6 - Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 7 - Subsequent Events",
     "role": "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-",
     "shortName": "Note 7 - Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dyai:ImpactOfCOVID19PolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dyai:ImpactOfCOVID19PolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Tables)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables",
     "shortName": "Note 2 - Cash, Cash Equivalent, and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 5 - Share-based Compensation (Tables)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables",
     "shortName": "Note 5 - Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 6 - Shareholders' Equity (Tables)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables",
     "shortName": "Note 6 - Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)",
     "role": "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
     "shortName": "Consolidated Balance Sheets (Current Period Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "dyai:AccountsPayablePolicyPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentInProcessCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "dyai:AccountsPayablePolicyPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentInProcessCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "dyai:AccruedExpensesPolicyPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "dyai:AccruedExpensesPolicyPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Details Textual)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual",
     "shortName": "Note 2 - Cash, Cash Equivalent, and Investments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details",
     "shortName": "Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
     "shortName": "Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2019-04-26_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-NovovetMember",
      "decimals": "1",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 5 - Share-based Compensation (Details Textual)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
     "shortName": "Note 5 - Share-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
     "shortName": "Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "role": "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details",
     "shortName": "Note 5 - Share-based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details",
     "shortName": "Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 6 - Shareholders' Equity (Details Textual)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual",
     "shortName": "Note 6 - Shareholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2020-08-13",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)",
     "role": "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details",
     "shortName": "Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited",
     "shortName": "Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
     "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments",
     "role": "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
     "shortName": "Note 2 - Cash, Cash Equivalent, and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies",
     "role": "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
     "shortName": "Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dyai20210331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited",
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables",
      "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-",
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited",
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables",
      "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-",
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dyai_AccountsPayablePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts payable.",
        "label": "Accounts Payable, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "AccountsPayablePolicyPolicyTextBlock",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dyai_AccruedExpensesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accrued expenses.",
        "label": "Accrued Expenses, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "AccruedExpensesPolicyPolicyTextBlock",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dyai_AccruedResearchAndDevelopmentInProcessCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents current accrued research and development in process.",
        "label": "dyai_AccruedResearchAndDevelopmentInProcessCurrent",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentInProcessCurrent",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_AlphazymeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to Alphazyme.",
        "label": "Alphazyme [Member]"
       }
      }
     },
     "localname": "AlphazymeMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_BDIHoldingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to BDI Holdings.",
        "label": "BDI Holdings [Member]"
       }
      }
     },
     "localname": "BDIHoldingsMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_BDIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding Biotechnology Developments for Industry, S.L., a Spanish biotechnology company.",
        "label": "BDI [Member]"
       }
      }
     },
     "localname": "BDIMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_CashCashEquivalentsAndInvestmentsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents fair value of cash, cash equivalents and investments.",
        "label": "dyai_CashCashEquivalentsAndInvestmentsFairValue",
        "totalLabel": "Total, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsFairValue",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementDurationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents duration of agreement for collaborative agreement.",
        "label": "dyai_CollaborativeArrangementDurationOfAgreement",
        "terseLabel": "Collaborative Arrangement, Duration Of Agreement (Year)"
       }
      }
     },
     "localname": "CollaborativeArrangementDurationOfAgreement",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_CollaborativeArrangementEquityInterestAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents equity interest acquired for collaborative agreement.",
        "label": "dyai_CollaborativeArrangementEquityInterestAcquired",
        "terseLabel": "Collaborative Arrangement, Equity Interest Acquired"
       }
      }
     },
     "localname": "CollaborativeArrangementEquityInterestAcquired",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents maximum obligation for research and development for collaborative agreement.",
        "label": "dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment",
        "terseLabel": "Collaborative Arrangement, Maximum Obligation For Research and Development"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumObligationForResearchAndDevelopment",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents minimum obligation for research and development for collaborative agreement.",
        "label": "dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment",
        "terseLabel": "Collaborative Arrangement, Minimum Obligation For Research and Development"
       }
      }
     },
     "localname": "CollaborativeArrangementMinimumObligationForResearchAndDevelopment",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementNumberOfSharesToBeReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of shares to be received for collaborative arrangement.",
        "label": "dyai_CollaborativeArrangementNumberOfSharesToBeReceived",
        "terseLabel": "Collaborative Arrangement, Number of Shares To Be Received (in shares)"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfSharesToBeReceived",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "dyai_CollaborativeArrangementOutstandingCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents outstanding commitment for collaborative.",
        "label": "dyai_CollaborativeArrangementOutstandingCommitment",
        "terseLabel": "Collaborative Arrangement, Outstanding Commitment"
       }
      }
     },
     "localname": "CollaborativeArrangementOutstandingCommitment",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents payments for additional development and commercialization for collaborative arrangement.",
        "label": "dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization",
        "terseLabel": "Collaborative Arrangement, Payment for Additional Development and Commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents payment for research and development agreement for collaborate arrangement.",
        "label": "dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement",
        "terseLabel": "Collaborative Arrangement, Payment for Research and Development Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementRevenueSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of revenue sharing for collaborate arrangement.",
        "label": "dyai_CollaborativeArrangementRevenueSharingPercentage",
        "terseLabel": "Collaborative Arrangement, Revenue Sharing, Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueSharingPercentage",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_CollaborativeArrangementVestingPercentages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents vesting percentage for collaborative arrangement.",
        "label": "dyai_CollaborativeArrangementVestingPercentages",
        "terseLabel": "Collaborative Arrangement, Vesting Percentages"
       }
      }
     },
     "localname": "CollaborativeArrangementVestingPercentages",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_ConcentrationRiskNumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.",
        "label": "dyai_ConcentrationRiskNumberOfCustomers",
        "terseLabel": "Concentration Risk, Number of Customers"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfCustomers",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "dyai_ConcentrationRiskNumberOfSuppliers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of suppliers accounting for 10% or more of the specified concentration risk benchmark.",
        "label": "dyai_ConcentrationRiskNumberOfSuppliers",
        "terseLabel": "Concentration Risk, Number of Suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfSuppliers",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "dyai_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to consultant.",
        "label": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ContractResearchOrganizationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to contract research organizations, or to research services purchased from such organizations.",
        "label": "Contract Research Organizations [Member]"
       }
      }
     },
     "localname": "ContractResearchOrganizationsMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to contractor.",
        "label": "Contractor [Member]"
       }
      }
     },
     "localname": "ContractorMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents premium paid on purchase for debt securities held-to-maturity.",
        "label": "dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase",
        "terseLabel": "Debt Securities, Held-to-maturity, Premium Paid on Purchase"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent after allocation of valuation allowance coverage of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance Coverage, Percent"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceCoveragePercent",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to employees.",
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ExecutivesAndKeyPersonnelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents executives and key personnel.",
        "label": "Executives and Key Personnel [Member]"
       }
      }
     },
     "localname": "ExecutivesAndKeyPersonnelMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_IDBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ID Biologics Inc.",
        "label": "ID Biologics Inc [Member]"
       }
      }
     },
     "localname": "IDBiologicsIncMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ImpactOfCOVID19PolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for impact of COVID-19.",
        "label": "Impact of COVID-19, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ImpactOfCOVID19PolicyPolicyTextBlock",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ownership percentage by noncontrolling owners for noncontrolling interest.",
        "label": "dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners",
        "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners"
       }
      }
     },
     "localname": "NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_NovovetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to Novovet.",
        "label": "Novovet [Member]"
       }
      }
     },
     "localname": "NovovetMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_NumberOfResearchOrganizations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of research organizations through which the entity operates.",
        "label": "dyai_NumberOfResearchOrganizations",
        "terseLabel": "Number of Research Organizations"
       }
      }
     },
     "localname": "NumberOfResearchOrganizations",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "dyai_OneCROMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding one contract research organization.",
        "label": "One CRO [Member]"
       }
      }
     },
     "localname": "OneCROMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_OpenMarketSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to open market for sale agreement.",
        "label": "Open Market Sale Agreement [Member]"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_OwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership.",
        "label": "dyai_OwnershipPercentage",
        "terseLabel": "Ownership Percentage"
       }
      }
     },
     "localname": "OwnershipPercentage",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dyai_PrepaidResearchAndDevelopmentInProcessCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current amount of prepaid research and development in process as of the balance sheet date.",
        "label": "Investment in Alphazyme"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentInProcessCurrent",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
       "order": 2.0,
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents facilities, overhead and other for research and development expense.",
        "label": "Facilities, overhead and other"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents research and development expense including related party.",
        "label": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
        "totalLabel": "Research And Development Expense, Including Related Party"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseIncludingRelatedParty",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseOutsideContractedServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
       "order": 1.0,
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents outside contracted services for research and development expense.",
        "label": "Outside contracted services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseOutsideContractedServices",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
       "order": 0.0,
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents personnel related costs for research and development expenses.",
        "label": "Personnel related costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePersonnelRelatedCosts",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentInProcessCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents current research and development in process.",
        "label": "dyai_ResearchAndDevelopmentInProcessCurrent",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessCurrent",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to research services agreement.",
        "label": "Research Services Agreement [Member]"
       }
      }
     },
     "localname": "ResearchServicesAgreementMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ResearchServicesPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of research services purchased during the period.",
        "label": "dyai_ResearchServicesPurchased",
        "terseLabel": "Research Services Purchased"
       }
      }
     },
     "localname": "ResearchServicesPurchased",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_SaleOfStockAuthorizedOfferingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents authorized offering amount of sale of stock.",
        "label": "dyai_SaleOfStockAuthorizedOfferingAmount",
        "terseLabel": "Sale of Stock, Authorized Offering Amount"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedOfferingAmount",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of commission paid on gross proceeds from sale of each share",
        "label": "dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare",
        "terseLabel": "Sale of Stock, Percentage of Commissions Paid of Gross Proceeds From Sale Of Each Share"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_SaleOfStockReimbursableLegalExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents reimbursable legal expense for sale of stock.",
        "label": "dyai_SaleOfStockReimbursableLegalExpenses",
        "terseLabel": "Sale of Stock, Reimbursable Legal Expenses"
       }
      }
     },
     "localname": "SaleOfStockReimbursableLegalExpenses",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_SaleOfStockTerminationAmountUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents termination amount under agreement for sale of stock.",
        "label": "dyai_SaleOfStockTerminationAmountUnderAgreement",
        "terseLabel": "Sale of Stock, Termination Amount Under Agreement"
       }
      }
     },
     "localname": "SaleOfStockTerminationAmountUnderAgreement",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of research and development costs.",
        "label": "Schedule of Research and Development Costs [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dyai_ServiceAgreementToPerformResearchProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding a service agreement to perform a research project.",
        "label": "Service Agreement to Perform Research Project [Member]"
       }
      }
     },
     "localname": "ServiceAgreementToPerformResearchProjectMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ServiceFrameworkAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to service framework agreement.",
        "label": "Service Framework Agreement [Member]"
       }
      }
     },
     "localname": "ServiceFrameworkAgreementMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents shares-based compensation award tranche two through five.",
        "label": "Share-based Compensation Award Tranche Two through Five [Member]"
       }
      }
     },
     "localname": "SharebasedCompensationAwardTrancheTwoThroughFiveMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ShortTermCorporateBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents short-term corporate bonds.",
        "label": "Short-term Corporate Bonds [Member]"
       }
      }
     },
     "localname": "ShortTermCorporateBondsMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_The2011PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding the 2011 plan.",
        "label": "The 2011 Plan [Member]"
       }
      }
     },
     "localname": "The2011PlanMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ThreeCROsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding three contract research organizations.",
        "label": "Three CROs [Member]"
       }
      }
     },
     "localname": "ThreeCROsMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_VLPbioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to VL Pbio.",
        "label": "VL Pbio Member"
       }
      }
     },
     "localname": "VLPbioMember",
     "nsuri": "http://www.dyadic.com/20210331",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Cash, Cash Equivalent, and Investments"
       }
      }
     },
     "localname": "statement-statement-note-2-cash-cash-equivalent-and-investments-tables",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Share-based Compensation - Stock Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-sharebased-compensation-stock-option-activity-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-5-sharebased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Share-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-5-sharebased-compensation-tables",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-note-6-shareholders-equity-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Shareholders' Equity"
       }
      }
     },
     "localname": "statement-statement-note-6-shareholders-equity-tables",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "dyai_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.dyadic.com/20210331",
     "xbrltype": "stringItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r36",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r187",
      "r188",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r297",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r187",
      "r188",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r297",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r178",
      "r187",
      "r188",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r297",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r178",
      "r187",
      "r188",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r297",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r105",
      "r106",
      "r174",
      "r176",
      "r320",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r105",
      "r106",
      "r174",
      "r176",
      "r320",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r108",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by billing status of receivables.",
        "label": "Billing Status, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r306",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_AccountsPayableCurrentAndNoncurrent",
        "terseLabel": "Accounts Payable, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r10",
      "r26"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "us-gaap_AccountsPayableOtherCurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r16",
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "us-gaap_AccountsReceivableNet",
        "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r16",
      "r109",
      "r110"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "totalLabel": "Accrued Liabilities, Current, Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r27"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Legal expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r217"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r189",
      "r191",
      "r220",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r191",
      "r211",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r115",
      "r136",
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r59",
      "r94",
      "r97",
      "r102",
      "r134",
      "r239",
      "r241",
      "r249",
      "r303",
      "r311"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r35",
      "r59",
      "r134",
      "r239",
      "r241",
      "r249"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r192",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.",
        "label": "Billed Revenues [Member]"
       }
      }
     },
     "localname": "BilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r61",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r24",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
       "order": 0.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash, adjusted cost"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r24",
      "r53"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
       "order": 0.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents, adjusted cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
       "order": 1.0,
       "parentTag": "dyai_CashCashEquivalentsAndInvestmentsFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and cash equivalent, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r49",
      "r53",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r254"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r235",
      "r236",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r156",
      "r307",
      "r314"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 39,807,659 and 39,747,659, outstanding shares - 27,554,157 and 27,494,157 as of March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r107",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r85",
      "r86",
      "r107",
      "r247",
      "r248",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r85",
      "r86",
      "r107",
      "r247",
      "r248",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r81",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r85",
      "r86",
      "r107",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "us-gaap_ConcentrationRiskPercentage1",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r107",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r163",
      "r164",
      "r175"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred research and development obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r179",
      "r186",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r43",
      "r298"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Costs of research and development revenue",
        "terseLabel": "Cost of Goods and Services Sold, Total"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "us-gaap_CostsAndExpenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r84",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "terseLabel": "Deferred Tax Assets, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted net loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee wages and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r66",
      "r71",
      "r73",
      "r78",
      "r135",
      "r158",
      "r159",
      "r214",
      "r215",
      "r216",
      "r233",
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "us-gaap_EquityMethodInvestmentOwnershipPercentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
        "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.",
        "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r243",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r244",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r179",
      "r180",
      "r185",
      "r186",
      "r244",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r179",
      "r180",
      "r185",
      "r186",
      "r244",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r124",
      "r128",
      "r137",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax",
        "negatedLabel": "Foreign currency exchange loss (gain), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
        "label": "us-gaap_ForeignCurrencyTransactionGainLossRealized",
        "negatedLabel": "Foreign currency exchange loss (gain), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r122",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r123",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
        "negatedLabel": "Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Short-term investment securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r121",
      "r125",
      "r305"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
       "order": 0.0,
       "parentTag": "dyai_CashCashEquivalentsAndInvestmentsFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Corporate Bonds, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r56",
      "r225",
      "r226",
      "r228",
      "r229",
      "r231",
      "r232",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
        "terseLabel": "Deferred research and development obligation"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Amortization of held-to-maturity securities, net"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "us-gaap_InvestmentsAndCash",
        "totalLabel": "Total, adjusted"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r59",
      "r134",
      "r249",
      "r304",
      "r313"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r59",
      "r134",
      "r240",
      "r241",
      "r242",
      "r249"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, adjusted cost"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r37",
      "r38",
      "r40",
      "r52",
      "r59",
      "r65",
      "r67",
      "r68",
      "r69",
      "r70",
      "r72",
      "r73",
      "r74",
      "r94",
      "r96",
      "r98",
      "r101",
      "r103",
      "r134",
      "r249",
      "r308",
      "r317"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r94",
      "r96",
      "r98",
      "r101",
      "r103"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r27"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "us-gaap_OtherAccruedLiabilitiesCurrent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r7",
      "r150"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses - various"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r47",
      "r119"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "us-gaap_PaymentsToAcquireHeldToMaturitySecurities",
        "negatedLabel": "Purchases of held-to-maturity investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r192",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid Expense and Other Assets, Current"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r4",
      "r7",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r5",
      "r7",
      "r149",
      "r150"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r46",
      "r119"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.",
        "label": "Proceeds from maturities of investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r213"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesBillingStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.",
        "label": "Receivables Billing Status [Domain]"
       }
      }
     },
     "localname": "ReceivablesBillingStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r223",
      "r357"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r56",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r159",
      "r217",
      "r312",
      "r325",
      "r326"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r66",
      "r71",
      "r73",
      "r135",
      "r214",
      "r215",
      "r216",
      "r233",
      "r234",
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r92",
      "r93",
      "r95",
      "r99",
      "r100",
      "r104",
      "r105",
      "r107",
      "r173",
      "r174",
      "r298"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Research and development revenue",
        "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction",
        "terseLabel": "Sale of Stock, Percentage of Ownership after Transaction"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r85",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r197",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-Free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-Free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable, shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Expired, shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Canceled, shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted, shares (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r199",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Outstanding, shares (in shares)",
        "periodStartLabel": "Outstanding, shares (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r190",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Expired, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Canceled, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r56",
      "r192",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r209",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (Year)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining contractual term, exercisable (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining contractual term, outstanding (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r32",
      "r62",
      "r63",
      "r64",
      "r66",
      "r71",
      "r73",
      "r78",
      "r135",
      "r158",
      "r159",
      "r214",
      "r215",
      "r216",
      "r233",
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables",
      "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-",
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r78",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables",
      "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-",
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r158",
      "r159",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised, shares (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r59",
      "r117",
      "r134",
      "r249"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r159",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r264",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r116",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r124",
      "r128",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury stock (in shares)",
        "terseLabel": "Treasury Stock, Common, Shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r31",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r31",
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "us-gaap_TreasuryStockValue",
        "negatedLabel": "Treasury stock, shares held at cost - 12,253,502",
        "terseLabel": "Treasury Stock, Value, Ending Balance"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
      "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnbilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.",
        "label": "Unbilled Revenues [Member]"
       }
      }
     },
     "localname": "UnbilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r224",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "terseLabel": "Unrecognized Tax Benefits, Ending Balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r79",
      "r80",
      "r82",
      "r83",
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies",
      "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-",
      "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Basic and diluted weighted-average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r358": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r359": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r360": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r361": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r362": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r363": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001437749-21-012046-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-21-012046-xbrl.zip
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M^O4O!;9 5?_/Z_9]IOD]9OM^0X__:K_KV/^,V:\8TE,?44=^V0)Z5#.P]0.
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M>I;4I0QUL8(AH!'P#_)C\%>^TB=C8"8H"/S_"0LN,#@4I&<&8D4W]Q <B.-
M[!L1&D@=7P,QNZL/%4.I60%[,$@0Q-Q4[/D+2^_;_,+43(+=S<_?#<14SH%N
M?FY4W 3B:^%A[B"&&8,X/MS;/0+$8"8!B/B&^7F#F)H3L?NYNX2 "0@U[Q )
M=<=Y@9B:?= '6YIC0:P))G#TGG_#KG_#H>[G0ZE.80,"(X.]/;U"!25PDH+R
MZNIJ@@;N$;[NH:$R9BXX'Y=@-T%L@%^@BW\D /SR>5]8J;$5!(.L(J^NHB*C
M("O_MT#]E\K_4*AG^PL13N^?&82S_:^Q?V47D <F7&#^";O[UYAK!@#47 4
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ML2X1*W!QK9G/ G%G;##A/O$# >0W1H/%64=>;7Q*@'\=([R^++RJ^M2/FQG
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M0F2L-4O_9?&OTC&@#+;N,8R#(CYD1KC$7Q4V.P^6<1XD\9\DJLT;6WM.:<^
MUVTP-:P#)__V[6W,&R);*OM$@U(1NN)2<!IRCK*S;+76L.@_(H9IJ*T\G.+:
M$O(I#A[BI%07E)O"Y)".)Z(W;*P@?3C.T.$XD*6BOQQ&$;.B@N5#57RHB@]5
M.?I0%0D+H -(2>B".MJQFY66T85X='GY745#=$$@FN#-0[7G<I!#-:,7VS7&
MO9^$03:O?I!MH$II;HJW 1T=K6Z=QK9D7NM!F[>CO2X[FFD-6\2$'<2%<19Q
M-Z<LOR=LL8NCTM6\^P[L-7*OD7N-W&OD7B/W&ODKU,C-')]VQ?</U1TRY96#
MDW OT*.;Q X=SI*0KD>.E\N]7-Y'+I=<:AWF\8I3J2F+=QD,'_BRJ&85,Y89
MG0CXP#@FI;X"K;S)=9]V$2-:O=DL*Q;59YTGJ/]#O ;G-3BOP7D-SFMP7H-[
MA1J<^:-TA&Y6TZ+7J!VMW<5PNWI\\UVPG71XR%"6]'<X*5YW][I[+TWMQ>T/
MNEH8< "O87D-RVM87L/R&I;7L%ZCAJ5U3(XIKS0B>1 GV40LGR+8OGTK"::2
M9X\BTU1)NQ?K7Y=8+TDY?5'T[4LAV-%TMBFR\X(<O5Y#DGA7+)=)K$OBBUYF
M2"SS_S=QQ=.]79L]OUGS@$9H-P-$;H+\[X.G*I!_9W%+$OH]X/-U3E>$!8_D
MADM)>V?S/LW=1S$ 8?,.&R>LB5I0!P.$35-R?CN5O^FF[PT\=@/KCK!5')+L
MIN!_")-:$PVMC0T0=,^_%4@5BU[2I+=NF;%\3Z_D?QWJE/RC?]Y50N='0A]9
ML)SSLS-I/!- ;4=$<M\SK2/I&VEFGZ"&(P[4UK[QX2 5:%-9,8V^\+.E^D-B
MD=#HZ1Q6XTX%M75'^BX'#T2]K#D& %](VR)J;.N ],WQ?D79!2T>\EF1O"11
MAD6KLP-P7+:.XJ009;=V1>@NG\*DX#I258!RL2SRJE+7[+" U>E"()%A-SFV
M_:EY(4B?D32<<QWT6^,QI-OM:  9/V(- %MO:6PX=76[H0!TSXG0PW+8 P&,
M6C'B*M()%$=#%P1 Q-SJ;9J7/48. \&VKVTN+XA4RD; 7NX*@FT-#'O9Z')A
M"=C+/APN\7]MUH85+1R061M*IDLBED+Z6*N2,D;;VMX^A)9JX97 Q2D5ZX/_
M)Y:*!%R/D1SX\X.$9#7%?*4KEYJRK0/2MR%@'RF-LDH_)HME0M>$;,Q4>X7
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MH)!;BQ A9P^V)J>#M0[=#K,U5YV]?^A"B6$\J:N9'AVGZ0!$.0UP]QHZOC+
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M\.Y*<1[1G$P-<LUOVR>ZSS#=DAKF1)']#[B[QWL'*DM8C#S9J7UB](0WWG6
MA':</+W@8 "@0V#QRN=Z4-:O?O!PG+_@<6Y:4#%>_!0%"IDP-, )0/*"D_EX
M!]&R2C8KXH$KVMYE;4WV;E&?WE-1]^A%VY2E#$5:7 H@+G!Y#$/H@"QM:R(N
MHC[#BDLLEV,Y2Y$6G^);W*656-4^<FAY#U>/561]GU!)5D7N2ZSPMH59Q6D@
MZFW1)&4SF@9BL(UA&HB#O@*D@>#TK-) 6&+VF :"(XN3!F)8+) 2WUY)@ :+
M2;M;\%7XG.0%L>S?H(K6'A ]+'DF%SI40P)K\G'1$OQ!0U6=\S).E#0;!D"+
M-I=D-Q*:3)*.)?K9ZWT=NHBNT1*(* G"[RNT@'6-AY,4-U Q2[CD([M4X8+.
M?6]$[^$2WUW4LH7[3:PMX^YI=FTEEL6\S6C6%M3[V,GM)E:%P9-;CEV1P2 7
M'9U*>R9<CN)$<8LUVFHDX;:HF9TS1===J"?RO"48TZGBE(FGCA4"SH25#7Q0
MPWQ9LOTTW9%@NCI)R>'_+LG+]ZBN+R!6B>!C\ED@-@8]&$J4!J502KT&)!,]
MW<^(OV,C+K$^0*H': V<(P(IAX3UB71%E$108#3@RR7&]?L9*&7A"IZ6GXDP
M(@?\CIH7DOK7:"6''/K"38;(?L^A%N$(! >9(^U&9'"_50A;"),C<E!*Q(DB
MQ8QZ9>:R\RS+&WK54'RC"$ QEM%,C.S5V,W$0XAB.G/)T=C6L_U8.D/:=-ZN
M0JQ*ER8T5<&P3523$,\M>EDE;O]YR7"NR5;^8YG!ZGQ900IXZ#U-_VNCA#3*
M5'SO0IIP]'/.>!RIR>Z X5"S.#/5]" !A@E04&": [9^JFQZXTW8>+=TO$D+
MBKX/U)Q+U* 5(ZF._B)$ENP/;)5(\HJ:SWJI(.ONAS_DL,)(5KM!UR.K/DPM
M$SJT?&]9A"Z@A$%'F;I*?CS_*8[KDMV4("=\CG '.<U7=:(,/!TK _LT=?),
MBB[[M[E?N, 1]#;A K#QW2$.M^+<%/:X>35O\.5_P:2*>!]PNF:.M7_W4QOI
MV+TM-]NF?@^?87$VZ%NG\87MD7K:<[@#= 88]1F@],%9G')Q.MP>.BUE++2\
M4=YA>?^05+_ AFB7G0(I=LI4^L#DWCC:L?=$B9@X8-0!O4=U],W=-QT/R)<O
M)R)#7[.A=Q>D[LX4X8:D)F%(G\OQ-^2WVAOR6V\;\MO8&_+;Z6W(Q]R6;,B#
M+'PE#R;T/S_!FH1>,^WES/4+R0B)T$\B U F_P8R@#GHHX<3GL6YN[ LXQS[
M5*XOKI>0B_<+Z1R[>[#8/XG<+1:85+EDEDO)2X7L,\LG"E'WH=\F1#AL;/3N
MQF;_&M%[6VS!@"F-T%J[[@7^H7: _!F"O#9,Y]5!NJ &GAO4^/R:-)\'^(]M
M7N<-_ 2KYSR%/E4@":THNI  T^M0B@3@PVM'SK@84TWJ!@'X*%Z]PB1;<,XT
M)Z7Y=Z="X>Y3<D8M249(M%[G-*JFOD]RO"^_JU!=WU<HA3"K;S WV8?72;H:
MBF;QTK>E,F:%(;3&9@761ND)S"5[W6\/F/RP!QD0S.1G%#5H80."FYEA[Q:
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M#I=,KJ ]I& /%;18F2]J#RTM7\[Q$BT,4,0SP#!'-P>Y72/(ZY2&CM\Z>L3
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MT"_^<>^LXVP=R,8\PJMPZ@RU@]Y56 E_SLM4JM (FMNJ-$?=AE9J*'FR>;4
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M!']+E&7FTA.E&*_:(D+Z;#_>#?I#>X__AG_8_@C_A^1JPC_Y?U!+ P04
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M1&QCYEG\/)D'9Q>;^V*U2A-$)"NNGD&'#\:6:NFZK6=0'RGC7D#)]DVK;9[
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M]@?>7%TD.,7S)*(W621^MJR=8]YJ(8EKO!8D,XH;:'CP-MIE>[Q\OEW/Q*0
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M!AD(KB  *%#6M]?:E0#LGA<Q]0@C5X"5U_J2!!>,'0"I9@X)BAQ[8'\[ .*
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MS9BUWCQ[@:W-D'V5$"1<9\0-?/E57WZU(WF^_"J4K&F2<\?-318GZR1FNX,
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MU%6*!^.61^JC*U3]N^/^PV.TX(DCO"CCA]D,B6.AC!)A\WR_HF R.Z1JD@U
MWH=#V! CQ2[0C+411R@HC& U5NSY+#F/(AZ(36_#C>0DO;6?S6(?8N*8SH&8
M-';A:]]U>"^,V6_QKGCSCDY98)G*(,/D]U,2/O *OXDP%AC2=5ABVG3,MB5V
M ^92.LJP&-[I]9?A*LG#M#VX4W& (3!Y2] J3.*KVE%3>T/8MC?)%XCPT],<
M+L*0P2Q/V#6J;+S*J#M?8I(G?Y9;^F3&R%\FPGO(E/I:B7AM,D[K"DJ'QJF
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M4JE0+!4JI7#K;.Y *F?,=%S5U&CPOJ/'S0_>+9W][[>O3]J #E7_9?;F%F
MD0_\ 3'38";]W\O'KV>NK9I.W[*'JLLL$P=9*Q2;X4'"JS_F@Q6?AKJ,G\VR
M_LJ%<CV HV6:WC"^'=VUS]SQB)[!2P5XB]I,\[_SG (^FJ"@KSH]_I7_!#MK
M1#'@V.Z\KX)',9]YKDV?YR*N=0;/)S"9]UZI$H)+:!:V9<R9!7\2-PMW9,=3
M'C[!#YK1#V90&J4[?-Q3G8#NF&-5RZ7&(DH5;P0X7([ */(X*[FQ?%83?.9.
MF( M9X+"-.NX \_4J:U;0QKY^O'JRPV#^3X[IYHU#.$W&7;?8@7.DK'HE,5C
M"QX@LEI19.EC-3ICN*$S#<<+;Y=+Q<KD7<VS;6IJX_CV_:?X67&&$6)9(.95
M>PZMV7&4!E3[K*JC6'+&!W%#8=H<8F9:S.OT31O$OX]/8C[0+,]T[7D@$@_#
MGUW\1#X/J*I?D)\(^>PRUZ 7B!,?]K^7BG^>@G;Y?":>X5O_MU @7ZA);=6E
M.NF-25?0WQ70'WFP;%<U2*$@6AQ25R4XE@+]TV,O_S[I6*9+3;?0!48Y(9KX
M]>\3E[ZY9T*+G5U\/O.']+EGZ6/BN&,#*+L/+Q<<]A<])Z7BR/U$^(V^.F3&
M^)S\\T_/<C]UV9 ZY(Z^DD=KJ)KBYB<R4G4=^."<%)E)BJ<E9GXB0#".99\3
MU7.M3R<7GW7VXO>D,V=DJ- HB&**S]C;.0Z)VN*2Z3HU+W[":WCC3K"[F,R;
M^XCZ5_\=(8A +I;D986CR52128$9SJ]- .FX ].W5>,6 /CV"QV?$ 9J,,30
MA?C7+HK AN52I5EL?3Z+#".=83W29^:@.G/OX,F\44V]=7'U6_OJMD-N[[K7
MCW?M[NW]7?LK_.JD/,3VD)HZ_._>&.KS"1$*]]\GH*'/>Q:H$=7LJP9(^ O^
M3\J==[B<<6^8HZG&;U2UKTW]"CCAY*)0*)7AY93[N[(T;QAT^ !-6/H-W'-.
M+OZSW;YP<K(G?'U>7S>VJJ&YPVE$:U1JU4JMTCR)],TB'7HF$[>_/UWYW4N1
M>=ZQAD/FXB"<MJFCM "^!;G.J'-"<%3P;A&DG</.368 4=H>@-X?FS^6Q8-K
MQ0RN*)"W]\%5JTDA!Z3P-%!M.CW(!S#Q*="H_N1:VH\'U;ZWGUP4U?]5#8].
MOIJ,-\Q 8+OHEJM3C0U5$,;R BR!V[L;D#JG*'=6FU M*;0/94+U1!A*,!7^
MBM/VW(%E@UK3UYM"38$IX/^KS:*1""U9GT4R.9-X%K>.XZTQ@T(%*&FE@=>*
MZ0[\WG/1#D<C9P>CKR:3H!D$>RG=@>\6[+4X4;J2;D %9IE;DJ.KB=%:G!A=
M22]D:3)QTC0A.X>FD8XH+0E!NK(PK<4)TX3,D9U)Q(FF=3&QIESB$ZBTE&:Q
MH=1KK97&7X]3#.LB8</Q-ZIKC#].PJX+_TW$*Y]$N:'4:E6E5&NL-HERBDA(
M8Q+5UAJ3V$ F=6VJ.IX]YM.0,^*369.9RTJY5E%JQ?)J,]A (&5B!HUBY229
M#QY,YL&;S 4#<>?@;O>H?=]_I [XX]K@WGY63?877V%8<S*5E>8P+9%6FX./
M#W\:]R.,&P(O/-%G[DBOB8_5IE!--(7?P:/7>* -&WADSH_+\26X]X.A:O]H
MOS&G\ 0C=1[I"S4]>D?=;Q0G%?<9AC?Y%QW/<:TAM6?>$=\NPOS,)SX,_3;7
MA%US-=C58F!7G,"N^*Y@5UL-=O64Z*ZM\=@]@$^C[$7M&?0PP;>2!FM,:[!9
MTN.JX/V ;R53K-%,B_HPT(GMQZJ@!)!\\D8C@Z4+2;_-G:C 5CDE&7B$D%Q-
M$[>6:I,56?I!'2?DYT.'7;.8+/ <LV[1-@SK%5?I;RS[RO)Z;M\S9F7B]B-8
MX!"ON_22F2DD#/_'3.&[:5/->C8Q*-)5WX">:9^M80"O,>:UP;Z_,4^':N=(
MBD5L>R4#MC#PMN-0U\'8(.?A@)HZU@OX(\\8,$0.#^95*"><6)&'JN;.;-Y"
M+&8YU0N58NAR2N(8AMJS4.*\T+9MJ^8S17?IRA-"Z+[??K8IOW4R@5JUB,N'
MH7%CDMRY#FXP:)N3B\!W7;Z$6RW68A8B@U%WU!%S50.IHF,YKG/?_VZ.;("E
M_F!;X.&YC#K7;YKAZ52_L:UA>VC!/:'G+L?RG?&]#5=_4,WE\MG7B4_4?F$:
M=8()2ME^_VJ"H!VP$7_[\NKV9\O H(HS([]#=+P0F-^8R8;>\+YGL&<^-) M
M_BC:IGX%OHIAC89ANEC-7*O4%\8O5R".;$(\!8+%-8V4"#8F6I1E\/W^B##B
MSR0ASA#R]??';1%R/:G@KJ]FIE2+<1'@+.-A'7BK;]N$=_-T%54)$$\LJH7W
M@9!/ KDU( /F.$\@LNRVKC,<J&J$P,&S9H; RQK#(7'8K0ZB&I#DZ?Q(S-IB
M=0HZ$BK0_I"^6N!W3$,G!?%7KZ<E_AHQ,<Y8*V,#G,;3>&AF:V%R-?$RG7N0
M(869+=BBX%Y-D)1B/4S?)<>$;]TSZ'W_^D^/N>-OU!U8^JWY0AV>$C=[EU),
M"Q7NNC$:J'_!7!<9:[[3(5IZHIIG,T33KPS:].!U56?&^(JZU!XR$_V]&Y79
M?,$?L.>M:Z:5FU6E49P?6ULAF?+W]JMJZT'(X7HX,JPQI7P1ZGZ$K4J=]&"H
M9@"<[H#B_AF\%Q4M/D#XRA5N6D#I.:*F(YR8"1E=CB>O2)+B([E^&S$A@$3B
M:%CVE)J+?(52<9[PV3TX?O\O$!,H;"&5<:*7,[#@'0$\@$CO3;I3,"ZR8-/(
MT-T/%+NOUDZAN$@15C($Q2[N@[COWYHZ>V&ZIQHBL#M@M'_]!B(+!?Q]OP_J
MP<X(]4Z$I.-X0SY5T'PC4&I4[X(H+440T2HN0$1MEXB(VNV^>6;9AT'M*T)]
MD2Q>E_RKX<MXN@U(%A/:?Z%CX$S',DUJ+(#&+"!GH'$Y#0W^UR/N 7*82Z7]
M),1 !!" Q"U(TP@@DI+?6@";);M9VHF277=@6][SX ::W ;,Y7AB05U> .KJ
M_D%]Q6PZX??=@64;^GPML,P)$,VC3-F.LVMX-;--1J X',]PU6F_?>N *6U#
ME#7#EP?)7Z4M\%>Y%+X\5'I9Q$AK :92*)?#EP<*F/):C!03X*B4-MC_D86,
M4IA!LM3DF*A*9/S<,ETO7M<\G1,JZ5N6:UHNQ:WHYV"(/__[A)H%SQ&X[--F
MK:IIM%%H-$NM0K5:+19Z]5(/2+-2+#5;5.T5U9.+1SH"D&)B*'$'%(:%*[5
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MZ9B[LV5[%P_J,PW(-#Q18>0LP\[\%8GPHDUKFVN9*AG8J)[_%D23@S&A/5@
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M.BGL@]_GTW7'[^HC0HP?UB<XME)4Q 5N43PEOU+?>B1CRYL4;X59T6<+YVN
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MP@D,I>6M>PB5TJ@VE'IM+YO?]DTDN]F'L1=2;&Z%%&-V8O(7!Y8!QIDCVMN
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M=$+.XD#^\U4\R!%W:0"\>]_YRLP?01\ZV"F&"I!DIL%,6N@9EO8C:MGQKB>
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M@Z X+V124#LO,(Y@Q*$Q*"C-\8H/YM:Q56J<DGOP)_B;(]5Q%\D5]]7B@@7
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MM0<]"T-EV4!IXWBO@X/2 &ADIU<5@RH#*?_$'@S[7.AV"6-X )9W*)6!]AG
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MO;)67MFF(]?5RC/2-A-EM7(J.RD_G[BDUJX5M3:]F3W4TTJ6TRIRRLE26<M
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M"_WX!M3C2R(,7+"?+-/](07+;U?)I*.WFFV]V4@7NQ(Y!GC$.0>P<5W)LAU
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M-?DHA:4 MD2IGMYO][;&J<-8M-]4;.AD;&A0S\&:V$1YOY@SGO^D8DD,K[O
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MO!1,/<8K=,(5/S);FV#=SD>49+6IM',I&]VXG]425%+[JD+]J);U9/2=OLH
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MFZ$#^!::T4@-R+6E5 8G-5P*8VW@EC@9YTJ,T/R*T"I#^QV7A+&^4DO5KIT
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MF)QK3C0ZTA #CQF1<H#XAJ%RAF7'@;,\()8_3TRCC"E#)UO(QXPP)Q4))/+
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M8Y]!.&TO +<T]B>B-PA[ 7Q"QZ>Y\&*A>9NOWD_<T%,G!E+R>I2'I<WZZB3
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MV+&<HTT,R],>,:J:(@[\$(^+0NCX3J)+,S5FP'=S(B(:GU$,1Z]+.R,N$A>
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M@D.G#++MM$L2W9Z,_)_B]5&XN"IC1E+;H228C9=[R%C#E'"=%5]X>74]''Y
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M@@3K<:+I2Z<M&K-N8"/:72U'^&AQP6-BV<R,"=_=]26^OH')@@MUN&< 4MM
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M"N^6!*6?C1(Q&<MXF)&Y:#\]&PS]3[^*GWS*XZY&E[RO=((WX5!_1LQ3.!&
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M::<M#7J.&N)2+@YGY>$\CAJA+,I9@EL.3KX#Y!*A+YA1%&KK2%8-\5@1Y@#
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MV/#/?SRA1?^/?SR9EK/DI__X_U!+ P04    " "[@*U2]7__<,H'   P)P
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M)#P3<C%@CS\7V@TO1 :6?8 Y.]<95V7CD.4\CH6:#EA'*-9IA4(-6508J\V
M\<+I(>HTRM<6JN;=F'!XI837P3_.N!%<N8&B+99#!Y>NR:68JH$1T]0-,VZF
M0@U('K=W,CZY3,5$N%%[,GZL)C8?8ELO;'6I8=3.QP<WZ/+[AC*_WT6;M<6K
MY6Y9X^OLC=#U8+8,?HW^%XF(. &/Z82=&:$BD7/)3BXA*IR8 ?LK00DPNS;A
MNRAXAE@H< 1SFGTLXX/U.EU2U:7 /G(SX0IL\Z]+"0OV,G+4T^UT=KKLNVC+
M54Q:%D8X@;/3X\DEQKZ: D9;E@EKR8!S#&MN@?7ZS?YAO_O\9X#73PKAM15.
M W:&9,'^TV+G?&ZU"ECD ;Q ,' W^('V.3Z1P";:Q&".&QVD5Y"R(K/ZV>8\
M6CY_+54&S#<'S((1R9#-1>Q2FJ3S&W'DHX-'2-T&_Z'?>+E<)=7[;<B(ZC'0
M985@#*A\Q2@7[STT;-TR[$7_QG&G+.7(*@9F N:8REPJ+/M<<,I$<H'MN3:.
M$MQ;= (:V/R;8OK-@L<B8J<4=\K3%7+4J8I:M?+XZ^W_P=NP<^@M6[$^]IX,
MZ'ZA'U\AA?E")%NP3TK/)<13"$IW5DZ,-0)9:>>+#XX9GJL%*Y0S!> Z6,AD
MR*/D7<ZP!$)@HT\33B1NF,Z$9WTOMR6@( )KN5F02,8_@4\']9P6VV)4!I>4
ME.F7^2(2)BHR%%,X'#7!Z&7S5$0ILP7]N1H_!P/5)&0 4C=R-D4W1IY+T4";
M8SJBU6G>'%73,9J)6X6;,EFL;L-]._B71VCO6R,46"(48H#@=.7SP"=LC=UF
MI5^HLD"GQ(VUD2QBG!-QM>+@ #$IB+MRA 4AFI NY15D*[38C:4Q*F)!$P<D
M44@40)SJG$IV;"T+B(C;E"52S^T2Q :FPCI#51&GQE)OU#)8P:)=*K.E[7U[
M\Y>'8_\+X7BQYKO'_SSJAL^'M@)<5<@0P>BRWO9>/67<@,</XD%0S8%^9F"I
M_A V)7$2RY!<B6#I.18VDMH6.(YHUVA9 BDW.H(8FRU[@KB) 8%8@J.N4:E^
M/B\DV')WPAYOAL^>P%,_/GP6ET_EHR@SL5PNPHC[5L!=@HT4VF^U9&VU!%<C
MBS=QCQ)S\(7$8 ,->$3UQ=E:)5@5<JRSS]ETHU;[I2O %]\C$/AM@7!T=..X
M&"P^(1I\TMV-UX#J@8@7]NY#*#%/@-4KE:E>%P8G0(*<">MI%Z5 ^7GH '%%
MV*ND;T!RC^,JUU_!,*@2 G4*)&_4Q6HI8G]#8XN)%;'  P49(,J*Q*<A13,5
MEJH$'_O6EQ2>I#6>"I&S_?$Q8#FGW2LDI]R"9GDEKJH-'%'6+JLE%_XW 1)$
M^L?Q$._!EM\%))-O I([L\T65N[.4W>&#,)L)F)" L=#J.<!;A%%5%42/+B)
MEZY"\ @^$5*X!:7OZY8EX'JO>H?5-S'752@E^5]6!N6%R1$PUI<;481,Y!7P
M]6EY\2<1-]@#.0&21+#V+K'A;WF0>N\;'=$#A3Q0R"Z0Q%\*DM+'6Q6P/X96
M18CON;8NVX,XR/$ZB@I#A[^57;YFUDQ;A^UT@8AS6=1Y>??!GMPP)$',84AO
M2%>*1W212"=H.ERKHM;K::E5RFT-22*#),%S",0^'/Q^5 RVP'/R)Y#5<7I#
M/OCJ+1I2;#T4:O=U5??LAYY8_/5>'7L!FRR/X<2=J_B'&9=%G?#V2/%;-%JK
MQI%*G3:VSJJ^ :?,,N$<P/89NAXZT9BWJ3\6J)^?Y E&"3*EI;,X_A*A+T,;
M/A<"U?=A7"C_8L(^?3B+_')G$;JGH03OWX*A,^F@&@E R%4O<.J$/@?^28&M
M"B["0%D:^,O*Y9W-7D"N<F]YPK^&B'F, RW4/'PCZ*L"$X<@<A$%05G&6')0
MD2'@T,7>F"K_77N[=1U'_V@O[AQZBR?WO1OZJ4X[5)$D!LDJ0%" YU>$E;]Y
MKO 7E E=J)F6,Z"LKOBTND W%25#EDN] .R=I[KD8;Z&;D3C-REY6G<ANH?7
M;TNI/@F]04<.;D/'(4F-.,/BGS?=1$H='3>ZG<NP43>57W6$W:/GX4KK[+C1
M1QM%?-R0$)>];^G+D%ZW$QZ&1R_Z_:-N]UGOL#%^SQ<L[ 6,>D=M/KY[N)1&
MO%KL-J%MVZ6S5O^NO[C==]G=O'"X+7;7R3_@INZVZNL,N* /:'8O\CH5D+"W
M=<#5GU[<:[3%8L8BR:T];OSY\N-%\^SENY/FJ_.3EW_0USDKO6?OWEZ<;[2E
M2=/H^78C12@[>_?AW^^O5D,)E+ON![5HTR='"%C_<=7_ 5!+ P04    " "[
M@*U25;$:O6T$  !G#@  #0   &5X7S(S-S@R-"YH=&W=5VUSXC80_AQ^Q=:=
MYI(9;&P#"<&&&4)(CFD"'#@S[:>.L&6LGBT[LDB@O[XK&P+A>DTZU]Y-;R83
MH]5J7YY=/9+<2"9QUXTH";IN0B4!/R(BI[*C+66HM[2-E).$=K0P%0F1>D E
M]25+N09^RB7EJ"UI3+,HY;3#4UST@Z[W!262!I!RJ-?LBYIMVA98;:O9-FV8
MW(&NO["]H)P*(E.Q9W1Z=0/OO;M;Z*?\D0I)!=2-AE$W3*U;.7(EDS'MTM5O
M=OV\93<,S,6ME<+*4<6M%5E5W'D:K"&7Z[C(@$L]9W_0-EAF)ATH!"%)6+QN
MP_'#,I6.QQ*:PX@^P31-""^%#F0D"!A?M,%D'$S#8MP!?RGR5+2!+&7J8$QN
M]L+1QNZ!06<71!%#,7PD@A$NVUQ!'#N2KJ1.8K;@;<$6D702(A:,MY4^PCOO
M#E81FS,)==NPW-J\Z]:R;N4S_M\=!/#N+1&\<'C,YWGF_)V/+\O1QW)3\4F2
M_<'4&UX/^SUO.![!Y'XZN^^-//#&KV7\GT1CM>#>F!E] V:#?A&156^:U6\2
M2V\&O:OQQ!M<?7-8MF!<F&<PO@;O_0!FO>EE;S28Z>-?;@>_0J_OJ1G;-.W_
M?ZO^OLPE"]<OG0ZY(BU>LB(\,1F!C"A\6!)%6O$:IC1+A80TA*LU"9@/0X4E
M)TJ?Q#CR#3A12XY_;-FVZ?33)"-\78PLYU21Z#6&@J2E?T#.$H7YA](\4!X@
MS[H$ B*)+N=QG/H=K;FRM&=)R;&6W3JW]J2/':UA:L""CA;3H)R]5CQ=MTWK
MS&I=-!JM5K/5:&K=.R+\".I6%=2\6R,;H$D.(</%NZ1G%%F12888$Q[ 8(4G
M"E]0Y/ D87FN ,(_I8EA4(BHH C+?O(E6-O<JS"L KK_"#T#!EB-D(AY%7P\
M#[ .5<B0@Y=8*Y I[+9HGAOE]@2,D 1IIHZB?56EH%H6?1=1HU'"::Z/5S%=
M0\\OBJ5:MHKSI%B2K.$C3Y\PVP5M?X==?&*=@H=8;)HU7,;8N3YV8JR*^5Q@
M01^63- $Z2!7(.6;MK?J)P0[58#5/ E.GX'=M<-S*VS0M2[J#4<UR?>(I5UB
MR7AY:5( J7L-81P;D94;8 LT88HC,D%SA6E539,X!EQ&T6F,B.<9@IQ7BU4A
MXX3[2HX& U:85CL-M99Q69(T4W<IG,BW9=@0BO$5H99D'E.8IR*@HJ,AS_@T
MCC>WJ.=QGA%_._[2.UH5"G$5.U*PT,&.#62DC)@_J<O94>4([XP"?ZAOL'6W
MU6HHI2N$'+>V##ZCU3I36H=4:YO_#M<VS\VS,\6U:]Q,.Z;=QH/?(OK7DKA<
MOYY"+:^5Q=K_?\BR_]3QMORO^'ZI]E;C(X2U_48/7YJ(IQX1KX/8CQ@-D=:0
MXB1[I# .0X;GTH$W?(D46^%K[;N /8(?DSSO:+>]F:=/>C<#_7(ZZ/VL7BA[
MLY.;:V]Z((M"7:1/GPK57H7)S>C^;N<--5#OKSX814T]N[!UBP?FGU!+ P04
M    " "[@*U2<FOV#6@$  !;#@  #0   &5X7S(S-S@R-2YH=&W=5VUSXC80
M_AQ^Q=:=YI(9;&P#.<# #"$DQS0!#IQI^ZDC;!GK:LN.))+07]^5#2')]9KK
MI+V;R4PF1JO5OCR[>B1U8Y4F_6Y,2=COIE01"&(B)%4]8ZTBLV5LI9RDM&=$
MF4B),D.J:*!8Q@T(,JXH1VU%$YK'&:<]GN&B'TQS*"A1-(2,0[WFMFNN[3K@
M=)QFIWX"LRLPS2>V5Y13050F'AF=GUW !__J$H89OZ5"40%UJV'5+=OH5PZZ
MBJF$]NG][V[]?<MM6IA+MU8**P>5;JW(JM)=9N$&I-HD109<F9+]23O@V+GR
MH!!$)&7)I@.'-^M,>3Y+J80)O8-YEA)>"CW(21@RONJ S3C8EL.X!\%:R$QT
M@*Q5YF%,W?R)HZW=9P:]?1!%#,7PE@A&N.IP#7'B*7JO3)*P%>\(MHJ5EQ*Q
M8KRC]1'>97]T'[,E4U!W+;=;6_:[M;Q?^8+_=\\">/<U$3QQ>,B7,O?^R<?K
M<@RPW%1\EN1P-/?'Y^/AP!]/)S"[GB^N!Q,?_.E+&?\OT3@MN+86UM""Q6A8
M1.34FW;UN\0R6,#@;#KS1V??'98=&&W[!*;GX'\8P6(P/QU,1@MS^NOEZ#<8
M#'T]X]KV&VC53VNI6+1YZG3,-6GQDA7ACJD85$SAXYIHTDHV,*=Y)A1D$9QM
M2,@"&&LL.='Z),%18,&17G+X8\MU;6^8I3GAFV+D>,>:1,\Q%"0M\R-REBC,
MWY3F@?(0>;9+("2*F&J9)%G0,YKWCO$@*3G6<5OOG4?2VY[1L U@8<](:%C.
MGFN>KKNV<^*TVHU&VZVWW8;1OR(BB*'N5$'/=VMD"S21$#%<O$]Z09$5F6*(
M,>$AC.[Q1.$KBAR>IDQ*#1#^:4T,@T),!458'B=?@K7+O0KC*LR0>>$7"^;D
M3F:\"@&>!EB%*N3(P&NL%*@,]AM42JO<G(#QD3#+]4'T6%4KZ(9%ST7,1"P)
MI]*<WB=T X.@*)5NV"K.DV))NH$_>':'N:YHYPWV\)%S##YBL6W5:)U@WP;8
MAXDNY4-Y!;U9,T%3) .I09+;IG?J1P3[5(#3/ J/'X#=-\-#(VS1==KUAJ=;
MY"UBZ998,EY>F31 ^E9#&,=&9&7[[X F3#-$+JC4F%;U-$D2P&44G2:(N,P1
M9%DM5D6,$QYH.1H,66%:[S/46B=E2;)<WZ1P0N[*L*43ZQM"K<@RH;#,1$A%
MST"6"6B2;.]0#V.9DV W?NT-K0J%N(H=*5CD8<>&*M9&[)_TU>R@<H W1H$_
M]#?<N=MI-;32&4*.6UN%7]!JG6BMYT3KVO\-TS:;[::KF7:#FVG/L[MX\%M$
M_U(2IYN74ZC)6EFLQ_^?<NR_=;LK_@N>GZI]K?$)@OIR5J]+P-</AY>=#&-&
M(SA_V(73*&)X&CWSAJ^/8@-\J]T6LEL($B)ES[@<+'QS-K@8F:?ST>!G_2IY
M-#N[./?GSV1Q9(KL[G.AWJ$PNYA<7^V]H0;J_=T'HZCIIQ8V;/&H_ M02P$"
M% ,4    " "[@*U2DI4MY/,<  !'(@  &               @ $     9'EA
M:2TR,#(P,#DS,%]G,6-O<'DN:G!G4$L! A0#%     @ NX"M4MMX%B5X#@
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M,#(Q,#,S,5]L86(N>&UL4$L! A0#%     @ NX"M4K1:(*]F.0  %]X$ !4
M             ( !7;@  &1Y86DM,C R,3 S,S%?<')E+GAM;%!+ 0(4 Q0
M   ( +N K5*T4;H<&1H! ,HY"P 4              "  ?;Q  !D>6%I,C R
M,3 S,S%?,3!Q+FAT;5!+ 0(4 Q0    ( +N K5+U?_]PR@<  # G   -
M          "  4$, @!E>%\R,S<X,C(N:'1M4$L! A0#%     @ NX"M4J+U
MOR7!!P  8R4   T              ( !-A0" &5X7S(S-S@R,RYH=&U02P$"
M% ,4    " "[@*U25;$:O6T$  !G#@  #0              @ $B' ( 97A?
M,C,W.#(T+FAT;5!+ 0(4 Q0    ( +N K5)R:_8-: 0  %L.   -
M      "  ;H@ @!E>%\R,S<X,C4N:'1M4$L%!@     +  L OP(  $TE @
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
